{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan announces U.S.  \highlight22\uc2 launch \highlight\uc2  of Fentanyl Transdermal System\b0\par\par\uc2 99 \uc2 words\par \uc2 11 March 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr, adding to its existing offering of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr. Mylan currently is the only manufacturer that offers eight Fentanyl Transdermal System dosage strengths, including three new strengths \u8211\'20\'13 the first and only available "intermediate" dosages. Mylan received final approval from the \uc2 FDA\uc2  for its Supplemental Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr. \par \par \uc2 Document FLYWAL0020150311eb3b0010d\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; NTRR: New Congressional Bills Could End Federal Prohibition of Cannabis\b0\par\par\uc2 278 \uc2 words\par \uc2 9 March 2015\par \uc2 Pharma Business Week\par \uc2 PHBW\par 107\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Pharma Business Week via NewsRx.com   \par \par \uc2 2015 MAR 9 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- As \uc2 Neutra Corp\uc2 . (OTCBB:NTRR) continues to develop \b \highlight22\uc2 new products\b0 \highlight\uc2  to serve the fast-growing U.S. cannabis industry, two new bills were \b \highlight22\uc2 introduced\b0 \highlight\uc2  to Congress last week that could put cannabis on the fast track to nationwide legalization.\par \par \uc2 U.S. Rep. \uc2 Jared Polis\uc2 ' (D-CO) Regulate Marijuana Like Alcohol Act proposes to legalize cannabis without fear of federal intervention, while Rep. Earl Blumenauer's (D-OR) Marijuana Tax Revenue Act seeks to tax cannabis sales at the federal and state level.\par \par \uc2 The new legislation is only the latest sign of shifting attitudes toward cannabis consumption in the U.S., where the majority of Americans support repealing criminalization to boost tax income and lower crime rates. If passed, the new bills will make adult access to cannabis hassle-free, increasing NTRR's value in the industry.\par \par \uc2 "This is huge news for companies like ours that are developing products for this industry," said NTRR CEO \uc2 Chris Brown\uc2 . "As fast as demand has grown for cannabis-related products in recent years, it is certain to skyrocket if the Federal government effectively legalizes the plant. Congress is now on the cusp of making that vision a reality, and NTRR will be there to capitalize by serving the emerging needs of a massive new consumer group."\par \par \uc2 The bills will be heard before Congress in the latest term.\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Neutra Corp\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document PHBW000020150306eb390002h\par }\page {\par\fs20\b \uc2 Briefcase\b0\par\par\uc2 1,019 \uc2 words\par \uc2 4 March 2015\par \uc2 Portland Press Herald\par \uc2 PTPH\par 4.D\par \uc2 English\par \uc2 \u169\'00\'A9 2015 Portland Press Herald. Provided by ProQuest Information and Learning. All Rights Reserved.  \par \par \uc2 Boothbay firm's DryRight tested on Marines' boots\par \par \uc2 Boothbay-based Biovation II LLC plans to \b \highlight22\uc2 launch\b0 \highlight\uc2  a \b \highlight22\uc2 new product\b0 \highlight\uc2  that can be inserted into wet boots to dry them quickly in the field without the use of a heat source. The product is being tested by the \uc2 U.S. Marine Corps\uc2 .\par \par \uc2 The product, called DryRight, is rolled and inserted into a wet boot. Its anti-microbial materials dry the boot and ensure the foot health of the wearer, the company said in a news release. Poor foot care is a significant contributor to lost combat readiness, it said.\par \par \uc2 Biovation said the Marines have been testing the product for months and have given it a positive review. The company plans to start production in April and said DryRight will be ready for shipment in June.\par \par \uc2 Production of the boot inserts will require additional hiring, the company said, although it did not specify how many jobs would be created.\par \par \uc2 Biovation, a technology design and manufacturing company, produces advanced, non-woven fiber products with integrated anti- microbial properties.\par \par \uc2 Portland investment group buys 6-8 City Center building\par \par \uc2 The 6-8 City Center building in downtown Portland - which houses Tom Veilleux Gallery, Men's Room Salon & Lounge and Styxx Nightclub - has been sold to a local investment group for $1.4 million, a broker involved in the deal said Tuesday.\par \par \uc2 The investment group, Six City Center LLC, is led by developer Drew Swenson, president of Portland-based Paragon Management LLC. The seller was \uc2 Chase Custom Homes & Finance Inc\uc2 ., which purchased the property in 2011 for $1.5 million, Portland Assessor's Office records show. Its assessed value for tax purposes is $2.3 million.\par \par \uc2 The deal was brokered by Michael Anderson of Paragon, who represented the buyer, and John Doyon of Malone Commercial Brokers, who represented the seller.\par \par \uc2 The four-story commercial property built in 1900 contains office space on its upper floors.\par \par \uc2 Diversified Communications buys California company\par \par \uc2 Portland-based \uc2 Diversified Communications\uc2  has purchased The Sleeter Group, a California company that consults with and provides educational opportunities to small-business accountants.\par \par \uc2 Diversified already provides similar services to corporate finance officers and accountants through its Institute of Finance and Management. The Sleeter Group runs an annual conference, networking forums and webinars, and also produces newsletters and digital and print educational materials. Diversified said The Sleeter Group will operate from the company's Portland office.\par \par \uc2 The purchase, announced Tuesday, builds on two other acquisitions \uc2 Diversified Communications\uc2  announced this quarter - D4 Medical Analytics, a health information technology company, and the Brisbane Fitness & Health Expo.\par \par \uc2 JPMorgan Chase\uc2  will pay $50 million to homeowners\par \par \uc2 The \uc2 U.S. Department of Justice\uc2  says \uc2 JPMorgan Chase\uc2  will pay $50 million to 25,000 homeowners for failing to properly review payment- change notices sent to homeowners who were in bankruptcy.\par \par \uc2 The Justice Department says \uc2 JPMorgan Chase\uc2  acknowledged it filed about 25,000 payment change notices that were sent to homeowners without a proper review. They were signed in the names of employees who no longer worked for the company or who hadn't reviewed the filings to check their accuracy.\par \par \uc2 The agency says the settlement will include cash, mortgage loan credits and loan forgiveness. The largest portion of the settlement, $22.4 million, will be made up of credits and second-lien forgiveness. It will go to about 400 homeowners who received inaccurate notices of payment increases during their bankruptcy cases.\par \par \uc2 The settlement is subject to approval by the U.S. Bankruptcy Court for the Eastern District of Michigan.\par \par \uc2 Pfizer\uc2 's pneumonia vaccine gets approved for use in EU\par \par \uc2 Pfizer\uc2 's blockbuster vaccine against pneumonia and other bacterial infections has won another approval, this time for use in \uc2 European Union\uc2  residents aged 18 and older.\par \par \uc2 Prevnar 13, called Prevenar 13 in some countries, is the best- selling vaccine ever.\par \par \uc2 It protects against 13 strains of pneumococcal disease, the most common bacterial cause of pneumonia and a top cause of death and hospitalization worldwide. It also causes children's ear infections, bloodstream infections and other illnesses.\par \par \uc2 New York-based \uc2 Pfizer\uc2  says more than 750 million doses have been distributed worldwide. Last year, Prevnar's global sales reached $4.5 billion, making it the No. 2 product for the company, which also makes Lipitor and Viagra.\par \par \uc2 Best Buy\uc2  to boost dividends, cut expenses as sales sink\par \par \uc2 Best Buy\uc2 , the world's largest electronics chain, will boost its dividend payments and step up cost-cutting efforts as it grapples with a slowdown in sales.\par \par \uc2 Best Buy\uc2  will offer a special dividend of 51 cents a share, or $180 million, and increase its quarterly payout 21 percent to 23 cents, according to a statement Tuesday. The Minnesota-based company also will begin the second phase of reducing expenses, aiming to wring $400 million from its operating costs over three years.\par \par \uc2 CEO \uc2 Hubert Joly\uc2  has been making the company more efficient since he took the reins in 2012, though he's had less success increasing revenue. The chain faces mounting competition from e-commerce. While same-store sales have grown the past two quarters, the company has said they may decline in the first half of this year.\par \par \uc2 Investors cheered the announcement and sent the shares up as much as 5.5 percent to $40.77 in early trading.\par \par \uc2 Barclays\uc2 ' net loss widens with costs of past problems\par \par \uc2 Barclays\uc2 ' fourth-quarter loss widened as the costs of correcting past problems overshadowed progress in streamlining the bank's business after the global financial crisis.\par \par \uc2 The London-based bank on Tuesday reported a net loss of 1.68 billion pounds ($2.58 billion), compared with 642 million pounds in the same period a year earlier. The loss reflects more than 2 billion pounds of one-time items, including 750 million pounds set aside to cover penalties for alleged manipulation of foreign exchange markets and 200 million pounds for misselling payment protection insurance.\par \par \uc2 "We remain focused on addressing outstanding conduct issues, including those relating to foreign exchange trading," said Chief Executive \uc2 Antony Jenkins\uc2 .\par \par \uc2 -- From news service reports\par \par \uc2 Caption: Boothbay firm's DryRight tested on Marines' boots  \par \par \uc2 Document PTPH000020150304eb34000a4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 HomeFree Announces Two New Retail Products: Chocolate Chip Mini Cookies Snack Multipacks, and Lemon Burst Mini Cookies\b0\par\par\uc2 562 \uc2 words\par \uc2 4 March 2015\par 13:45\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 WINDHAM, N.H., March 4, 2015 /PRNewswire/ -- HomeFree(R), "treats you can trust," announces two \b \highlight22\uc2 new product launches\b0 \highlight\uc2 , Gluten Free Lemon Burst Mini Cookies (6/5-oz.) and Gluten Free Chocolate Chip Mini Cookies Snack Multipack (6/4-1.1 oz.), as the newest additions to its line of nationally distributed, gluten free, allergy friendly cookies. These \b \highlight22\uc2 new products\b0 \highlight\uc2  are launching at Natural Products Expo West, March 6-8, 2015, featured at booth #8330.\par \par \uc2 HomeFree Gluten Free Lemon Burst Mini Cookies are free of the most common 8 food allergens - peanuts, tree nuts, eggs, dairy, wheat, soy, fish and shellfish. They also contain no soy, sesame, or corn. Like all HomeFree products, these cookies additionally are certified kosher pareve, non-GMO, vegan, and a good source of whole grain.\par \par \uc2 HomeFree's new Gluten Free Chocolate Chip Mini Cookies snack pack helps to fulfill the demand for "free from" convenience snack options on grocery store shelves. There are many mainstream cookie multipack options packed in trays with clear wrap, but not special diet options. Now consumers seeking to include people with special dietary needs can purchase cookie snack multipacks that do so.\par \par \uc2 Food Allergy Research & Education (FARE) estimates that there are approximately two children with food allergies in every classroom. According to the American Academy of Allergy, Asthma, & Immunology (AAAA I), peanut is the most prevalent allergen among food allergic children, and one of the food allergens most commonly associated with anaphylaxis. Peanut free classrooms are therefore common. Single serve snacks such as HomeFree cookies manufactured in peanut free facilities prove to be a convenient solution for consumers purchasing snacks for peanut free classrooms.\par \par \uc2 "Everyone wants to be included at snack time," said Jill Robbins, a clinical psychologist who founded HomeFree after her son developed multiple food allergies. "Our new snack pack of our best-selling Gluten Free Chocolate Chip Mini Cookies will make inclusive shopping and snacking easier. We are also excited to launch such a flavorful and wonderfully textured lemon cookie that everyone can enjoy together."\par \par \uc2 All HomeFree products are made in HomeFree's dedicated facility free of peanuts, tree nuts, eggs, dairy, wheat and gluten. HomeFree is a pioneer and leader in the industry with regard to allergy safety, and is Safe Quality Food (SQF) certified, a certified woman owned business, and a certified \uc2 B Corporation\uc2  for a strong commitment to social and environmental responsibility.\par \par \uc2 HomeFree cookies are available for retail in 5 oz. boxes ($4.99 SRP), the new Chocolate Chip Minis Snack Multipack ($4.99), and single serve Grab & Go boxes (SRP $1.39), and for food service in single serve bulk boxes and countertop displays, and loose bulk. Current flavors are Chocolate Chip (large and mini), Double Chocolate Chip Mini, and Vanilla Mini, and the new Lemon Burst Mini, offered nationally and in Canada, and through the company's website, {\field{\*\fldinst{HYPERLINK "http://www.homefreetreats.com"}}{\fldrslt{\cf2 \uc2 www.homefreetreats.com}}}\uc2 .\par \par \uc2 Contact:\par \par \uc2 Jill Robbins, Founder and President\par \par \uc2 info@homefreetreats.com\par \par \uc2 (603) 898-0172\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20150304/179584"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20150304/179584}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/homefree-announces-two-new-retail-products-chocolate-chip-mini-cookies-snack-multipacks-and-lemon-burst-mini-cookies-300045514.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/homefree-announces-two-new-retail-products-chocolate-chip-mini-cookies-snack-multipacks-and-lemon-burst-mini-cookies-300045514.html}}}\par \par \uc2 SOURCE HomeFree, LLC\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.homefreetreats.com"}}{\fldrslt{\cf2 \uc2 http://www.homefreetreats.com}}}\par \par \uc2 Document PRN0000020150304eb34000jp\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Cyclacel Pharmaceuticals\uc2  Files 8K - Other Events >CYCC\b0\par\par\uc2 294 \uc2 words\par \uc2 4 March 2015\par 12:08\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Cyclacel Pharmaceuticals Inc\uc2 . (CYCC) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on March 03, 2015.\par \par \uc2 On March 3, 2015, the Company issued a press release announcing the launching of the Offering. On March 4, 2015, the Company issued a press release announcing, among other things, the pricing of the Offering. A copy of each press release is attached hereto as Exhibits 99.1 and 99.2, respectively, and is incorporated herein by reference.\par \par \uc2 Neither the filing of the press releases as exhibits to this Current Report on Form 8-K nor the inclusion in the press releases of a reference to the Company's internet address shall, under any circumstances, be deemed to incorporate the information available at the Company's internet address into this Current Report on Form 8-K. The information available at the Company's internet address is not part of this Current Report on Form 8-K or any other report filed by it with the SEC.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_8-k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_8-k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/0001571049-15-001620-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/0001571049-15-001620-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Cyclacel Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US23254L3069"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US23254L3069}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 04, 2015 12:08 ET (17:08 GMT)\par \par \uc2 Document DJDN000020150304eb34002ss\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Successfully Navigating the New  \highlight22\uc2 Launch \highlight\uc2  Landscape in the Biopharmaceutical Marketplace\b0\par\par\uc2 217 \uc2 words\par \uc2 4 March 2015\par \uc2 Biotech Week\par \uc2 BIWK\par 1025\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015, Biotech Week via NewsRx.com   \par \par \uc2 2015 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Recent biopharmaceutical product \b \highlight22\uc2 launches\b0 \highlight\uc2  have produced both noteworthy failures and successes. As \b \highlight22\uc2 launch\b0 \highlight\uc2  landscapes continue to evolve, organizations are constantly rethinking the factors that play the biggest role in the current \b \highlight22\uc2 launch\b0 \highlight\uc2  environment.\par \par \uc2 According to research by benchmarking firm, \uc2 Best Practices, LLC\uc2 , pricing is one of the key \b \highlight22\uc2 launch\b0 \highlight\uc2  issues organizations struggle with. When asked what minimum level of superior efficacy is required to charge more than a branded competitor, two-thirds of participating \b \highlight22\uc2 launch\b0 \highlight\uc2  leaders indicated a \b \highlight22\uc2 new product\b0 \highlight\uc2  requires at least 11 percent to 30 percent superior efficacy in order to win a higher price in a competitive market.\par \par \uc2 The related report, "Success Factors and Failure Points in Biopharmaceutical Product Launches: An Updated Road Map for Strong Market Entry," presents a framework for launch success: the ability to differentiate, a defined target patient population, investment in launch activities, engagement of thought leaders, education of key stakeholders, demonstration of value, utilization of new technologies and avoidance of launch pitfalls.\par \par \uc2 Keywords for this news article include: Drugs, Therapy, \uc2 Best Practices Llc\uc2 , Biopharmaceuticals.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document BIWK000020150227eb34000ry\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 BioDelivery Sciences to Present at the 27th Annual ROTH Conference\b0\par\par\uc2 768 \uc2 words\par \uc2 3 March 2015\par 07:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 RALEIGH, N.C., March 3, 2015 /PRNewswire/ -- \uc2 BioDelivery Sciences International, Inc\uc2 . (\uc2 NASDAQ\uc2 : BDSI) announced that \uc2 Dr. Mark A. Sirgo\uc2 , President and Chief Executive Officer of BDSI, will present at the 27(th) Annual ROTH Conference. The presentation is scheduled for Monday, March 9, 2015 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) at The \uc2 Ritz-Carlton\uc2 , Laguna Niguel, in Dana Point, California.\par \par \uc2 Dr. Sirgo will be discussing progress with BDSI's commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  of BUNAVAIL(R) , the recent submission of a \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) for BELBUCA(TM) (formerly BEMA Buprenorphine) for chronic pain, and the timeline for Phase 3 data for Clonidine Topical Gel for the treatment of painful diabetic neuropathy.\par \par \uc2 The presentation will be webcast live and can be accessed at {\field{\*\fldinst{HYPERLINK "http://www.bdsi.com"}}{\fldrslt{\cf2 \uc2 www.bdsi.com}}}\uc2 . For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.\par \par \uc2 About \uc2 BioDelivery Sciences International\par \par \uc2 BioDelivery Sciences International, Inc\uc2 . (\uc2 NASDAQ\uc2 : BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA(R) ) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.\par \par \uc2 BDSI's development strategy focuses on utilization of the \uc2 FDA\uc2 's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.\par \par \uc2 BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.\par \par \uc2 BDSI's headquarters is located in Raleigh, North Carolina.\par \par \uc2 For more information visit {\field{\*\fldinst{HYPERLINK "http://www.bdsi.com"}}{\fldrslt{\cf2 \uc2 www.bdsi.com}}}\uc2 .\par \par \uc2 BDSI can now be followed on \uc2 Facebook\uc2  (\uc2 Facebook.com\uc2 /BioDeliverySI) and \uc2 Twitter\uc2  (\uc2 Twitter.com\uc2 /BioDeliverySI)\par \par \uc2 Cautionary Note on Forward-Looking Statements\par \par \uc2 This press release, the presentation described herein, and any statements of employees, representatives and partners of \uc2 BioDelivery Sciences International, Inc\uc2 . (the "Company") related thereto (including, without limitation, at the presentations described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes, " "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the \uc2 Securities and Exchange Commission\uc2 . Actual results (including, without limitation, the results of the commercial launch of BUNAVAIL and the Company's clinical trials for, and \uc2 FDA\uc2  review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.\par \par \uc2 BDSI(R) , BEMA(R) and BUNAVAIL(R) are registered trademarks of \uc2 BioDelivery Sciences International, Inc\uc2 . The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by \uc2 BioDelivery Sciences International, Inc\uc2  All other trademarks and tradenames are owned by their respective owners.\par \par \uc2 (c) 2015 \uc2 BioDelivery Sciences International, Inc\uc2 . All rights reserved.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20110217/CL49801LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20110217/CL49801LOGO}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/biodelivery-sciences-to-present-at-the-27th-annual-roth-conference-300044079.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/biodelivery-sciences-to-present-at-the-27th-annual-roth-conference-300044079.html}}}\par \par \uc2 SOURCE \uc2 BioDelivery Sciences International, Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020150303eb330006a\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Pacira Pharmaceuticals\uc2  Files 8K - Other Events >PCRX\b0\par\par\uc2 247 \uc2 words\par \uc2 2 March 2015\par 17:59\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Pacira Pharmaceuticals Inc\uc2 . (PCRX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on March 02, 2015.\par \par \uc2 Pacira Pharmaceuticals, Inc\uc2 . today announced the receipt of a Complete Response Letter (CRL) from the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) following a review of its supplemental New Drug Application (sNDA) for the use of EXPAREL(R) (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia. Pacira will immediately schedule an End-of-Review meeting with the Division of Anesthesia, Analgesia and Addiction Products of the Center for Drug Evaluation and Research to discuss the contents of the CRL.\par \par \uc2 A copy of the press release relating to this announcement is attached as exhibit 99.1 hereto.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1396814/000110465915015879/a15-5734_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1396814/000110465915015879/a15-5734_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1396814/000110465915015879/0001104659-15-015879-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1396814/000110465915015879/0001104659-15-015879-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Pacira Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US6951271005"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US6951271005}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 March 02, 2015 17:59 ET (22:59 GMT)\par \par \uc2 Document DJDN000020150302eb32004mg\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw300\pich25\picscaley100\picscalex100\picwgoal4500\pichgoal375
47
49463839612C011900F7FF00009CBA55C0D9DCF1F631ACC59BD9E8E5F5F9F8FCFDA4DAE53EB0C832B5D1009EC307A9CAF1FAFC5DBCD10086ABEEF8FA00A2C687
CDDD80D0E3A0DCEAC2E9F12AA9C4FAFDFE3FB9D458BBD1D3EDF2F4FAFC17A2BF92D6E6CCEAF072CADFA3DDEAAADCE746BBD5B0DFE80099C0009AB9ABE0ECC0E5
EDD8F1F6BBE6F000A2C5E3F2F6E0F4F87CCDE0009AC1059EBC009CC27BC8DA24A6C2B8E5EF6AC8DE00A5C800A3C63EADC6D4EEF492D1E0ECF7F91DA5C1D0EEF5
C4E6EEF0F9FBB4E0EA4CBDD74CB5CCADDEE90095BEECF8FBF6FCFDE9F6F98BD3E596D7E772C4D717ADCC81CADB00A0C51DAECDB0E2ED0EA1BE96D3E100A0C5D7
EFF498D9E800A4C744ADC61BA4BF8FD5E643B1C96AC1D5E8F6F857B8CEB7E1EA9BD6E3169EBC94D7E7009BC2C8E8EF04A6C9D5F0F60081A748B4CBA5DEEB22A2
BECCECF42BB3D0E4F4F80094BE0093BCEBF7FA0094B50097B694D3E1B5E4EE49B4CC63C5DC0094BD0CA7C984D1E3F2FAFB0095B68CCFDE65C6DC76CCE0008CAF
D2EDF2CAE9F0F6FBFC25A8C3E8F7FAC6EAF200A0C466BFD37CCADF6CC3D62FA7C20090B226B1CFA1D8E464BCD187D3E438B6D28FD0DF56B6CC0C97B7B4E3EE7C
CDE172C2D55BC2DA7CCDE0DDF3F765BACFCEEBF191D1E00098B8F0FAFC68C0D4CBECF30090BB0FACCBBDE4ED74C5D8BBE3EC61C4DB5DC3DA3AAFC80094B40096
BF00A1C5EBF8FB13A8C90093B4C9E7EE12ACCC00A1C645B2CA4BB3CA36AEC719ACCB00A8C900A2C7009EC3009CC2009AC1009FC4009DC3009EC4009CC2FEFFFF
FCFEFE009CC3FDFEFFFFFFFFFDFEFE0097BF009DC2FBFEFEF9FDFD009BC1009FC4FAFDFD79CCE0009DC4009FC5C8EBF3C2E3ECFEFEFF79CDE19DDBE900A3C7E3
F3F7009DC376C6D8009DC2009AC20099C0E1F3F74DB5D150BED7009FC37CCEE19FDBE9B2E3EE62BED3C0E2EBACDFEB009FC4BEE7F0009CC2B9E2EBE7F5F8EAF5
F8C6E7EE4FB6CD00A2C500A1C536A3C049B1CE7CCBDF3BA6C1007EA627A4C096D8E739B7D37CC3D678CDDF54BFD8A7DFEB03A4C80092B387D2E351C0D913ABCC
17A9CA6FC3D69ED7E4FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34423839384231373531444631314536383342314337334644453946314437322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3442
383938423138353144463131453638334231433733464445394631443732223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3442383938423135353144463131453638334231433733464445394631443732222073745265663A646F63756D656E744944
3D22786D702E6469643A3442383938423136353144463131453638334231433733464445394631443732222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000002C01190040
08FF00FF091C48B0A0C18308132A5CC8B0A1C38710232EDC25828BC48B18336ADCA8704AAE70B472850C17CEDAA4515FC249833061203D5B2AA519E1102C5C2E
534604DAA1412B1C146B73E6AC092A34580D0EBC2E8CCB252D9DBD81C4428CA3D5939DC000D6487E91316369AE5E28FEAD40638DAA9A650467080169ADCEB081
4398C00C67ABD2C05F17B2862B46818DB58F3669259325638A349222BFC43A3170C5BD625455CA0AD470178837066FC42882D002192A029FFC213610530C0BFF
7A3868F04B603937A1FE19F81361A0AF4C070476706240839B4FFFC891E823F040265F03239CFEF74407691366FE98903DE0C9BF0C24FCD8CE21100429D21D62
C0FFB3F86F4003819BAA0CECE2C6C0401864086A1974E35F9967139E95416D5B9C94FC4DA0E0C504F959018841451080DF33F69C801F81104248803D69FC6301
0AFF4518A1148110C3C011042AA881413B2C42E0331FF0C246370448584602D6F492803D3D1444CC0D2D6AF88C0C2BF862800C5E10E0458D02156005016809C4
40091942B8880004F5304186F1A0C0DF41966186102FC4B8C7D02E234A048C971219004C46BC1840264705ED62079B70C629E79C74D669E79D782A54434F2A99
328397C3E4F3572FD0B434102F33A8815849CE1064413DC1F00992A4208D53891F17A434A94D24F5948B10D0A03290053FE84592106510148F1ABD2046554F91
59FF538D5D04F9C2881087F129694FD664F38F2F89F6D4CB02F5FD5ACF1CCAEC458306BFC8634B4FB6A8B3C23FCF08F18532E38CD3C43F058C32C3B40359665D
413DB8704E9445EC62211957309403095A4224C01E7B70269009008091679E5390148E3ABCFC130F2DE340C1692FB4A46A8F29914D4A29146B88F30F1BF57880
CCC5C83883CC363F84448D2C9048451535057F248D3450103CCE3225ACD1E9CB808164CB32469842D24FE3F8648D2D06872344580349300755508C731849E324
F3513047CCD0AA10F6F8E24CCE360573CF301A4063CB170B00328C5A0627630DD5E35443C197971974890E6C10948113E5AC0BDA3F5A00E1B6139CE570873F03
69FFE00412131FB205421DE8602F2F7F7401C025024D731E42410C00030C02C1B0C900C41964001E9940F98F000328F1381EA06090C840A0A8275015800B74CC
06B5ED2B3B9CBB7890CE02613042EBEC6CEEE2C3E9BC072F3C437544B24D247510512B05ED441289043B14C44B3CED1C4FC907EA16B48204941CEFFCF7C653D2
830513740FBEF3DE1BC158411AA01F0921322047D0105294C18117F8E74FC084F21BD4431D47CA1FFE38F0010E9C4D207ED80625DE97A481D8A379943082069E
D13C05D6216002F9453C8C17897658A112F1C8C795FE21AE831820113A4000199CA088F5F102138D60880636319D88A46113711B4814B0E0B9E115440B7118A1
43FFFAE5AFAA790035825249A108B28D9A88441A22B1851706D2831A204D1447F00207B6C801296CC3034360805242928B055C2001F24043CFA4D10A2B643004
9A42584F8A518281C8C1141FC9852C12C0087920020AD2088929E05090009C8C245348802213A00E6AF4641CA2D84520E6F0919EA88190C4580064A8F2052688
4120525883C168218D2F7CC416C120A4424A5810CDE4D0201688832B06D2810654C11000100106DF75805AEA00074412081F2A10032738E24D02B904027C7087
F57D0200ABA0A2239C10830A6440374E8886400C1081067849005DD04E140A810145C0C211153200297CF01E2C20F30103D017171EF78F7E44210354D0D73FA2
80FF810D54A1025118881525630528688A942021D4110462045B88641CD928C0099C059235A8F20101A00314A0A08E5674541D5030992C9AF08394F4620ADB1A
C80FE6A28648FC630643CB852D4491861BF08460B6E0842F98F0179F456F201E5003AFDC321023CCC291C54043FF76208BA9108C0D4A51C928A0819840967214
4CA0463116231062780026919146121E5019108C8B20AEFC0731FAB0857E6CA06D9E991B125497CC2A90F55DC0FBC703622089D46462035740000260E10E1024
530759F88706EEC08372A822738D28052C044B0A52D860447EF8431488E1864AA4C105BF8802006A040C3C74C1053168C439CEF40F5E00C02257E84311DC9083
22FF540099A91B48152827100B342013B020C5606DA0041EFC431D461B872082190F2814831AD2B085357640814E48831A29A9C70CE420873CFC401AC5086430
CEB0026B9C4C1AE3E8C5C9D4DB8B7158230969C80B7AE76BB45EA8B718C18845082215DD29E4410EA2E8EE0554D6DEAC8E8DBEEAE553B4C83A906D74E20BF4A5
AF7B85A0072968631C42080069FC50836C052300AD39832C6C318E2920C21AE1CD0A6304108CF08E630D01E81F96CC7A90271CE209458806285451430B90621D
0219C600F2C5861DD7D01C2E7005064480874744A035FF38412960108D1BE8E00A61EA03DE6C838E3D7440200FA8002CA290062C3CA2420381452618EC873DD0
D3FF0F8678C235A2C186D065EF1F6F180391FC100312B0F61F9B70C1405C80058268800403884234AEA0831BACC9879016C82E4681C76224617D9196489632CD
E94E7BFAD3A00EB5A8474DEA52EFCB323848480E3A70896B14444D0DF183101B32A68200C30F7FCEB4018209113EE5621C33505E90F5F097714083030511832D
5A150E6A08E24004A9041340524449FDFA041A6042310023127FE5221750E0870C0AC2093C7EBB1834B0974000918D1713452843194A3A8E30EB1530020AA618
4A50D630944E58830E3F0D84290E638A7A904900E9A54B0D865006A391721CA922A1144692AD12EC401DB228004158591018DC21141DE0031FAA4086331DA302
40FF5E88390E810789DCE01D8580F23FB6C0584F27820B6F89C8407B220D21788034BC48E24A0C251001B4F765D2980503A828886E5B4308423085D4A15E8C62
9C0053540BC73882618D9DE5CAD829FDC70E4C451269C8229872A0A45682C175F3767B0D071CC83200F9C8AE73BD922A09C03F3441326A0B21E073E894A5A1B4
82F092C41AF5B0C2D8A0205D55FEA20005B83309695C103EB0AD33EC2288013AF08D57FE230799B0480FDA66901C30E31CA4D1210954310828E34B9F5D3D0733
B8834001DCD90FC8FC551A58AB812D6C8107A9E7C503AE6480DCFFA31CDAE90D1551E387D4CB8607CC089340065AC47098C2030688473098B2448154622EE89D
42FF48ACB12C81F480AA04DB060A64C07EF68BE3031233803C8AA175691040136C18C235D090750C08240D5AF711060512D2100BA841043F1029E1100C65F000
6C907FFA50132561047FB60B8C102904F30C6C800A8060071700135F214163E429B69007BBF001646769EB030C09600A3D032DC1D00D68132F039156071157E6
E70466D0073D10047BC04E7A950908E00D6FB0056E30085E1205AA800759100D96E002A9573844000A1BD01A5B004DDB0400969006E5800777A02F1AA0037CB3
4FF8B0074482036DB00BBCE0024FD00C8A6509B1030085B04DAA7008E7F20FFEB00135E20D82261031A0050D300F01C5002E600302F00011B0070FD01AE21733
B9FF220D659150D02005E6370B87310EACB00B43200887110C0BA01DBC9007C1300ED0250DBD005D4EA575E1B00322230DD0C00D7071019B140ED8F00F80005E
2AB10F60B214B4600D09C00B43002396243192466922610D8B8041FF100834604AE1F0054330106C9004F4B7179550066065784CC10A36815E5A7169034104F2
50168FB4080EC17135B8197AD500F0600618405638F80F0D304B35F8569FB707E4601B2ED05739E00678500E2AA00245700573F80F1D50059C01034EE00B3C30
1C95A305451090E5A0048A781D150904222002E8A0577B501FE5B0075860018FD6036E301D4A00033C000BBFB00B2E003C73B51E4A302A0810070F100D2AD003
79FF88197B02120B400C13400B5FD0330438056E64000B602AB4600B73F111D68008A8F10BC410081F5006F65095F650021E903366D70D21407FD2300533000E
25000ECFC07F36310732300CE9508D2A510C5F002B3E2307BE30094E140C1C0007E0100414500F91680A5ED03F93508D5F70011F2096E02007357089092003B2
1048B2A001F230159C3207DB500049600BC5E04916E20178D46C9CF20521A08C09B169AD140389351019A003DC114B73D30F1540106B735724401E9FF707FC88
0F0790266A6200185438A7E90F15600224A04F4AE00A1AB09B6A02659BD00851701ABC000BD7A004AD23104580097160080EE003D9130148106676600115C003
3EFF101F02F192AB339D16000BFDE00B7E6000C7C09BEAD288B95003447204EA001936310EB6B003C0C00A36431556454A72F46B4CC00B95A0066C670DA6600D
6CB7A065470325D0959B426D9CA2750BB00D8DC973EA655550140ECA2004A2C09720C16D14FA116BC009041154DE566D9D620DF6C0080E150C1AA76C0FF50512
73024DF505AC9006F9200489210BE2609625B100A4379A94676855906A03E10D577026F108023AC060FFC0A467D2037B8001DAF10FC2391D061003D330107620
02ACB53645CA070E7008D7F40F89D006C72010BC100AB967074E900940D80787300044D20CE5702545A00AB4A2015D968FFFC003007007526A9EFFC03AE10203
A4FFE0253DD803675203D030A953B0740321053430A9EA4003562015933A0E8B6000C36001A46A0172300E10000D82F003672008D090AAAF3AA9B05A03FC5002
067001AE0AABB21AAB3470011CB000EAF0A904E00BA58A3593600BA94A0B3F30034C3005B10A0D1EA195E90034351802F7A0ABA99AAA53900A21A00975600B5A
0309412601B4A00E442A1062E009AE0A0D50D00AD0A00E74F0490C85AAAA3A0E67207306818EE19208F0E00A8C56431682058A30100C8001AF80005500B03900
045970091530003E80AF601003408000A41005AC15053449103C000FC5F20F69800036000431100A927700D3D90C710084FFF00B37E00A076B033030427D0004
7F5B16012D371078409EFF4006393B1069400AAF60031BD001F86A6A78E2016B110C34F0B148BB7147FAB4523BB5C3B30BF5B006A8240BF24AB52474003FCBB5
601BB674E2B2250007DD4001590AB64D28B66CDBB66EFBB670AB110101003B}}
\par\par \b \uc2 Oculus Innovative Sciences \highlight22\uc2 Announces New \highlight\uc2  Animal Healthcare Division and  \highlight22\uc2 Launch \highlight\uc2  of MicrocynAH(R) Advanced All-Animal Healthcare Products\b0\par\par\uc2 1,078 \uc2 words\par \uc2 26 February 2015\par 08:08\par \uc2 GlobeNewswire\par \uc2 PZON\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 GlobeNewswire, Inc. All Rights Reserved.   \par \par \uc2 Oculus Innovative Sciences\b \highlight22\uc2 Announces New\b0 \highlight\uc2  Animal Healthcare Division and \b \highlight22\uc2 Launch\b0 \highlight\uc2  of MicrocynAH(R) Advanced All-Animal Healthcare Products\par \par \uc2 \f2 \par    -- \f28 \b \highlight22\uc2 \f2 New products\f28 \b0 \highlight\uc2 \f2  include multiple Microcyn(R)-based all-animal wound and skin \par       care liquids and hydrogels as well as all-animal ophthalmic gel \par  \par    -- Current \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  in the United States and Canada is intended to be followed \par       by summer expansion into Europe \par  \par    -- MicrocynAH(R) advanced animal healthcare products' safety and efficacy \par       profiles validated by two major animal healthcare studies and over 30 \par       human studies \par  \par    -- MicrocynAH(R) products provide superior shelf stability, photo stability, \par       safety profile and pricing \f28 \par \par \uc2 PETALUMA, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- \uc2 Oculus Innovative Sciences, Inc\uc2 . (\uc2 Nasdaq\uc2 :OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of the company's new animal healthcare division. In conjunction with the unveiling of the new division, six new MicrocynAH(R) advanced all-animal healthcare products were commercialized for the care of wounds, skin and eyes in the United States and Canadian markets. Expansion into the European market is targeted for this summer.\par \par \uc2 Oculus has partnered with SLA Brands, one of the animal healthcare industry's leading sales organizations in the United States and Canada, to bring the new MicrocynAH(R) products to market.\par \par \uc2 "We are very excited to be partnering with an innovator in animal healthcare and see tremendous opportunity in establishing the MicrocynAH family of products as the category leader in animal wound and skin care, " said Michael Lasky, a partner in SLA Brands.\par \par \uc2 The first U.S. products include multiple sizes of the MicrocynAH Wound & Skin Care liquids, MicrocynAH Wound & Skin Care Hydrogels and MicrocynAH Ophthalmic Gel. In March, the company also intends to introduce two new MicrocynAH Farm and Ranch products for larger animals.\par \par \uc2 "Our inaugural portfolio of advanced all-animal MicrocynAH products formulated with our proven Microcyn(R) Technology platform are second to none," said \uc2 Dan McFadden\uc2 , Oculus' newly appointed VP of animal healthcare. "The Microcyn technology, with over 45 patents, 10 \uc2 FDA\uc2  clearances, and 10 CE marks, has proven itself successful in over 30 human and animal clinical studies from around the globe. At the same time, our R&D team is not resting on its laurels. As I speak, they are pioneering major advances in the key hypochlorous acid ingredient that competitors are only attempting to emulate--and not with a great deal of success. This includes significant improvements in product stability as well as in the actual chemistry--including the removal of bleach from the original liquid formulations. And the MicrocynAH pipeline is robust with new product offerings that we intend to make available over the coming year. In other words--and pun intended--the family of MicrocynAH products will not be a one-trick pony."\par \par \uc2 For more information or to order in the United States and Canada, distributors and retailers can phone SLA Brands at (415) 747-1001. More information and a consumer online store are also available at {\field{\*\fldinst{HYPERLINK "http://www.microcynah.com"}}{\fldrslt{\cf2 \uc2 www.microcynah.com}}}\uc2 .\par \par \uc2 Animal Healthcare Market\par \par \uc2 According to the \uc2 Freedonia Group\uc2 , an international industry market research firm, the demand for animal health products in the United States is forecast to increase 3.9% annually to $12.7 billion in 2016. Animal healthcare is a relatively recession-resistant industry as it is regarded as a necessary expense of animal ownership or husbandry. Furthermore, as pet owners increasingly treat their companion animals as members of the family, pets' lifespans will continue to lengthen, driving strong sales of health products.\par \par \uc2 About \uc2 Oculus Innovative Sciences, Inc\uc2 .\par \par \uc2 Oculus Innovative Sciences\uc2  is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at {\field{\*\fldinst{HYPERLINK "http://www.oculusis.com"}}{\fldrslt{\cf2 \uc2 www.oculusis.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of \uc2 Oculus Innovative Sciences, Inc\uc2 . and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "believe," "preparing," "anticipates," and "launch," "create," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's common stock and warrants may be delisted from \uc2 NASDAQ\uc2 , the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the \uc2 Securities and Exchange Commission\uc2  including its annual report on Form 10-K for the year ended March 31, 2014. The Company disclaims any obligation to update these forward-looking statements, except as required by law.\par \par \uc2 Oculus(R), MicrocynAH(R) and Microcyn(R) Technology are trademarks or registered trademarks of \uc2 Oculus Innovative Sciences, Inc\uc2 . All other trademarks and service marks are the property of their respective owners. High-resolution product photos are available. Please call or email request.\par \par \uc2 \f2 \par CONTACT: Media and Investor Contact: \par          \f28 \uc2 \f2 Oculus Innovative Sciences, Inc\f28 \uc2 \f2 . \par          \f28 \uc2 \f2 Dan McFadden\f28 \uc2 \f2  \par          VP of Public and Investor Relations \par          (425) 753-2105 \par          dmcfadden@oculusis.com \f28 \par \par \uc2 Document PZON000020150226eb2q00030\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release:  \highlight22\uc2 Launch \highlight\uc2  of Turing Pharmaceuticals  \highlight22\uc2 Announced -  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Drug \highlight\uc2  Company to Focus on Treating Unmet Medical Needs Across Broad Therapeutic Areas\b0\par\par\uc2 755 \uc2 words\par \uc2 24 February 2015\par 11:56\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.  \par \par \b \highlight22\uc2 Launch\b0 \highlight\uc2  of Turing Pharmaceuticals \b \highlight22\uc2 Announced - \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Drug\b0 \highlight\uc2  Company to Focus on Treating Unmet Medical Needs Across Broad Therapeutic Areas\par \par \uc2 Turing \b \highlight22\uc2 launches\b0 \highlight\uc2  with three major product acquisitions: intranasal ketamine program, Syntocinon(R) Nasal Spray, and Vecamyl(R); company \b \highlight22\uc2 introduces\b0 \highlight\uc2  senior leadership team\par \par \uc2 PR Newswire\par \par \uc2 NEW YORK, Feb. 24, 2015\par \par \uc2 NEW YORK, Feb. 24, 2015 /PRNewswire/ -- Turing Pharmaceuticals AG announced its official launch today, along with news of three acquisitions for its commercial operations and development pipeline. The company also introduced its senior management team.\par \par \uc2 New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options.\par \par \uc2 Turing's Founder and Executive Chairman is \uc2 Martin Shkreli\uc2 , who has a history of success in the drug industry as founder and former CEO of Retrophin, Inc. (\uc2 NASDAQ\uc2 : RTRX). At \uc2 Retrophin\uc2 , Mr. Shkreli led the acquisition of three key products in the six months following the company's IPO in 2014, and significantly accelerated their commercial success.\par \par \uc2 In addition to Mr. Shkreli, Turing has assembled a management team comprised of senior executives with extensive experience in the drug industry, including: \par \par \uc2 \f2 \par    -- Howard Dorfman -- \f28 \uc2 \f2 SVP\f28 \uc2 \f2 , General Counsel; Mr. Dorfman formerly worked at \par       \f28 \uc2 \f2 Ferring Pharmaceuticals\f28 \uc2 \f2  and \f28 \uc2 \f2 Bayer Pharmaceuticals\f28 \uc2 \f2  (US) as well as at law \par       firm \f28 \uc2 \f2 Ropes & Gray\f28 \uc2 \f2  \par  \par    -- Hass Patel, Ph.D. --VP for Chemistry, Manufacturing and Controls; Dr. \par       Patel was previously with Pharmasset, \f28 \uc2 \f2 Reliant Pharmaceuticals\f28 \uc2 \f2  and \par       \f28 \uc2 \f2 GlaxoSmithKline\f28 \uc2 \f2  \par  \par    -- Nicholas Pelliccione, Ph.D. -- VP, Regulatory affairs; Dr. Pelliccione \par       was formerly with \f28 \uc2 \f2 Schering-Plough\f28 \uc2 \f2 , \f28 \uc2 \f2 Regado Biosciences\f28 \uc2 \f2 , Aeterna Zenaris \par       and \f28 \uc2 \f2 Chugai Pharma\f28 \uc2 \f2  USA \par  \par    -- Michael Harrison -- Chief Financial Officer; Mr. Harrison was formerly \par       with \f28 \uc2 \f2 Retrophin\f28 \uc2 \f2  \par  \par    -- Nancy Retzlaff -- Chief Commercial Officer; Ms. Retzlaff joins in early \par       March from \f28 \uc2 \f2 Mesoblast Ltd\f28 \uc2 \f2 .; she was previously with \f28 \uc2 \f2 Pfizer\f28 \uc2 \f2 , \par       \f28 \uc2 \f2 Schering-Plough\f28 \uc2 \f2  and Bayer \par  \par    -- Megan Roberts, Ph.D. -- VP and Product Leader for Vecamyl; Dr. Roberts \par       previously worked at \f28 \uc2 \f2 Genentech\f28 \uc2 \f2  and BioMarin \f28 \par \par \uc2 \f2 "Our success in bringing to market a line of new therapeutic products very much depends on the caliber of our people," Mr. Shkreli said. "We're thrilled to have assembled such a strong bench of senior talent for our launch and look forward to announcing additional key positions in due course."\f28 \par \par \uc2 \f2 Simultaneous to its launch, Turing announced the acquisition of three major assets from \f28 \uc2 \f2 Retrophin\f28 \uc2 \f2 : an intranasal formulation of ketamine, Syntocinon(R) (oxytocin nasal solution) and Vecamyl(R) (mecamylamine HCl tablets).\f28 \par \par \uc2 \f2 Turing is developing its new intranasal formulation of ketamine for a variety of psychiatric indications. The company is making significant investments in a novel delivery mechanism and other innovations to develop ketamine for the treatment of several serious psychiatric conditions for patients who currently have limited treatment options, and expects to commence clinical trials in the coming year.\f28 \par \par \uc2 \f2 Turing's plans further include a development program for Syntocinon(R) in addressing multiple indications across several therapeutic areas.\f28 \par \par \uc2 \f2 The acquisition of Vecamyl(R) provides Turing with its first FDA-approved product and revenue stream, which it plans to grow through a robust clinical development and education program.\f28 \par \par \uc2 \f2 Turing's strategic focus is to acquire and advance development of external compounds while also pursuing internal drug discovery through proprietary research and development to best address the needs of diverse patient populations. Reflecting its mission to address unmet medical needs, Turing has also acquired two early-stage compounds to be developed for various orphan drug indications. The company is strongly committed to growing shareholder value.\f28 \par \par \uc2 \f2 "Our goal is to build a diverse portfolio and pipeline of therapies that can make a significant difference to patients," Mr. Shkreli said. "We are creating a strong, experienced team at Turing with a solid track record of success to execute on our objectives."\f28 \par \par \uc2 \f2 About Turing\f28 \par \par \uc2 \f2 Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in New York City. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. For more, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.turingpharma.com"}}{\fldrslt{\cf2 \uc2 www.turingpharma.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Allan Ripp 212-262-7477 aripp@rippmedia.com\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit: \f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/launch-of-turing-pharmaceuticals-announced--new-drug-company-to-focus-on-treating-unmet-medical-needs-across-broad-therapeutic-areas-300040452.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/launch-of-turing-pharmaceuticals-announced--new-drug-company-to-focus-on-treating-unmet-medical-needs-across-broad-therapeutic-areas-300040452.html }}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE Turing Pharmaceuticals AG\f28 \par \par \uc2 \f2 /Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.turingpharma.com"}}{\fldrslt{\cf2 \uc2 http://www.turingpharma.com }}}\uc2 \f2 \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 February 24, 2015 11:56 ET (16:56 GMT)\f28 \par \par \uc2 Document DJDN000020150224eb2o002t5\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 NTRR: New Congressional Bills Could End Federal Prohibition of Cannabis\b0\par\par\uc2 554 \uc2 words\par \uc2 24 February 2015\par 05:00\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2015  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par TAMPA, Fla.--(BUSINESS WIRE)--February 24, 2015-- \f28 \par \par \uc2 \f2 As \f28 \uc2 \f2 Neutra Corp\f28 \uc2 \f2 . (OTCBB:NTRR) continues to develop \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  to serve the fast-growing U.S. cannabis industry, two new bills were \f28 \b \highlight22\uc2 \f2 introduced\f28 \b0 \highlight\uc2 \f2  to Congress last week that could put cannabis on the fast track to nationwide legalization.\f28 \par \par \uc2 U.S. Rep. \uc2 Jared Polis\uc2 ' (D-CO) Regulate Marijuana Like Alcohol Act proposes to legalize cannabis without fear of federal intervention, while Rep. Earl Blumenauer's (D-OR) Marijuana Tax Revenue Act seeks to tax cannabis sales at the federal and state level.\par \par \uc2 The new legislation is only the latest sign of shifting attitudes toward cannabis consumption in the U.S., where the majority of Americans support repealing criminalization to boost tax income and lower crime rates. If passed, the new bills will make adult access to cannabis hassle-free, increasing NTRR's value in the industry.\par \par \uc2 "This is huge news for companies like ours that are developing products for this industry," said NTRR CEO \uc2 Chris Brown\uc2 . "As fast as demand has grown for cannabis-related products in recent years, it is certain to skyrocket if the Federal government effectively legalizes the plant. Congress is now on the cusp of making that vision a reality, and NTRR will be there to capitalize by serving the emerging needs of a massive new consumer group."\par \par \uc2 The bills will be heard before Congress in the latest term.\par \par \uc2 NTRR has already taken measures to position itself as a leader in the U.S. cannabis market by marketing and developing new indoor horticultural innovations to make cannabis cultivation easier and more efficient than ever before. Last week, the company announced that its joint venture partner, Vertigo Technologies, Inc., sold its first self-contained, indoor horticulture system to a California cultivator.\par \par \uc2 About \uc2 Neutra Corp\uc2 .\par \par \uc2 Neutra Corp\uc2 . is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, \uc2 Neutra Corp\uc2 . plans to compete alongside \uc2 GW Pharmaceuticals\uc2  (OTCBB: GWPRF), \uc2 INSYS Therapeutics, Inc\uc2 . (\uc2 NASDAQ\uc2 : INSY) and \uc2 ENDEXX Corp\uc2 . (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit {\field{\*\fldinst{HYPERLINK "http://www.neutracorp.com"}}{\fldrslt{\cf2 \uc2 www.neutracorp.com}}}\uc2 .\par \par \uc2 Notice Regarding Forward-Looking Statements\par \par \uc2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.\par \par \uc2 Document BWR0000020150224eb2o0001s\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Actavis \highlight22\uc2 launches \highlight\uc2  generic Pulmicort RESPULES\b0\par\par\uc2 134 \uc2 words\par \uc2 13 February 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Actavis\uc2  (ACT) announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  its generic version of \uc2 AstraZeneca\uc2 's (AZN) Pulmicort RESPULES 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) \uc2 AstraZeneca\uc2 's request for a permanent injunction is denied. \uc2 Actavis\uc2 ' Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for its generic version of Pulmicort RESPULES received final approval from the \uc2 U.S. Food and Drug Administration\uc2  in August 2012. Pulmicort RESPULES is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended June 30, 2014 total U.S. brand and generic sales of Pulmicort RESPULES were approximately $1.1B. \par \par \uc2 Document FLYWAL0020150213eb2d007n1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 BioLife Solutions  \highlight22\uc2 Launches \highlight\uc2  New Cell Thawing Media Products in Response to Worldwide Shortage of Dextran Solutions\b0\par\par\uc2 748 \uc2 words\par \uc2 11 February 2015\par 06:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par 10% Dextran 40 in 0.9% NaCl or 5% Dextrose Packaged in Bulk Bag Containers for Cell Preparation \par  \f28 \par \par \uc2 \f2 BOTHELL, Wash., Feb. 11, 2015 /PRNewswire/ -- \f28 \uc2 \f2 BioLife Solutions, Inc\f28 \uc2 \f2 . (\f28 \uc2 \f2 NASDAQ\f28 \uc2 \f2 : BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that it has commenced GMP manufacturing of low molecular weight (LMD) Dextran solutions for use in thawing human cells after cryopreservation. The Company has \f28 \b \highlight22\uc2 \f2 launched\f28 \b0 \highlight\uc2 \f2  these \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  in response to inquiries from numerous customers and clinicians who have been subjected to an extended worldwide shortage of dextran solutions that are used off-label to transition frozen cells to room temperature.\f28 \par \par \uc2 Aby J. Mathew, PhD\uc2 , Chief Technology Officer at BioLife, remarked on the production of these new products by stating, "We have heard from many current and prospective customers in the clinical cell therapy community asking if we can assist them in dealing with the current shortage of dextran solutions used to thaw cells following cryopreservation. We assembled a focused team within BioLife to assess this opportunity and are pleased to be able to offer these critical cell processing media products, manufactured per GMP under the same quality system as our flagship CryoStor(R) cell freeze media and HypoThermosol(R) cell and tissue storage and shipping media".\par \par \uc2 BioLife's Cell Thawing Media products are manufactured per GMP guidelines using USP components, water for injection (WFI) quality water, and are subject to release criteria including sterility per USP <71>, endotoxin per USP <85>, pH, osmolality, and appearance for no visible particulates.\par \par \uc2 Product orders are being accepted at this time, with initial shipments estimated for the week of March 15, 2015. Product information follows:\par \par \uc2 \f2 \par  \par Product Name                       Part Number   Package \par ---------------------------------  -----------  --------- \par  \par Cell Thawing Media 10% Dextran 40  980203       250mL Bag \par (in 0.9% NaCl) \par  \par Cell Thawing Media 10% Dextran 40  981203       250mL Bag \par (in 5% Dextrose) \par  \par To place an order, please call 866.424.6543. \par  \f28 \par \par \uc2 \f2 About BioLife Solutions\f28 \par \par \uc2 \f2 BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol(R) and CryoStor(R) platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.biolifesolutions.com"}}{\fldrslt{\cf2 \uc2 www.biolifesolutions.com}}}\uc2 \f2 , and follow BioLife on \f28 \uc2 \f2 Twitter\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2  from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.\f28 \par \par \uc2 \f2 Media & Investor Relations\f28 \par \par \uc2 \f2 Daphne Taylor\f28 \par \par \uc2 \f2 Senior Vice President, Chief Financial Officer\f28 \par \par \uc2 \f2 (425) 402-1400\f28 \par \par \uc2 \f2 dtaylor@biolifesolutions.com\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/biolife-solutions-launches-new-cell-thawing-media-products-in-response-to-worldwide-shortage-of-dextran-solutions-300034229.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/biolife-solutions-launches-new-cell-thawing-media-products-in-response-to-worldwide-shortage-of-dextran-solutions-300034229.html}}}\par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 BioLife Solutions, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://biolifesolutions.com"}}{\fldrslt{\cf2 \uc2 http://biolifesolutions.com}}}\par \par \uc2 Document PRN0000020150211eb2b00029\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Cogmedix Announces Record Growth in 2014\b0\par\par\uc2 413 \uc2 words\par \uc2 10 February 2015\par 12:57\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 WORCESTER, Mass., Feb. 10, 2015 /PRNewswire/ -- Cogmedix, a wholly owned subsidiary of \uc2 Coghlin Companies Inc\uc2 . and a medical device engineering and manufacturing services provider to a broad range of medical and dental equipment innovators, announced significant growth in 2014. The \b \highlight22\uc2 launch\b0 \highlight\uc2  of several \b \highlight22\uc2 new products\b0 \highlight\uc2  as well as the expansion of several existing programs was credited for this record growth. The leadership team expects several initiatives in business automation to continue strengthening the company's position as the leader in medical device manufacturing.\par \par \uc2 "In 2014, Cogmedix sales grew by 40% while our talented team of caring associates increased by nearly 25%," said \uc2 Matt Giza\uc2 , Vice President and General Manager of Cogmedix. He continued, "Already this year we've added several new roles including associates in quality engineering, manufacturing engineering, product test, production supervision, and program management. This supports our growth and is part of our continued investment in our infrastructure."\par \par \uc2 With a strong product pipeline in several new market segments including imaging, blood management, and various detection and diagnostic technologies, Cogmedix is poised for additional growth in 2015. In January, the company announced it had completed its move to a larger, newly renovated corporate headquarters and state-of-the-art medical device manufacturing facility at 17 Briden Street in Worcester. This new location is adjacent to \uc2 Worcester Polytechnic Institute\uc2  (\uc2 WPI\uc2 )'s Gateway Park and Massachusetts Biomedical Initiatives (MBI). This relocation supports Cogmedix' growth by providing the additional capacity necessary to accommodate expanded complex electro-mechanical finished medical device manufacturing as well as purpose built test labs to support its growing niche in laser and optically based medical devices.\par \par \uc2 About Cogmedix:\par \par \uc2 Cogmedix is a team of talented and caring associates bringing OEM medical technology to life. Providing turnkey manufacturing services to a broad range of medical and dental OEM's, Cogmedix delivers high quality products to market with compliance, competence, and commitment. Cogmedix provides a high level of flexibility in product launch and demand management and aligns itself with innovative companies that maintain similar high standards in honesty and integrity. Cogmedix is a subsidiary of \uc2 Coghlin Companies, Inc\uc2 ., a privately held concept to commercialization firm spanning four generations. Visit Cogmedix and sign up for the e-Newsletter at {\field{\*\fldinst{HYPERLINK "http://www.Cogmedix.com"}}{\fldrslt{\cf2 \uc2 www.Cogmedix.com}}}\uc2 .\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/cogmedix-announces-record-growth-in-2014-300033817.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/cogmedix-announces-record-growth-in-2014-300033817.html}}}\par \par \uc2 SOURCE Coghlin Companies\par \par \uc2 /\par \par \uc2 Document PRN0000020150210eb2a000ki\par }\page {\par\fs20\uc2 Business\par \b \uc2 earnings; \uc2 Amgen\uc2 \u8217\'20\'19s profits soar 27 percent in fourth quarter\b0\par\par\uc2 166 \uc2 words\par \uc2 29 January 2015\par \uc2 Press-Telegram\par \uc2 KRTLB\par 11\par \uc2 English\par \uc2 Copyright 2015, Press-Telegram. All Rights Reserved. Distributed by NewsBank Inc.   \par \par \uc2 Amgen Inc\uc2 . cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.\par \par \uc2 The world\u8217\'20\'19s biggest biotech drugmaker by revenue said it\u8217\'20\'19s starting a cycle of several important \b \highlight22\uc2 new product launches\b0 \highlight\uc2  - big enough that last year it announced major job reductions and other cost cuts to free up money for the \b \highlight22\uc2 launches\b0 \highlight\uc2 .\par \par \uc2 Thousand Oaks-based \uc2 Amgen\uc2  reported net income of $1.3 billion, or $1.68 per share, up from $1.02 billion, or $1.33 per share, a year earlier. The bottom line was boosted by Congress renewing an industry research tax credit at year\u8217\'20\'19s end, retroactive for all of 2014.\par \par \uc2 Revenue totaled $5.33 billion, up 6 percent. Analysts expected $5.2 billion. Enbrel for rheumatoid arthritis and other immune disorders saw sales jump 11 percent to $1.34 billion.\par \par \uc2 Document KRTLB00020150129eb1t00015\par }\page {\par\fs20\uc2 Business\par \b \uc2 Amgen\uc2  tops Street 4Q forecasts\b0\par\par\uc2 650 \uc2 words\par \uc2 28 January 2015\par \uc2 The San Mateo Daily Journal\par \uc2 SANMDJ\par \uc2 English\par \uc2 Copyright 2015 The San Mateo Daily Journal. All Rights Reserved. Distributed by NewsBank, inc.   \par \par \uc2 Amgen Inc\uc2 . cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.\par \par \uc2 The world\u8217\'20\'19s biggest biotech drugmaker by revenue said it\u8217\'20\'19s starting a cycle of several important \b \highlight22\uc2 new product launches\b0 \highlight\uc2  \u8212\'20\'14 big enough that last year it announced major job reductions and other cost cuts to free up money for the \b \highlight22\uc2 launches\b0 \highlight\uc2 .\par \par \uc2 The company also reaffirmed its October forecast for 2015 profit, for revenue of $20.8 billion to $21.3 billion and adjusted earnings per share of $9.05 to $9.40 \u8212\'20\'14 in line with analysts\u8217\'20\'19 forecasts.\par \par \uc2 Amgen\uc2 , based in Thousand Oaks, California, on Tuesday reported net income of $1.3 billion, or $1.68 per share, up from $1.02 billion, or $1.33 per share, a year earlier. The bottom line was boosted by Congress renewing an industry research tax credit at year\u8217\'20\'19s end, retroactive for all of 2014.\par \par \uc2 The maker of injected osteoporosis medicine Prolia said that excluding one-time items, adjusted profit was $1.67 billion, or $2.16 per share. Analysts surveyed by FactSet expected $2.05, on average.\par \par \uc2 Revenue totaled $5.33 billion, up 6 percent. Analysts expected $5.2 billion.\par \par \uc2 Five of \uc2 Amgen\uc2 \u8217\'20\'19s medicines posted double-digit sales increases.\par \par \uc2 Enbrel for rheumatoid arthritis and other immune disorders saw sales jump 11 percent to $1.34 billion. The Neulasta and Neupogen franchise, for boosting low levels of infection-fighting white blood cells caused by cancer and other disorders, posted combined sales of $1.45 billion.\par \par \uc2 Amgen\uc2  just got approval for a new way to administer the drug \u8212\'20\'14 through a skin-patch device that injects the medicine automatically the day after a chemotherapy infusion. That spares weak patients undergoing chemotherapy, particularly those in rural areas, follow-up treks to the doctor or hospital to get a Neulasta injection the next day, or, worse yet, the 11 daily injections of the older Neupogen that are needed after each chemo round.\par \par \uc2 In December, the company got U.S. approval and then launched an infusible drug called Blincyto, for patients with a rare blood cancer in which bone marrow makes defective white blood cells: B-cell acute lymphoblastic leukemia with a genetic abnormality. Blincyto is part of a new drug class that harnesses the body\u8217\'20\'19s immune system to fight cancer.\par \par \uc2 Amgen\uc2  has some other, experimental drugs likely to get approved and launched later in 2015. Those include Corlanor for chronic heart failure, Repatha for lowering cholesterol and, for advanced melanoma, talimogene paherparepvec, which needs a pronounceable brand name.\par \par \uc2 Also Tuesday, \uc2 Amgen\uc2  applied for European approval and full U.S. approval of Kyprolis, a medicine for relapsed patients with the bone cancer multiple myeloma. The drug won accelerated approval in 2012 in the U.S., for patients who had failed after treatment with at least two multiple myeloma drugs. Additional study data, since provided, was needed for broader approval allowing treatment of more patients.\par \par \uc2 \u8220\'20\'1COverall, this was a solid quarter for the company,\u8221\'20\'1D Edward Jones analyst Ashtyn Evans wrote to investors. But she noted the increase in Enbrel sales was mainly due to price increases, and during the fourth quarter, \u8220\'20\'1C\uc2 Amgen\uc2  had negative trial results for an ovarian cancer drug and discontinued development for another cancer product.\u8221\'20\'1D\par \par \uc2 Evans also warned that \u8220\'20\'1Cmost of \uc2 Amgen\uc2 \u8217\'20\'19s sales come from a small group of biologic drugs that could begin to face competition in the next few years,\u8221\'20\'1D including the first biosimilar version of a biologic drug ever approved in the U.S. \u8212\'20\'14 a near-copy of \uc2 Amgen\uc2 \u8217\'20\'19s Neupogen.\par \par \uc2 Meanwhile, \uc2 Amgen\uc2  is one of several companies developing biosimilar versions of rivals\u8217\'20\'19 medicines, with nine different ones in patient testing.\par \par \uc2 In trading Tuesday, \uc2 Amgen\uc2  shares declined 84 cents to $158.89.\par \par \uc2 \u8212\'20\'14\u8212\'20\'14\u8212\'20\'14\par \par \uc2 Follow Linda A. Johnson {\field{\*\fldinst{HYPERLINK "https://twitter.com/lindajonpharma"}}{\fldrslt{\cf2 \uc2 https://twitter.com/lindaj\u8212\'20\'14onpharma}}}\par \par \uc2 Document SANMDJ0020150129eb1s0000l\par }\page {\par\fs20\uc2 Business\par \b \uc2 Amgen\uc2  tops Street 4Q forecasts\b0\par\par\uc2 LINDA A. JOHNSON   \par \uc2 642 \uc2 words\par \uc2 27 January 2015\par \uc2 Corvallis Gazette-Times\par \uc2 CRVLSGT\par \uc2 English\par \uc2 Copyright 2015, Gazette Times. All Rights Reserved. Distributed by NewsBank, Inc.   \par \par \uc2 Amgen Inc\uc2 . cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.\par \par \uc2 The world's biggest biotech drugmaker by revenue said it's starting a cycle of several important \b \highlight22\uc2 new product launches\b0 \highlight\uc2  \u8212\'20\'14 big enough that last year it announced major job reductions and other cost cuts to free up money for the \b \highlight22\uc2 launches\b0 \highlight\uc2 .\par \par \uc2 The company also reaffirmed its October forecast for 2015 profit, for revenue of $20.8 billion to $21.3 billion and adjusted earnings per share of $9.05 to $9.40 \u8212\'20\'14 in line with analysts' forecasts.\par \par \uc2 Amgen\uc2 , based in Thousand Oaks, California, on Tuesday reported net income of $1.3 billion, or $1.68 per share, up from $1.02 billion, or $1.33 per share, a year earlier. The bottom line was boosted by Congress renewing an industry research tax credit at year's end, retroactive for all of 2014.\par \par \uc2 The maker of injected osteoporosis medicine Prolia said that excluding one-time items, adjusted profit was $1.67 billion, or $2.16 per share. Analysts surveyed by FactSet expected $2.05, on average.\par \par \uc2 Revenue totaled $5.33 billion, up 6 percent. Analysts expected $5.2 billion.\par \par \uc2 Five of \uc2 Amgen\uc2 's medicines posted double-digit sales increases.\par \par \uc2 Enbrel for rheumatoid arthritis and other immune disorders saw sales jump 11 percent to $1.34 billion. The Neulasta and Neupogen franchise, for boosting low levels of infection-fighting white blood cells caused by cancer and other disorders, posted combined sales of $1.45 billion.\par \par \uc2 Amgen\uc2  just got approval for a new way to administer the drug \u8212\'20\'14 through a skin-patch device that injects the medicine automatically the day after a chemotherapy infusion. That spares weak patients undergoing chemotherapy, particularly those in rural areas, follow-up treks to the doctor or hospital to get a Neulasta injection the next day, or, worse yet, the 11 daily injections of the older Neupogen that are needed after each chemo round.\par \par \uc2 In December, the company got U.S. approval of an infusible drug called Blincyto, for patients with a rare blood cancer in which bone marrow makes defective white blood cells: B-cell acute lymphoblastic leukemia with a genetic abnormality. Blincyto is part of a new drug class that harnesses the body's immune system to fight cancer.\par \par \uc2 Besides launching that drug soon, \uc2 Amgen\uc2  has some other, experimental drugs likely to get approved and launched later in 2015. Those include Corlanor for chronic heart failure, Repatha for lowering cholesterol and, for advanced melanoma, talimogene paherparepvec, which needs a pronounceable brand name.\par \par \uc2 Also Tuesday, \uc2 Amgen\uc2  applied for European approval and full U.S. approval of Kyprolis, a medicine for relapsed patients with the bone cancer multiple myeloma. The drug won accelerated approval in 2013 in the U.S., for patients who had failed after treatment with at least two multiple myeloma drugs. Additional study data, since provided, was needed for broader approval allowing treatment of more patients.\par \par \uc2 'Overall, this was a solid quarter for the company,' Edward Jones analyst Ashtyn Evans wrote to investors. But she noted the increase in Enbrel sales was mainly due to price increases, and during the fourth quarter, '\uc2 Amgen\uc2  had negative trial results for an ovarian cancer drug and discontinued development for another cancer product.'\par \par \uc2 Evans also warned that 'most of \uc2 Amgen\uc2 's sales come from a small group of biologic drugs that could begin to face competition in the next few years,' including the first biosimilar version of a biologic drug ever approved in the U.S. \u8212\'20\'14 a near-copy of \uc2 Amgen\uc2 's Neupogen.\par \par \uc2 In after-hours trading, \uc2 Amgen\uc2  shares declined 44 cents to $158.45.\par \par \uc2 ___\par \par \uc2 Follow Linda A. Johnson {\field{\*\fldinst{HYPERLINK "https://twitter.com/lindaj_onpharma"}}{\fldrslt{\cf2 \uc2 https://twitter.com/lindaj_onpharma}}}\par \par \uc2 Amgen tops Street 4Q forecasts   \par \par \uc2 Document CRVLSGT020150430eb1r000vv\par }\page {\par\fs20\b \uc2 Perrigo \highlight22\uc2 launches new products \highlight\uc2 , gummy vitamins\b0\par\par\uc2 328 \uc2 words\par \uc2 26 January 2015\par \uc2 Kalamazoo Gazette\par \uc2 KG\par \uc2 1\par \uc2 English\par \uc2 (c) 2015. Kalamazoo Gazette. All rights reserved.   \par \par \uc2 URL: {\field{\*\fldinst{HYPERLINK "http://www.mlive.com/business/west-michigan/index.ssf/2015/01/perrigo_co_launches_generic_cl.html"}}{\fldrslt{\cf2 \uc2 http://www.mlive.com/business/west-michigan/index.ssf/2015/01/perrigo_co_\\b launches\\b0 _generic_cl.html}}}\par \par \uc2 By Al Jones\par \par \uc2 ajones5@mlive.com\par \par \uc2 Perrigo Co. PLC\uc2  announced the launch of two new products, as well as an agreement to produce gummy vitamins and dietary supplements.\par \par \uc2 The store-brand pharmaceuticals maker said it has begun distribution of a 0.05 percent equivalent of anti-itch skin treatment Clobex Spray, used to treat moderate to severe plaque psoriasis in individuals 18 years or older. The launch was agreed upon in a litigation settlement between \uc2 Perrigo\uc2  and \uc2 Galderma Laboratories LP\uc2 .\par \par \uc2 According to \uc2 Perrigo\uc2 , the name-brand product realized about $100 million in sales in a year.\par \par \uc2 Perrigo\uc2  also announced it has launched its therapeutic equivalent to \uc2 AbbVie\uc2 's low-testoterone treatment AndroGel 1.0%, used to treat men who have low or no testosterone.\par \par \uc2 The \uc2 U.S. Food and Drug Administration\uc2  previously approved \uc2 Perrigo\uc2 's new drug application for a testosterone gel 1.0% product. The company announced the product was rated as equivalent to the name-brand product.\par \par \uc2 According to \uc2 Perrigo\uc2 , annual sales of AndroGel 1.0% topped $300 million.\par \par \uc2 Also, \uc2 Perrigo Nutritionals Division\uc2  signed a supply agreement with Oakbrook, Illinois-based \uc2 Ferrara Candy Co\uc2 . to manufacture store-brand gummy vitamins and dietary supplements.\par \par \uc2 According to \uc2 Perrigo\uc2 , the five-year agreement gives it exclusivity on a full line of gummy vitamin, mineral and supplement products using Ferrara's gummy technology and manufacturing capabilities. The products will be sold under the labels of major retailers.\par \par \uc2 According to IRI multi-outlet data, annual sales of vitamin and dietary supplement gummies have been about $625 million and are forecast to reach $1 billion by 2017.\par \par \uc2 Chairman, President and CEO Joseph C. Papa said \uc2 Perrigo\uc2  is excited to add children's and adult multivitamins, calcium, fiber, heart health and letter vitamins to its store brand portfolio.\par \par \uc2 @kz-business @kz-news @kz-river perrigo\par \par \uc2 Document KG00000020150127eb1q00003\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 GlaxoSmithKline\uc2  announces availability of two  \highlight22\uc2 new products \highlight\uc2  for asthma\b0\par\par\uc2 55 \uc2 words\par \uc2 26 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 GlaxoSmithKline\uc2  announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has \b \highlight22\uc2 launched\b0 \highlight\uc2  four inhaled respiratory therapies in the US, all delivered in its Ellipta inhaler. \par \par \uc2 Document FLYWAL0020150126eb1q003c0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Sanovas\uc2  Commercializes Its Breakthrough Device-Reprocessing Product Designed to Identify Poorly Cleaned Medical Devices that Could Trigger Infections\b0\par\par\uc2 587 \uc2 words\par \uc2 26 January 2015\par 08:35\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 SAN RAFAEL, Calif., Jan. 26, 2015 /PRNewswire/ -- In wake of recent headlines about cross contamination of patients by inadequately reprocessed medical devices (see story in \uc2 USA Today\uc2 ), \uc2 Sanovas Inc\uc2 ., a Life Science company accelerating the development and commercialization of next-generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that its MicroCam Inc. subsidiary has commenced commercialization of the MicroCam(TM) System via its OEM partnership with Healthmark Industries, which has \b \highlight22\uc2 launched\b0 \highlight\uc2  its \b \highlight22\uc2 new product\b0 \highlight\uc2 --Flexible Inspection Scope.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20150123/171098LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20150123/171098LOGO}}}\par \par \uc2 "Sophisticated modern surgical instruments, such as endoscopes, have revolutionized surgery, of course. But they are very difficult to clean, " said Ralph Basile, vice president, marketing, Healthmark Industries. "The \uc2 Sanovas\uc2  MicroCam lets us inspect medical devices, such as endoscopes, with clarity of image that heretofore was not possible with affordable technology."\par \par \uc2 The MicroCam System represents an entirely new concept in medical imaging that has not been possible, until now. The MicroCam System is a highly integrated platform of proprietary micro optics, electronics and software. The 'Plug 'N Play' capabilities of the 3mm-diameter, MicroCam System enable it to be sold as an OEM product as well as a branded MicroCam product, which MicroCam Inc. is pursuing simultaneously with its OEM strategy.\par \par \uc2 "MicroCam is paving the way for a paradigm shift in minimally invasive surgery toward multimodal imaging methods, linearly integrated medical devices, and natural orifice surgery," said \uc2 Larry Gerrans\uc2 , Co-Founder, President and CEO of Sanovas, and inventor of the MicroCam system. "MicroCam's small-diameter 'Plug 'N Play' optics represent a highly disruptive leap in technology, cost, and portability. This is a unique platform solution whose time has come. The technology will, most certainly, evolve the interventional capabilities in the existing market and expand the growth of minimally invasive surgery to nearly 3.1 billion patients in the emerging markets."\par \par \uc2 Healthmark Industries Co. is a supplier of infection control products with a special focus on cleaning verification. The company has incorporated MicroCam units into a new product recently launched, the Flexible Inspection Scope, empowering sterilization processing professionals to be able to literally "see" inside tough-to-clean medical devices, such as arthroscopic shavers and endoscopes, prior to sterilization/high level disinfection, to visually inspect that they are clean.\par \par \uc2 MicroCam Inc. is one of \uc2 Sanovas\uc2 ' portfolio companies that are delivering potentially blockbuster minimally invasive surgical products which enable surgeons to access, image, measure, diagnose and treat diseased and obstructed passageways and anatomies in areas of the human body that have been largely inaccessible...until now.\par \par \uc2 About \uc2 Sanovas\par \par \uc2 At the heart of the \uc2 Sanovas\uc2  companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as one millimeter in diameter that have previously been unreachable. \uc2 Sanovas\uc2  expects to commercialize the technology in coordination with its various partners to address unmet clinical needs in Oncology, Pulmonology, Cardiology, Neurosurgery, ENT, GI, General Surgery, Urology and Gynecology.\par \par \uc2 Contacts:\par \par \uc2 Steve Goldsmith\uc2 , \uc2 Sanovas\uc2 , 415-729-9391 x1023, Email\par \par \uc2 Ronald Trahan, APR, Ronald Trahan Associates, 508-359-4005 x108, Email\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/sanovas-commercializes-its-breakthrough-device-reprocessing-product-designed-to-identify-poorly-cleaned-medical-devices-that-could-trigger-infections-300025039.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/sanovas-commercializes-its-breakthrough-device-reprocessing-product-designed-to-identify-poorly-cleaned-medical-devices-that-could-trigger-infections-300025039.html}}}\par \par \uc2 SOURCE \uc2 Sanovas Surgical Technologies\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.sanovas.com"}}{\fldrslt{\cf2 \uc2 http://www.sanovas.com}}}\par \par \uc2 Document PRN0000020150126eb1q0006q\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Antares Pharma Files 8K - Regulation FD >ATRS\b0\par\par\uc2 227 \uc2 words\par \uc2 26 January 2015\par 06:06\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Antares Pharma Inc\uc2 . (ATRS) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on January 26, 2015.\par \par \uc2 On January 26, 2015, \uc2 Antares Pharma, Inc\uc2 . issued a press release announcing that that the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) has issued a complete response letter regarding the Abbreviated New Drug Application for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the \uc2 FDA\uc2  provided revisions to labelling and cited minor deficiencies.\par \par \uc2 The full text of such press release is included as Exhibit 99.1 to this Current Report on Form 8-K.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1016169/000119312515019400/d860393d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1016169/000119312515019400/d860393d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1016169/000119312515019400/0001193125-15-019400-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1016169/000119312515019400/0001193125-15-019400-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Antares Pharma, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US0366421065"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US0366421065}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 January 26, 2015 06:06 ET (11:06 GMT)\par \par \uc2 Document DJDN000020150126eb1q00141\par }\page {\par\fs20\b \uc2 Mylan Inc\uc2 . Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Epivir-HBV(R) Tablets\b0\par\par\uc2 403 \uc2 words\par \uc2 26 January 2015\par \uc2 AIDS Weekly\par \uc2 CDCW\par 43\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 AIDS Weekly via NewsRx.com   \par \par \uc2 2015 JAN 26 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Lamivudine Tablets, 100 mg, which is the generic version of \uc2 GlaxoSmithKline\uc2 's Epivir-HBV((R)). Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.(1)\par \par \uc2 Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 284 ANDAs pending \uc2 FDA\uc2  approval representing $109.1 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Use of Lamivudine has been associated with lactic acidosis and fatty liver disease. Acute exacerbations of Hepatitis B have occurred upon discontinuation. In patients with unrecognized or untreated HIV, resistance may emerge while treating Hepatitis B with Lamivudine.\par \par \uc2 Keywords for this news article include: HIV/AIDS, Hepatitis, \uc2 Mylan Inc\uc2 ., RNA Viruses, Retroviridae, Liver Diseases, Gastroenterology, Infectious Disease, Vertebrate Viruses, Primate Lentiviruses, Digestive System Diseases.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document CDCW000020150123eb1q0000z\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Advaxis Files 8K - Other Events >ADXS\b0\par\par\uc2 235 \uc2 words\par \uc2 23 January 2015\par 07:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015, Dow Jones & Company, Inc.   \par \par \uc2 Advaxis Inc\uc2 . (ADXS) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on January 22, 2015.\par \par \uc2 On January 22, 2015, the Company announced that the \uc2 U.S. Food and Drug Administration\uc2  has cleared its Investigational New Drug application to conduct a Phase 1b clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. The clinical trial, which will be the first-in-human study of the Company's lead Lm-LLO immunotherapy product for HER2 expressing cancers, is expected to begin patient enrollment in the first half of 2015.\par \par \uc2 Exhibit No. Description\par \par \uc2 99.1 Press Release dated January 22, 2015.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315215000242/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315215000242/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315215000242/0001493152-15-000242-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315215000242/0001493152-15-000242-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Advaxis, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US0076242082"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US0076242082}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 January 23, 2015 07:31 ET (12:31 GMT)\par \par \uc2 Document DJDN000020150123eb1n002b2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw388\pich38\picscaley100\picscalex100\picwgoal5820\pichgoal570
47
49463839618401260070000021F904010000FC002C0000000084012600870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0073081C4890E00F81070FE648281047C187391C368448B1A2C58B032546C488
5121438F1C438AB4A870E1C893284D964CC9122443950861A65938E687C234206926AC990367CF85337FD44CF831E8D09E0F8CDAFCF9234D52A03A4DFA0C8AE3
60D58D3E22FEB8FA33A840AF5B23567510312BD98656C3660D5B756B58B70EDD2EAC1A3747561C641DE2D06BF7ECD60712F9EEDD48416C5FAD7CA3E21CCA732D
4C981F117A8C4C19B2E5981F2B27BC7A57ABDD8D9C3D77BE7B30EBE7814B377F866BF2AADCB497334715BA13E8C1993889D2F6D9B4E9429B407C067FA0E6A09A
DF0B75CC3C9E06C818203DA13B2F12BDE70FE7D77F1C2F1E5C47D3EEBD95DFFFD658B7605D1F0F6A8E71ECF0418E0A19DD5F7DE003877BC039DCC7BC5852E3DC
827FFDE05E5E02E5755005ED65E55E619E9D25917EA9DD66924A1A858598409DB135D146A77DE690690499661564FEA1B6D15B1B4E68D0442BA918A28939F567
626B324EF82186A755B813486FC0A812194241379373C9F994C31850DD94DA188BD126216D501DE71B1009E186831A5929F55B4DE269F7570E0EC03622436314
C193540D2526D10F33F8479E7D28A2E8986708719523872266A4278B81E9A9A14D645236D39A27FAA0C36AFB016A1710E7A195A85D258919116E26AD65678BA9
C574E98AE57944A84B6DEDA72288276A5ADA8A980D34157491F9541358BDA9FFB498753461D7A44DCFE9B65C0E459051411A3C018AE46E506AC79470B8397926
43822D8503B014E2FAD256F065852060F081E943B50F2C7521A21B7ABAE28111C1471E82F949842E83EE1D549843F00938D79868525AE77F33C6756389DE4E68
A18A99CE98694E9221D76F5957ED3B6268745926A1A80D5BC89588A1F9A816C06095298694D62149E591124A47EB41C1D904A44E3AF800244FCB35E5DD514D3D
D0E30F4072F75D4D40484925CD8036C92A90DE490C30A045D854746F80129DB4D136BDC1B4D34B331DF50F4514A12F8E2F9976238778BD882ED70DE72774605E
A17119A102C5EB59A402A38D1C4C8EBD8A5C552C7B8B62877EBA28EA6300AEFF1D138276FB8B990C3196FAEFDE8ED55699C141DDE65B8FCCC53413754BE59643
70BF31341553CFA50122B4C276BC259154A681D3E95036E8EFD43DB3EEA54DCDC10EE8CE482F4DFBC12DDE8929570DF35592690E72DD1A6AC1A269E94419BEA8
12BD1C8E387C7F3B166FD2B015DA78EA4B73755BA05BF855FC6F5D750D9B629F20F9E7BCBF9D4E146C953D1D375BD067CE262D638E5B1754714C5A17644291D3
06F3915F41887A2404AB97D1AC3DA8894BD26E77BBDCD42E6A69F855EB76969BD83D505C428B917D360298F3F18E43C2FB4198D2B590EE698E6F0AC95646AAA5
BC47B1ED6E85F3568F4E6730C1A5EA5E764B1F0EBC231FB1EDCD3535D15E0EFFB3879598804835E519489E54322CF1C14E80B379D5E4064840C79D6C5A81EACA
4B7882244AA5CE288F6959979C851E52FDA638B24BA3ED9286469CDC6E8D51A312EDB816990AD5053602290C7AF4529A6EA5AF791BDC900F82453767D18B2C98
3248124FB5C4D3B0E72B506A9CDC2233278025AA4F097B4C62E62411AFE0704605E214AA42C3BC1D21474A60D1C9FFDC6732E0144C95FEEB4A540492BF6921E9
2751111FB4C0C8392285483E4BB3A01A2AB040D72D245E6E6C5D84D4E8C012BA2871846A4F9FC2A51F0E39C03E8901CD67CC35A3990C0F4EFB9958027F87234B
DE10949409963A61D22873DAF05B5761E1B814B21619315253C034A2A3C675FF4798148F3723139264704206A8E0E65000C5A54241264B9A34749001641900FD
D545590AC5434A944CD48002074DC0A18215D44E11D49086A265AE381CED281A89E940670D0F448BAC1E0EBE862FF091B38323D4D3D67853998929C4355C918B
DE9EF710B9B8A663038B955251782F1A49845404A310680846D58CBE725E97FCE97EFE89A625B9844B9EF4E484BCF9933138C42BEAA1895E06A594B4FE400C13
826BE57A32C09810323F7B440DEBDEB08C7DD46319D0D88726D4A08950E480AFD1A88732A2E15765C0216AA0A84734E8110D7D2C43133691A0A2F6D92E01AD09
6D6E9217364BD22E106A2D2C79D1DE69FE25B11E0A043FFA914F35ADD2AEA0FF96505F2A1C48526EB3DBBAFA6845AAFD92BCD8C6220291273FADD19E134513CA
B374289B0DC18F28E994CA9B8CAC78F19B101769E310B301B28BD38CA836AF72A641C50CAE383853856E79D11445AA373E81C33E94E1D137684213CB00EC3216
0207650836131EF5AF267E9386BE82221370504326FABA5FE0586E5A974A835FB0BA959C92250D3DEA21F7AA225D6902A5472CDAC81BDE4095E5CD945652F9C1
0CB98934BC2AD19BF5AB926F7A62262891D874A6438DE706D22311F9E6C18E52D241FC88109C48A4389C31DD52F4B39632CD53AADA711A026CA240591DF35517
2519A548FA91677D14A839F0EEB3C6AA09189B19C3A683A80FD24052D32129FF4B3349AB43CA7C1031E00AC7387E585646E39AECFC40BE98CDD41BFC0B8AA5BC
611F94B3495F05F483C5722C2199986FB7224825E822E601A088866934A18CA8C6651FA0D607882D3426E9E60714A0DE07283638A8FE82BA1E70F84F1AF60187
193C4013D0A0276353BD8CBAC817D4D1C804421230EB37B887AF1216C81B18BB9037D4631F5212CAAE19DBE98D448318029AF524B487EA7D24761FB0C2D1A181
9D89763D60C1DE3C3459D5E05F504383AC3DD9C71B66B0E7392B23D93F48C0B8410D870428A4BFC906C5326625DF245D3B3F70A8479C91428C5413C3ACC0F208
92D0BB6BC1F2250D9A902CA81B1C6F6FEF63196AE0097D4B338607B47BBEB4FF5CC8C9410D40DAC24BC7B7D34734BAB5B46ED9D7260ED004B4890928C1FE40E7
505B5A05E41BEB584DA8020C5288031AAE0387A0DA9B1B9C29602C2B9050809B9EE5BC8A1E673D60F9767A4DF4D8874002EB1484D40314D7D4F94FBDCD240C9B
E4D6D096C1A231A40350B349E75ED139B81D4009501BBB8B1F7F831A3E1A13C666C2DF8255551A1AAE09A7856B206A00770E801E1104E81C0EEE29B67B2A3089
686822BD8B76CD3E28A1DA8568221AEEB34B62DDE35FB9E200EFF969784272BE0F3205F6F3C59E50A441918349CC3752BA4400637BA4F301D7E4F5FAD0C41846
DC9319FC601FC4207126D2E090315C7BE1C56733CA6FA38C657C14C315159EFF8E96A2F6CCB9EECFB5CF5C0E68FD03681083E64B13C83EF4017FE63D353F3A97
88DA276C21C176864E1C944D09A00FFBE00032607903761578870309B07ECAA011DD176F09287FA08000E6910399500F3F80009107077C046A9A400194100D25
17119C9678CAE05F1C7368C2D63C024180FBE07C82A55A709706FEC64E07E27B6AE00063907802215FD47758D0B6110907622938100ED0815127104F77165C07
260A756BD130288B754B932776A8F16CCBD01416671733305F0C387909787CDE9425FB90096D9203FEE51448027B39005720436B32602269405FD3B30FD03003
02715FAAB20CCA00429B312043E663B9B10CD14060E72784418703F25504B3FFF6582D6534396007B5B759D0431008D05762537ECF2510ED367219C5367D2258
53F651FF025848E85FF49179F2D683334316DEA60C99566E0D215F6F8003A82625E92158B4D683D477109A10597F180DF2B583024106DE460CB208620E2158D0
B00C0E90783F05847B531291F7060E006864E10091E68133608B9D046C2048645C9700A6011F9CA60681D157F33560DA830391966AFB400FBCA57361F615DDA7
0C0F176C0D518E6F90095CE619760640F62815F216173AE787D140096B316BD0E779336167CB000A03F9885A215766A586F3D57DCA771056481A5A913415A00F
CAC0522C155B02F131872642EE61042CA76E3C573AD9C188E0B65B5A052277FFF100C9B00FFA47829FE447F8C5604E612862812E1AE100B376787A076D0E9015
47F85A0DA7877BC17570E09303318F9B400C8DF7764B296F58537BCA500FCB567693070DA7376B62E0950282067E050AA1400CBAB87E24056ECBF00938027798
573045218F7F5815DF086DF611694EB11591A70994C057CA302C483983391259C616132788721C567C240558DEC4776247175CB76C193733F126610D377FE107
403E90003B19846350779430173A475F86D91332306B97A509D3F71597754B2C486F56781BCB70769BA00C8E0775C1E3178A2258142093CF278FB49603145009
CAC9720F508CF0F503BFE20302726846903497E41ED491039BC093EE8177F4FFA153F98100FE9606C9D710C1E32E9F9100F39500388000E809758B95033D3003
0D1058E3F9001590827E98470BB10F9B8000F7A11033A076F6784D34B10F25B771C7810314608FCB605940009857718611315BEBA70902E05FC1564D70A78E30
05138756669E447B66A56F72281099100D93609EEBE781B42458076022A7473D6042A007507CFA815F4E6172F590326F688F1ED97E9A9000C4C05893404BCFA7
0916988D957824CF2221F6F800762698B494714271623F719065370648590F9A603547327F09507269307DC37270E9A58762C019423A9EB6F131A620760E0404
B2080A9A50A79DA662020A07C9000A1266132D5A6EB3934C15500C3C993477FF915B61A1A2A0E07C24E95C6F4039F1669737708DEDB2956992513A970949E86D
C6287F8798037DC55E38F097FE97111F3701C7B7103E407BF2F78725D48370209FF3E7183A37062AF888FAF18491B1A115E09ED2C89A0C5A5A7B738D0D68223E
B00FA720208ACA101D681397574285E9526A2896FAA18457386FB1BA8033A00CEFF65AF987240E808C9F17795E29061510AE89279B6F864B032900A0E614BE47
0C0EC1AE67A94A49B10F9580A60EE5875DE04D6B28848B0A7AF7761066A2506A3250074174DDB2330FE000135B7C02A2738531AC3C77101FB728496364DE1626
D7611EA4B61127877A04D1B112C18E204810D1500C61E11E3909262CEB6DC9FFE610FB3683833129F5CA22CF39607BA80F3B58AD9F81856A0872031169390084
B3A68E0AF19C41F803E939032C481070376A70931F91C63113F200A1096A2D88B3304880CAE020395B6D933785751158A9A609CE856EEE2170834A93EFF166C9
07189106B4EBF100350B6E3635110E096A7F487339A08C9F271003E97BE5467DDE9406F48059046175A9461075A89C9EB941D24516D6B9347EB5B9B0031D55E9
73B4E74068741075B09C1F0B1F4F878895D2425F51669E715620C183B4D974FF41622AE25C62A160F6825C7A489BDB531046425B6DA60601695D024152045174
01F416A8743939566424A506B8FBAB0931038F566456B5123F201EFB611A49FF4158605A10D38B521DC2666C3626EA454B1D855C3A7613A9870364F00666A510
CADBBC73D145B0AB10ECD5446CB2B483453700E4660C018739764B63A664197956B08B4BC0F2516A300921D75E78D221C0719DF3952D80B26CDD57684B2B6F9A
B534FEF55811A273A1B0B1D8FA18E3894DAA6527A5821709804847B93DC7455BF059C17BF10016E81FEFE2BE39D55CEA57270791533FC5BD101148A7711F3E34
6402613510624958F74E517C2F8844C550582280312004117544611F84431735A2A0363210DE9528F59B26AE05AB3C31906C611F7285511EF92CBB154083843D
40915D5CB4C5928321A6B61145503236017782E58840300CD0576098F500A7FFAB33F0B533FE450C09F6677DF5800F84101D84365AF51FC4F55AACB55A8E542E
E9821F22942239422D3A05538B8424EB61C49E9C40CCFA282FA211898335A09127D342612ED436A0E4CAC475CBA9923BC16A2159B2439A2C3C121549A6A215AA
5CA46FF824E193BF9362575081B8B3C4C64DA45017B3C299F7B1D43906920B6C85D69F985501197834B9314715707AF2286A342747FD02221A86AC666429ACF1
19A4521E48CC47DA242F76C164D58403E768555F33CBC475449F6530684331C16C22E95347B0BCC51A644EA7B21A2E9C49A715BBE58355D9A4196305571255C7
7DF28BE9A51364E010648A267655A4024C1B4F312C6F15CDE30151B8423775FFC1B87A1C18C644016CF606CC5B3447637E219C34553162632A366A8447F44C27
6CF3C3D5F45AAEAC35FF31A217481EFC7CCF6FA11F8BD424351443243BC6A2882A2EE14E7A9316A012D6E564460FC14991523D8263C74E45CAEB017198E1C2B3
513DAE974AEB2110DE85BC3D8194017415DE354919493DBA44139FB327D8A451CA9459E6A71BDC7C7EF0112F17DC3A7B32C600A8D4FAE22DEC3164FE81D550E8
21433C8813211161A2BBF7372104ED305D162D7DB319112DCC03E17CD5B3D6B75C5538292A5D5CCCFB245496FD123A62C1A9D248A4714B5E415EDA2B3D5671C6
ED251459B13E05611ACBA2CC01D45665E55064B584B475A87E76418FBD33B4FF53BA2D15DE474D6A44863D5B432317E822D1A4214DF5D98601A0978D1E9A22C4
50B4395A0275F30D128F643D6D5DD6C3731912BD378FC1DB7CB367F3AD4F95E43080685507BD106FBC1A59E15D96724B206236CC7C51573128B8945EFED36475
E691669C1E0C4523CB2C3AF092D80A1447E7771D91E840E79C4CBD413B6FC44EBA15273EE41F47141633612D7C3161BD23A7880227A055C453C54444C11431D6
3C257B4EE85D38608D194EBE149B6DCB03EE22F6F410FD04424A3430AB435421C9A471834B56C81420C31568B0125922DDAF61173C1154EA71543F60363321E1
6B7C5111A7120339DAB83D9D8B8D3AA5FBB16F144C53833A1F835C8DF2595859EDCB78733EA496D8F2F14124E4D9FF97D8B4BCD5646EE751EC3CB0413E31F53C
ED24E06BDD5545F5496D4DDF66BDDF47F53661EDDBA8ADC761717C54F616636612E8C5CC4C6A67857DD8ECF513B3BE1A842D386636565FC1E1FF01B421D8D416
536304732AE8B2C32B670447D9D152E607DC3744E00913EAE21217A636B38401DAE70D265837221D36DD3B1230D8B3D0B53D548133237992EAB2B1D5FD74478D
62C45BA35578C4E5665D1EA6D174599472FC2B71A502751725D3EDFD137BAD562D9756624EEB0F7310651C84A6E14D72B68A74C22FE874F17C3310A9C91F9AF4
1F9A3BDA9EA210B5F58E58F51EE4D3101A8C40A8C22073E2201DF4DF5B51636134C5135D8DAE2CC4391154F79E2AE5912CB96C4366BDE54AEDC9E9CE440E45F3
E384D199F4D78D61D8734156AA111504FFF488621A064EC75913CDEC65C023BE63F066217E11365A7E387D332FF777F5067E4F177237555ECAFFBCCCDFA16415
A4A2D0F6611632E23B064120870351B8B15DFA6CCB3742E4ADCBDFF1DEDFB7EC185A02DDAA35F702832F5425CBFB544939B1D962E1D6D6553923AD35E2A35636
616799EFEBAD116725E1158D7B24272D144DE44469AED5F7585615802494FE54923ED73CCF2C18914D2502111AE6101FFFC29B8E2FC11D5D19A1214BAFE72601
1F265421B5B55A45A1E8302FF497DDCB21E6D658E62A4E824B5CAD7E465C55E544E08B5E3CA983DB7CD2E8520AFE50D26471A1DCAAD4CC54BF1A796EE1632671
75EC505981EB3D81CF6465E10C1BBBDA34A2008123478E1F0207FE189810218E823F1CF8788043A08F8439280E642890420E860E081EFC8810FFE4C790233F32
4C68502447830337E678C051A4C00A1823B20C6910C74D9518098EF92132A8C99525491E3D8950A851994D1BE64833308DD21F40A7023D28B020D18414958244
C9B422CA8B5B093EC02A542BCA855F732A9C1955EBC131238B8A59D9B6AED0BA1CA30EDC2B304DCB815EA172952AB52AC2BE1663EE34F898A3648273B362DCDA
B3A2E3C91039C21CE871EC678B9515E6102D9072D9B0864B3FA0581335C598A43D869D38F0C14CD10E964A66FB312AC2E10251329C7952F9D68BA68F5F5EBA99
EAE2E1048953B5FE9669D8E4DC2B17056F383AD2B04D7B9ADDBA728C8F31BE7388A99CF6231A8B7D115E2C5BB5BE5EC553E1039DEB07BC7EBAFF0F2B90A2A2E8
AF856492282597C0FA8822EED6AA2D870A9EC3ECB3E04A7BC9B4C57C0AEE2B8A74D0ACA5E61C5C4942877422C9339F92C3C922AD20C88840E13E5C0EA4AFD2CB
CEA8BCF242B1C7C3AA230EAA07AE5ACCC0A596F4512D92B0330F48928A78D2C78474782AA1A80094EBA331041B8DBEBA8E3C48A4A8D2A88BBDA608AC2B8D13F9
2A32070013530A87A806FC6B321C6A8AC93317299250B9CDC00222A3E6047A08A69D10BA2D870E098228C0D2567A4E25B6026CA9A19D287220A30AABC4813540
5143493687BA22CDC606DD023239F47C1234C5D3EA1C2A48A5869BEA071D8603EA87A9B8DAF049EFAA8C754DA5943CE922E3222C2CA98250122A8344FFAAF201
08ACDCFC5040FDAAC2610C034B230941902E02AAAE72BD1C884AA8BEF2F6302F7D882A20003B}}
\par\par \b \uc2 Chaffetz pharmaceutical measure to remove barriers to the development of combination drugs; Rep. Jason Chaffetz (R-UT) News Release\b0\par\par\uc2 411 \uc2 words\par \uc2 22 January 2015\par \uc2 Congressional Documents and Publications\par \uc2 CONGDP\par \uc2 English\par \uc2 (c) 2015 Federal Information & News Dispatch, Inc.   \par \par \uc2 WASHINGTON, DC - Intended to spur the development of drugs previously considered economically infeasible, HR 406 was \b \highlight22\uc2 introduced\b0 \highlight\uc2  by Congressman Jason Chaffetz today. The bill would extend to new combination drugs containing molecules already approved by the \uc2 FDA\uc2  the same five-year market exclusivity as a drug product containing an entirely new active ingredient.\par \par \uc2 The existing Hatch-Waxman law gives \b \highlight22\uc2 new drugs\b0 \highlight\uc2  a period of five years of "market exclusivity" to help them defray the cost of undergoing the \uc2 FDA\b \highlight22\uc2 new drug\b0 \highlight\uc2  approval process. Therefore, regardless of the patent situation of a \b \highlight22\uc2 new drug\b0 \highlight\uc2 , the company can count on having five years as the exclusive seller of the product. Thirty years ago when Hatch-Waxman was enacted, all \b \highlight22\uc2 new drugs\b0 \highlight\uc2  were "new chemical entities," that is, new molecules that had never before been approved. No one at the time considered the possibility that a \b \highlight22\uc2 new drug\b0 \highlight\uc2  might be created combining existing molecules (that is, molecules that had already been approved).\par \par \uc2 Today, however, it is clear that much of the future of conventional medicine is in combination products. This has proven especially true in the fields of cancer, AIDS and other complex diseases.\par \par \uc2 "As the law is currently written, virtually all combination new drugs are excluded from the five years of market exclusivity and therefore are not being developed," said Chaffetz. "A new drug that has been created using one or more existing molecules should not be required to go through the same rigorous, lengthy and expensive \uc2 FDA\uc2  new drug approval process."\par \par \uc2 The legislation is supported by a coalition consisting of large research-based pharmaceutical companies like \uc2 Sanofi\uc2  and BI, small innovators like Pozen, and independent generic companies like TEVA who recognize that the future of the generic industry depends upon Congress encouraging the development of new medicines.\par \par \uc2 This may well be the first time ever that the research-based and generic pharmaceutical companies have joined on an issue involving market exclusivity. The bill extends to new combination drugs containing molecules already approved by the \uc2 FDA\uc2  the same five-year market exclusivity as a drug product containing an entirely new active ingredient. "This legislation is intended to allow companies to develop new medicines that are not financially or economically feasible under existing law," Chaffetz said.\par \par \uc2 Read this original document at: {\field{\*\fldinst{HYPERLINK "http://chaffetz.house.gov/press-release/chaffetz-pharmaceutical-measure-remove-barriers-development-combination-drugs"}}{\fldrslt{\cf2 \uc2 http://chaffetz.house.gov/press-release/chaffetz-pharmaceutical-measure-remove-barriers-development-combination-drugs}}}\par \par \uc2 Document CONGDP0020150123eb1m0002f\par }\page {\par\fs20\uc2 Business\par \b \uc2 ResMed\uc2  Q2 Profit Up 6%, Results Beat View\b0\par\par\uc2 348 \uc2 words\par \uc2 22 January 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 ResMed Inc\uc2 . (RMD, RMD.AX), a maker of medical equipment to treat respiratory disorders, on Thursday reported a 6 percent increase in profit for the second quarter from last year, helped by the \b \highlight22\uc2 launch\b0 \highlight\uc2  of \b \highlight22\uc2 new products\b0 \highlight\uc2 . Results for the quarter beat analysts' expectations.\par \par \uc2 ResMed\uc2  develops medical equipment for the treatment of respiratory disorders, with a focus on sleep-disordered breathing.\par \par \uc2 Mick Farrell\uc2 , \uc2 ResMed\uc2 's chief executive officer said, "We are pleased to report strong double-digit revenue growth, demonstrating excellent progress with our new product launches. We achieved robust commercial performance across all regions, including double-digit growth in the Americas."\par \par \uc2 The company's second-quarter net income wass $91.81 million or $0.64 per share, up from $86.64 million or $0.60 per share in the same period last year.\par \par \uc2 Net revenues for the quarter grew 10 percent to $422.95 million from $384.34 million in the prior-year period.\par \par \uc2 On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.62 per share for the quarter on revenues of $405 million. Analysts' estimates typically exclude special items.\par \par \uc2 Revenue in the Americas rose 12 percent to $231.0 million, while revenue in combined Europe and Asia Pacific increased 8 percent to $192.0 million.\par \par \uc2 Gross margin for the quarter was 62.2 percent, lower than the prior year, mainly due to an unfavorable product mix and declines in average selling prices. These were partially offset by manufacturing and supply chain improvements.\par \par \uc2 The company's board of directors declared a quarterly dividend of $0.28 per share. The dividend will have a record date of February 12, 2015, payable on March 19, 2015.\par \par \uc2 RMD closed Thursday's regular trading at $61.86, up $1.76 or 2.93 percent on a volume of 2.02 million shares. In after-hours, the stock further gained $0.64 or 1.03 percent to $62.50.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020150123eb1m0018h\par }\page {\par\fs20\b \uc2 Mylan Inc\uc2 . Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Diovan(R) Tablets\b0\par\par\uc2 408 \uc2 words\par \uc2 19 January 2015\par \uc2 Pharma Business Week\par \uc2 PHBW\par 91\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2015 Pharma Business Week via NewsRx.com   \par \par \uc2 2015 JAN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Valsartan TabletsUSP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of \uc2 Novartis\uc2 ' Diovan((R)) Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.(1)\par \par \uc2 Valsartan TabletsUSP 40 mg, 80 mg, 160 mg, and 320 mg, had U.S. sales of approximately $2 billion for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 284 ANDAs pending \uc2 FDA\uc2  approval representing $109.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Valsartan Tablets can cause injury and death to the developing fetus and therefore should be discontinued if pregnancy occurs. It should also not be administered in people who are allergic to any component of the product or co-administered with aliskiren in patients with diabetes. Signs and symptoms of hypotension should be monitored as well as renal function and potassium levels.\par \par \uc2 Keywords for this news article include: \uc2 Mylan Inc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC\par \par \uc2 Document PHBW000020150116eb1j00024\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Epivir-HBV Tablets\b0\par\par\uc2 120 \uc2 words\par \uc2 15 January 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Mylan Inc\uc2  (MYL) on Thursday announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Lamivudine Tablets, 100 mg, which is the generic version of \uc2 GlaxoSmithKline\uc2 's Epivir-HBV.Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.\par \par \uc2 Lamivudine Tablets, 100 mg, had U.S. sales of about $18.1 million for the 12 months ending September 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020150115eb1f006y1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Epivir-HBV tablets\b0\par\par\uc2 146 \uc2 words\par \uc2 15 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Lamivudine Tablets, 100 mg, which is the generic version of \uc2 GlaxoSmithKline\uc2 's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 . Currently, Mylan has 284 ANDAs pending \uc2 FDA\uc2  approval representing $109.1B in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 . \par \par \uc2 Document FLYWAL0020150115eb1f006mx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Epivir-HBV(R) Tablets\b0\par\par\uc2 393 \uc2 words\par \uc2 15 January 2015\par 14:29\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, Jan. 15, 2015 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) today announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Lamivudine Tablets, 100 mg, which is the generic version of \uc2 GlaxoSmithKline\uc2 's Epivir-HBV(R) . Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.(1)\par \par \uc2 Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 284 ANDAs pending \uc2 FDA\uc2  approval representing $109.1 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Use of Lamivudine has been associated with lactic acidosis and fatty liver disease. Acute exacerbations of Hepatitis B have occurred upon discontinuation. In patients with unrecognized or untreated HIV, resistance may emerge while treating Hepatitis B with Lamivudine.\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/mylan-launches-generic-epivir-hbv-tablets-300021442.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/mylan-launches-generic-epivir-hbv-tablets-300021442.html}}}\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020150115eb1f000i1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Eli Lilly\uc2  upgraded at Goldman\b0\par\par\uc2 35 \uc2 words\par \uc2 15 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 As previously reported, Goldman upgraded \uc2 Eli Lilly\uc2  to Neutral from Sell. The firm upgraded shares based on \b \highlight22\uc2 new product launches\b0 \highlight\uc2  and pipeline assets, and cost reductions. Price target is $70.\par \par \uc2 Document FLYWAL0020150115eb1f001bl\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Johnson & Johnson\uc2  downgraded at Goldman\b0\par\par\uc2 50 \uc2 words\par \uc2 15 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 As previously reported, Goldman downgraded \uc2 Johnson & Johnson\uc2  to Sell from Neutral. The firm expects \b \highlight22\uc2 new product\b0 \highlight\uc2  cycle flow to slow following a period of outperformance and for valuation to be pressured from increasing competition to recently \b \highlight22\uc2 launched\b0 \highlight\uc2  drugs. Price target is $97.GSCO\par \par \uc2 Document FLYWAL0020150115eb1f001bg\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw145\pich40\picscaley100\picscalex100\picwgoal2175\pichgoal600
47
494638396191002800F7FF00716A5D2C210E5A6D71112D33E5E4E2DAD8D5C5C2BDCCC9C4787165A6A2997B8A8E4D443452666BADB6B9675F51D0CEC9B0ACA580
7A6EABA79FF2F2F0889699DADEDF3227153D3321281E0AD4D2CEEDECEA55696E64767B8A8479BEBBB56B7C8061594A2E23104B4231A6B0B38190948E887EB3BC
BF41575D8781763E555A352B199B968DCAD0D27C766A6D6558847E72B8B4AE2D464C3A515766787C30484E665E50564D3E5148385D55465F72767A74684C6166
585041696153465B60E4E3E14E63682942483A301E413826A0ABAD4A5F64364D53403624342917443A29766F63C8C6C12B444AF1F1EFBBB7B1ADA9A19F9A92F0
F2F295A1A5928C82C3CACB869498F6F6F5D6D4D0D2D7D877878B68797EFAFAF9FCFBFBDDDBD8FDFDFDC1BEB90F2B325B5344271C08F7F7F61D373E544B3CE0DF
DCA19C94302613AAA59DF9F9F8C8CFD0A4A097C3C0BBDBDFE0BDC5C6BFBCB6A8A39BFCFCFC18333A98A4A7433928261B07E9E8E6FBFBFA5047371E383F6F685B
E1E4E5F0EFEDD9D7D4E3E1DF382E1CF2F3F4CFCDC86C65571B363CE7E6E4F5F4F3E6E9EA635B4C274046E2E0DEFBFCFCBFC6C8C1C8CA324A50ECEBEACAC7C2D3
D0CC374E545C5344849296B7B4AD8983788C867BFCFCFD98938A88827719343BEAE9E8463D2CEAE9E7DEDCD9B4B0A9FAFBFBC5CCCE756E61A49F97979188918B
81CDD3D4A2ADB0C7C5C0E3E6E7EEF0F07F786DA9B3B5CECCC7D8D6D28B989CBBB8B2B3AFA8938E849CA7AA8C877C948F85DFDEDBA9A49CB5B2AB384F55A39E96
453C2BECEEEFEFEEECDFE3E46F8084E8EBEC574F40777064867F74C3CACCF8F8F7AFABA4AEB7BAE8E7E5F9FAFA9C978E5B6E73B7C0C2AFABA3736C5FC7C4BF75
6E62728387C4CBCD5F5748BCB9B3645C4EC9C6C1969187EDEFF0C7CECFEBEDEE97A3A6483F2ECED4D5A29D95F5F6F6F6F5F4142F36243D44C2C9CAA09B934C43
33F6F7F8CCD2D3F3F4F4CBC8C393A0A3929FA2C0C7C97E776C96A2A574848849402FBAC2C49E99909E9A919FAAADDCE0E1BAB6B0B5B1AA284148E5E8E9E7EAEB
ACA8A00E2A31251A06FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34423235433037343633384331314535384231344433354232383933364645392220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3442
323543303735363338433131453538423134443335423238393336464539223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3442323543303732363338433131453538423134443335423238393336464539222073745265663A646F63756D656E744944
3D22786D702E6469643A3442323543303733363338433131453538423134443335423238393336464539222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000009100280000
08FF00950854E2EA9FC183FFCE0CB46230C3C0870333FC4B339000C27F04049EB9F86FC542835CE294096067080A0D07230D84C3F185121D1CBF0C14F4AFCDC0
2E06BB4054D2A2048C311729EEFC78F0160221FE4250F370D09F537F79BC70ECF1B48941274FB33E75F24FC2D32717BDFA3BC211895311060D4DD2EA4F88C47F
779EBAB8C8E9294E84009E5A84F27489C1256C9F5AE0875049E0AA07610460DBC2A0D6635311FFC37AD81FD7B84E875D1CF6B410423F4F5118CC1B5888D57F0B
9C02BA98EB699C8B179CC633C8D7A9DF7F802BFB2B77D070E5D3AF1607CEF44FEB05A008A93A3D4DD95F000BD0A3B344EDB4CEC53A4F4121DCF5D4C0BF2B4FC5
ECFFD161D6690983979E7E4218E1E928848A9E12A3DDF7EFD3E7163064C5B0FE9F6F7FD105388141833CC54B04613C15C2046C95729172FE30F7154707A5E754
32077992550408EDE154086AFC838D6B06152086539D1804C9536920945A75083DD11D7DB6D9E7D41406E1F1C5104F35E69F641CC921DC100CFD439A3FB2B085
C623C949D61C5814FEB3A253DA19044A560B200488530E18D4C2537F1CE4C2020BE421C73F5C58E0D47B06356147569EF4F66188FFD4E6CF6DB9F983E3418AE8
E7CF1006FD771A471AAE791034642EC0C653C2A8E90F2B4D2E77D58451A6E9943B07B517DE80FF7CF2540206B1F254255112E8145906C1A1552E0761E74F9734
DEFF69A39E17D9E01406810279912F4F897026474FF5B0C2AD77FD03A1844E41196581FEA06590084EC5E6CF1706A501A6418B3A65411C747224963F16FDD341
B44EBD6050214FED72909D783EB5E74165A896ABA4516EE994357E00EB540F6A1CC1E541C74EEAD42C57146CF0AF5D3DE5CB3F7DBC894629E619F48C53BC1CC4
8970DA4673004798F9038141B6FAF38D53791894A4538AAC5B1F6EEE2264869F20CCEB8F3A06176CC6419A6895C73C8306FB0F3E4F5D6350C093E93668C75C79
E014088238158641FEFA63EE41D6B205C20F17BDD89815FA056085596218F2CF97FE54AC728D2CDF68D018B144ED0F2E32B3F5B4411340AB95056C38B62FC84E
DDFF30B4934623648E53F359E254265B2C16C0163F3C452D423020A5951037578862DA3CFC5383536DFCD349B908B13BEB73686895C416716B35B7417DECF1A6
56F3F9FC8F2B4F7D4C7473810D2A6EDFFFC4EBCFC66BF92388334E05600C475BC8C28356362034A53F1ACC12F1B0FE98A281E3A1AF9C676080E49B7A56AB17F5
820A5AB521FB3F1E8E35C6ED4FE9F0C4FBF0A37E506E623CD235EAA638B58C0E4E2152EA3F0580903F2271104BF9A31238E0DC3F9AE60F1C54A278C88955BB02
13021DDCA1304F6103FCDEF7388EA82101F6F20722CEF707E164827DC9FADF3FF0503A7F18AE810631C0BE5CB511154ECC2935FC9B3F2210027F60406C5C584C
08FF34E5BFECA12D4F7B100E065EC11141A9F0225DF093A3FCD103848C0B40C2005C0A55A89C16EE291CFA69A13F2AF78F472CE18C64FC472A5A46B50F39A50C
0749A03F5A984309CE6A0A76CA83FCE4442F8E44E28C4BC003428297952A1E6402E4D30AB2FCA1AC52556D65BDCB8A750EB2C6A521E40B4FA10742D095154D1C
640A5A49639DB4E72E2F2CCF299EC4601F2F9220A714E420594CCAF9B0C5964536324A9CBC5591FE81820D21A40F7EC2C003D6764A5921C46E4E614A0CB302A8
8B882E6DB4FA430F9DE21D3E46284A577CD5AF30E9B459A2A91B8A14987302049DE91C935108894556947990230540091170DB10B870916CDA61505C7B0A879C
49FF4AB5FD83144F11024A64464EE80C288A4F5900317A7022A7C4C19BFF505556161918AED4F329B5F8E57D76691002243230D5E0489EB28410DFF9839D6733
669EDE0582A7D4C09AB933482D2A53062E40F41F72A417EED8625184E4A983CFB2A41FA5B59FD7708485A043C80BBDC69167AEF42004102329BE375183784153
5AB90127FCA3110AF9E1214572C85004F21684E0010102111B427021909E5EA409B6100106C470011D148B231E51C2C610F20081D882423611C85D74D25684DC
63202D008A50C6CAD1250C827C21E0411CF6F8C4CA5AF6B298CDAC6637CBD9CE7AF6B3A00DAD68474BDAD29AF6B4A84DAD6A577B5926B896093400022D168190
0AFFE4800CFD980303D670901D30410A06390513E8601016B87615FF0B846B5970903530600EFD20430E2A701054302106D43508037E6B100ABCF6B50A380811
7401867E48A21EACCD6C3FD6CBDE7E30402AFFA80021DADB8F0190C3201CE807330C42827EF8C02074E84722541885F552C1208D18007D09E106834861BD4538
880CFA5105836481BEFDD08241DE816158A4F7B2EB15051618A185F53600BFFDD003320EF18618F4E3040659473F6260105DD4B717FFF8403F364060031B2405
337EC3211A805B0E3898BD4430C8842BFC8F0BA7000B50C6822A0C22891DFFC20D1BE8C7263E6CD9F546E1204006864168D00F4A1C6404FD008354A6B1DE40F0
81FFBD23F8079029D0E37E1C1813E56DC54128D10F471C79BD6408C63F966CE17E4498236416F33FCEC1073E70B9B25E3E8800326C1026F403B806A142A4D351
5E510478BDCC088538FA218F3A1FB8C0763EC8839970E44418A11F391834850B3D0E2DD85A0B38CEF17AF3A1851104E2D190EEC7970D32690DFFC3D298FE87A6
856D9057D30108FAD5F229D6BB0D53FF03D5073E32ABFFB1EA3594B719846E32861DFD8F6CF8A0BD9B4006B05518696253FAD8973EC8B2873D03588FDA1EF9E8
477E83F0446C5FDBC7DA0EB834FA11043233F9C24CA882C2AB306C83A003163B50F01CE0BB6E0AB55BCEFD503499CD6C1034ABD920DCA86F3F74F10F78887CBF
14EFC202151AEC6F3CF743CF06E1B39FB9DD0F56072211EC3DB8A139B2882C64411B06F1C67A9551F1288578C425EEC789FF915F15B3D8C530368836D86BE676
B0D7C314CAB2247E4184F5A2E3C7411E729103FE0F13E4BCD04F8EF294FF41661A1423189F0E45D12D8EE1F71A44BEF41D40230E020E05F7030BFFC0841ED6FB
8628A1B9BD3190FB3F12BCE006D37CDBFF98F4ACC54D5F639BC0EFEC35C2DC29F4DDD8CEB6B6B7CDED6E2F020426FCD7C2C72D153B82D00F7130C0F106712E74
A59BDD7F58F7F4FFD08723B8FB0FEF7E9709E135082376306A3D68611F9B4FBEF297CFFCE63BFFF9D08FBEF4A76FD98000003B}}
\par\par \uc2 Top Stories\par \b \uc2 Merck Accelerates Drug-Submission Plans\b0\par\par\uc2 By Peter Loftus   \par \uc2 721 \uc2 words\par \uc2 11 January 2015\par 23:19\par \uc2 Dow Jones Top Global Market Stories\par \uc2 DJTGMS\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2015 Dow Jones & Company, Inc.   \par \par \uc2 Merck & Co\uc2 . has accelerated its plans to submit \b \highlight22\uc2 new drugs\b0 \highlight\uc2  for hepatitis C and lung cancer for regulatory approval, in a bid to close the gap with competitors in two lucrative segments.\par \par \uc2 The Kenilworth, N.J., drug maker hopes that an overhaul of its research-and-development engine in the past 18 months has positioned it to \b \highlight22\uc2 introduce\b0 \highlight\uc2  the \b \highlight22\uc2 new drugs\b0 \highlight\uc2  at least several months earlier than expected. It is possible the drugs could hit the market later this year if government regulators approve them.\par \par \uc2 Merck has made speed an important focus of its R&D overhaul, in an effort to get to market as fast as possible with new drugs. The company has cut spending on many of its research programs and shifted resources to more promising projects including cancer immunotherapy and hepatitis C. One tack to speed development: enrolling patients in clinical trials of its experimental hepatitis C treatment more quickly than originally planned.\par \par \uc2 "The tempo has changed," said \uc2 Roger Perlmutter\uc2 , who took over as president of Merck Research Laboratories in 2013. "What we are doing is focusing our efforts more profoundly, increasing the speed at which we complete things."\par \par \uc2 The company said Sunday it will file an application around midyear for U.S. regulatory approval to expand the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadliest cancer.\par \par \uc2 Keytruda is known as a PD-1 inhibitor and is designed to work by stimulating the body's immune system to fight tumors. Keytruda and other new cancer immunotherapies are expected to form a multi-billion-dollar market in coming years, especially if they are shown to be effective for multiple cancer types.\par \par \uc2 The \uc2 Food and Drug Administration\uc2  first approved Keytruda in September to treat the skin cancer melanoma. Use of the drug to treat lung cancer would represent a far bigger commercial opportunity because there are more patients. More than 220,000 new cases of lung cancer are diagnosed in the U.S. each year, versus about 76,000 for melanoma, according to the \uc2 American Cancer Society\uc2 . Keytruda costs about $12,500 a month.\par \par \uc2 Late-stage clinical trials of Keytruda in lung-cancer patients aren't scheduled to be completed until at least 2018. But Merck has reported early-stage trials showing Keytruda shrank tumors in at least 20% of lung-cancer patients, and has conducted interim analyses of the ongoing studies, which could support a regulatory application.\par \par \uc2 In October, the \uc2 FDA\uc2  designated Keytruda as a "breakthrough therapy" for lung cancer, a status that confers closer communications between agency officials and Merck, which could facilitate an early agency decision.\par \par \uc2 Bernstein analyst Tim Anderson said in a research note last week that an \uc2 FDA\uc2  approval of Keytruda's use in lung cancer in the second half of 2015 would be about six to 12 months earlier than many analysts have been expecting.\par \par \uc2 He expects such an approval to bump Keytruda's 2015 sales to about $900 million, versus Wall Street consensus estimates closer to $400 million.\par \par \uc2 Merck's main competitor in cancer immunotherapy, \uc2 Bristol-Myers Squibb Co\uc2 ., initiated an application last year for \uc2 FDA\uc2  approval of its own PD-1 inhibitor, Opdivo, as a treatment for lung cancer. The agency hasn't issued a decision. The \uc2 FDA\uc2  approved Opdivo to treat melanoma in December.\par \par \uc2 Merck also plans to file an application in the first half of this year for \uc2 FDA\uc2  approval to market a new two-drug, single-pill combination to treat the liver disease hepatitis C. The drugs, grazoprevir and elbasvir, cured at least 90% of infected patients in a mid-stage clinical trial and Merck is testing them in late-stage studies.\par \par \uc2 The company previously said it expected to file for regulatory approval of the hepatitis C regimen sometime during 2015.\par \par \uc2 In hepatitis C, Merck is trying to catch up to market leader \uc2 Gilead Sciences Inc\uc2 ., which analysts estimate raked in at least $12 billion in combined sales in 2014 from the blockbuster drug Sovaldi and the first all-oral combination drug, Harvoni. \uc2 AbbVie Inc\uc2 . recently introduced the second all-oral regimen, Viekira Pak.\par \par \uc2 Merck isn't expected to overtake Gilead, but could grab a significant portion of a large market.\par \par \uc2 Document DJTGMS1120150112eb1c0002w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Vertex says NDA for ivacaftor use in children accepted by \uc2 FDA\b0\par\par\uc2 244 \uc2 words\par \uc2 11 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Vertex Pharmaceuticals\uc2  outlined 2015 business priorities to support the development, approval and \b \highlight22\uc2 launch\b0 \highlight\uc2  of new medicines that treat the underlying cause of cystic fibrosis in conjunction with the J.P. Morgan Healthcare Conference. Vertex currently expects that by the end of 2015, more than 3,700 people may be eligible for treatment with Kalydeco, including children ages 2 to 5 and, in Europe, adults with the R117H mutation. Vertex today announced that its \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for the use of ivacaftor in children ages 2 to 5 who have the G551D or one of the eight additional gating mutations was accepted for filing by the \uc2 FDA\uc2 , and a target review date of March 17 was set under the Prescription Drug User Fee Act for the \uc2 FDA\uc2 's approval decision. In Europe, discussions are ongoing regarding reimbursement for patients with non-G551D gating mutations.\par \par \uc2  Additionally, a Marketing Authorization Application variation for ivacaftor in people ages 18 and older with the R117H mutation and an MAA line extension for ivacaftor in children ages 2 to 5 with gating mutations have both been validated by the \uc2 European Medicines Agency\uc2 . In Australia, Kalydeco was listed on the Pharmaceutical Benefits Scheme as of December 1, 2014, which is intended to provide reimbursement for all eligible patients ages 6 and older with the G551D or other gating mutations. Patients in Australia have now begun to receive treatment with Kalydeco \par \par \uc2 Document FLYWAL0020150112eb1b000p1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 "I  \highlight22\uc2 Launched \highlight\uc2  at Brookstone!" is Common Theme for This Year's High-Tech Startups\b0\par\par\uc2 1,352 \uc2 words\par \uc2 5 January 2015\par 19:02\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Product developer and specialty retailer Brookstone will use CES 2015 to unveil its "I \f28 \b \highlight22\uc2 \f2 Launched\f28 \b0 \highlight\uc2 \f2  at Brookstone!" campaign to attract and promote world's next generation of unique companies looking for the perfect launchpad \par  \f28 \par \par \uc2 \f2 MERRIMACK, N.H., Jan. 5, 2015 /PRNewswire/ -- Brookstone has always focused on designing its own lines of innovative music systems, therapeutic massagers, app-controlled robots, and checkpoint-friendly luggage. They've also used their tech-savvy army of store associates to help \f28 \b \highlight22\uc2 \f2 introduce new products\f28 \b0 \highlight\uc2 \f2  from the most exciting startup companies from around the world.\f28 \par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20150105/167109LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20150105/167109LOGO}}}\par \par \uc2 At CES this year, Brookstone is unveiling its "I Launched at Brookstone!" campaign to promote new homegrown products, introduce the new tech products from exciting startup companies, and meet-and-greet with the next generation of startup companies looking for the fastest way to bring their products to the biggest possible market.\par \par \uc2 "The 'I Launched at Brookstone!' campaign is about two things," says Brookstone Chief Merchandising Officer Steve Schwartz, "promoting our newest product partnerships and helping the next generation of startup companies bring their products to a worldwide market as fast as possible."\par \par \uc2 Schwartz continues, "Brookstone is uniquely able to develop and market startup products because we have in-house design, packaging, marketing, retail, e-commerce and wholesale teams under one roof. We look forward to showcasing our latest products at CES this year, as well as taking time to talk with startups about their upcoming products. If you've got a product ready for the big time, stop on in for a quick visit."\par \par \uc2 Brookstone will be located at CES Booth #36043, Las Vegas Convention Center, South Hall #4, from January 6-9, 2015. Brookstone will also participate in the Pepcom Digital Experience media preview event on January 5, 2015 in the Mirage Events Center at the Mirage Hotel.\par \par \uc2 Among the new products that Brookstone will showcase during CES are:\par \par \uc2 Plastc(TM)\par \par \uc2 A Plastc Card will truly slim your wallet -- you'll only need one card to store all the information of up to twenty cards. Plastc brings all your cards into one sophisticated device. Plastc's e-ink touchscreen gives you easy access to many types of cards, including loyalty cards (even cards with only barcodes), store cards, gift cards, debit/credit cards, ATM cards, and even access cards. With a magnetic stripe and barcode display, the Plastc Card will work in all the places you already frequent. Plus, with NFC and Chip and PIN capabilities a software update away, you'll soon be ready for the future of payments. Anticipated retail price: $155. Available 2015.\par \par \uc2 Perfect Bake(TM)\par \par \uc2 Developed by Pure Imagination, LLC, the patented app-controlled smart baking system that will revolutionize the way people bake at home, turning anyone into a master pastry chef. The heart of the Perfect Bake system is a smart digital scale that connects with an innovative app (Android and iOS compatible) designed to make baking foolproof and fun, guaranteeing perfectly delicious results every time. It hand-holds the user throughout the entire baking process, from recipe selection, scaling and prep, measuring and adding ingredients, mixing, and portioning to baking and cooling. Retail price: $69.99. Available now at Brookstone.com.\par \par \uc2 Perfect Drink(TM)\par \par \uc2 A revolution in home bartending, the Perfect Drink smart scale and free app contains hundreds of drink recipes and guides home bartenders with real-time pouring instructions. Choose serving size with Perfect Drink to make one drink or a party pitcher and watch as the virtual glass fills on the user's smartphone or tablet screen. The app senses the perfect pour, alerts the user when to stop and compensates for overpouring by instantly re-adjusting the other ingredients. Retail price: $69.99. Available now at Brookstone.com.\par \par \uc2 iTOi(TM) Video Studio\par \par \uc2 iTOi (pronounced eye-to-eye) makes it possible for iPad users to record personal videos when eye-contact is important. The desktop video studio includes the iTOi Video Booth with a patented optical solution that makes it possible to look directly at the camera while recording. The iTOi Video Producer app for iPad allows users to record their scripts with a teleprompter to produce personal videos easily. iTOi also works for video chat, making a more human connection for anyone with chat or video conference partners. Retail price: $149.99. Available now at Brookstone.com.\par \par \uc2 BodyForm(R) Foam Roller\par \par \uc2 Featuring deep tissue and vibration massage, the BodyForm Foam Roller is the first product launched by Brookstone in partnership with Dolvett Quince, fitness expert and lead trainer on NBC's "The Biggest Loser."\par \par \uc2 This vibrating foam roller was created for those who work out and those who work all day. It is ideal for beginners, fitness enthusiasts and expert athletes alike to use pre- and post-workout to help warm-up, relax and effectively rehab muscles anytime, anywhere...no appointment necessary. Retail price: $69.99. Available now at Brookstone.com and coming soon to Brookstone stores nationwide.\par \par \uc2 News from Big Blue Audio(R) In 2014, Brookstone made the world a much louder (and happier) place with its Big Blue Audio collection of Bluetooth(R) compatible wireless speakers. Its best-selling system was Big Blue Party(TM), a 360-degree, bass-thumping, no-cord-needed speaker that could be used indoors or out.\par \par \uc2 Big Blue Audio is bringing three new family members to CES in 2015, offering industry-leading features, audio quality, design and value:\par \par \uc2 Big Blue Splash\par \par \uc2 Pound for pound the best speaker in its class with sound that will drown out the competition. A new multiple-user feature lets up to four (4) users connect their devices to Big Blue Splash. True to its name, this water-resistant wireless speaker boasts a built-in subwoofer and passive radiator for big bass, speakerphone capability with water resistant microphone, NFC pairing, and a rechargeable lithium ion battery for at least six hours of battery life (measured at 75% volume). It can also connect to a second Bluetooth speaker using the new Big Blue Button. Big Blue Splash is perfect for pool, home, office, bathroom or travel. Anticipated retail price: $149.99. Available 2015\par \par \uc2 Baby by Big Blue\par \par \uc2 A new entry level-priced Big Blue Audio wireless speaker that doesn't sacrifice on sound quality and features. The small, floating Baby by Big Blue is water resistant to IPX7 standards, includes a passive radiator for enhanced bass, and offers convenient NFC pairing. Perfect for the pool, bathroom and travel. Anticipated retail price: $69.99. Available Mid 2015\par \par \uc2 Big Blue Button\par \par \uc2 A ground-breaking audio accessory, the Big Blue Button lets you pair together two Bluetooth speakers from one device to deliver even bigger stereo sound at the touch of a button. With easy pairing and a small footprint, the Big Blue Button will be compatible with current and new Big Blue Audio speakers and with most other brands of Bluetooth compatible wireless speakers. Big Blue Button will play both wireless speakers in stereo mode with a range expected to exceed 33 feet in either direction and features a rechargeable battery life of 10 hours. Anticipated retail price: $69.99. Available Mid 2015.\par \par \uc2 About \uc2 Brookstone, Inc\uc2 .\par \par \uc2 Brookstone, Inc\uc2 . is an innovative product development and specialty lifestyle retail company that operates approximately 240 Brookstone branded stores nationwide and in Puerto Rico. Typically located in high-traffic regional shopping malls and airports, the stores feature unique and innovative consumer products. The Company also operates a Direct Marketing business that includes the Brookstone catalog and an e-commerce website at {\field{\*\fldinst{HYPERLINK "http://www.brookstone.com"}}{\fldrslt{\cf2 \uc2 http://www.brookstone.com}}}\uc2 .\par \par \uc2 Note to Media: For high-res images please visit {\field{\*\fldinst{HYPERLINK "http://bitly.com/brookstoneces"}}{\fldrslt{\cf2 \uc2 http://bitly.com/brookstoneces}}}\par \par \uc2 Contact: Mike Rosen or Tommy Morales\par \par \uc2 Blue Wolf Communications\par \par \uc2 516-767-9653 (Office)\par \par \uc2 516-647-1348 (Mike @ CES)\par \par \uc2 mike@bluewolfden.com\par \par \uc2 tommy@bluewolfden.com\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/i-launched-at-brookstone-is-common-theme-for-this-years-high-tech-startups-300016028.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/i-launched-at-brookstone-is-common-theme-for-this-years-high-tech-startups-300016028.html}}}\par \par \uc2 SOURCE \uc2 Brookstone, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.brookstone.com"}}{\fldrslt{\cf2 \uc2 http://www.brookstone.com}}}\par \par \uc2 Document PRN0000020150106eb1600003\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 LEO Pharma \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Drug \highlight\uc2  Application Submission of the First Aerosol Foam for Plaque Psoriasis\b0\par\par\uc2 559 \uc2 words\par \uc2 5 January 2015\par 19:01\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2015  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PARSIPPANY, New Jersey, January 6, 2015 /PRNewswire/ --\par \par \uc2 LEO Pharma\uc2  announces it has submitted a \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) for calcipotriene and betamethasone dipropionate aerosol foam, 0.005%/0.064%, to the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for the treatment of plaque psoriasis.\par \par \uc2 (Logo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130221/595427"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130221/595427}}}\uc2  )\par \par \uc2 The first aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed with the aim of improving treatment for patients with plaque psoriasis - the most common clinical form of psoriasis.\par \par \uc2 The regulatory submission in the US is based on studies of patients with plaque psoriasis. These include the Phase 3a PSO-FAST study which evaluated efficacy and safety at four weeks([) (1) (]) and the Phase 2 MUSE safety study.([) (2) (])\par \par \uc2 Barbara J. Osborne, President and CEO, commented:\par \par \uc2 "Psoriasis is a chronic, debilitating disease. Patients with inadequately managed plaque psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancer.([3) (])\par \par \uc2 With the regulatory submission announced today, we are taking a step further towards providing additional topical treatment options for people living with psoriasis."\par \par \uc2 Regulatory filings in Europe and other countries are planned during the course of 2015 and 2016.\par \par \uc2 With this latest submission, \uc2 LEO Pharma\uc2  demonstrates a strong commitment to dermatology.\par \par \uc2 NOTES TO EDITORS\par \par \uc2 About Psoriasis\par \par \uc2 Psoriasis is a chronic, inflammatory disease, which is frequently accompanied by multiple physical and/or psychological comorbidities, such as metabolic syndrome and psoriatic arthritis.([) (3) (])\par \par \uc2 Plaque psoriasis is estimated to affect about 2-4% of the population in the US.([) (3) (]) 80% of patients are affected by plaque psoriasis - the most common clinical form of psoriasis.([) (3) (])\par \par \uc2 Topical treatments are first-line therapies for the majority of patients since approximately 80% of the patients have mild or moderate plaque psoriasis.([) (3) (])\par \par \uc2 About \uc2 LEO Pharma\par \par \uc2 Founded in 1908, \uc2 LEO Pharma\uc2  is an independent, research-based pharmaceutical company. \uc2 LEO Pharma\uc2  develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company has its own sales forces in 61 countries and employs around 4,800 people worldwide. \uc2 LEO Pharma\uc2  is headquartered in Denmark and is wholly owned by the LEO Foundation.\par \par \uc2 For more information visit {\field{\*\fldinst{HYPERLINK "http://www.leo-pharma.us"}}{\fldrslt{\cf2 \uc2 http://www.leo-pharma.us}}}\par \par \uc2 References\par \par \uc2 1. LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris. 2013. ClinicalTrials.gov Identifier: NCT01866163.\par \par \uc2 2. Taraska V, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Presented at the Skin Disease Education Foundation's 15th Annual Las Vegas Dermatology Seminar & the 11th Annual SDEF Psoriasis Forum, October 30-November 1, 2014. Abstract #13\par \par \uc2 3. Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. The Society for Investigative Dermatology. J Invest Dermatol 2013;133(2):377-85\par \par \uc2 Global Media Contact\par \par \uc2 Polly Lutter\par \par \uc2 Senior Global Communications Manager\par \par \uc2 LEO Pharma A/S\uc2 , Denmark\par \par \uc2 polly.lutter@leo-pharma.com\par \par \uc2 Tel: +45-41-37-12-27\par \par \uc2 Amanda Agostino\par \par \uc2 Client Executive, \uc2 Burson-Marsteller\par \par \uc2 amanda.agostino@bm.com\par \par \uc2 Tel: +1-(212)-614-4129\par \par \uc2 SOURCE \uc2 LEO Pharma\par \par \uc2 Document PRN0000020150106eb1600002\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan Announces U.S.  \highlight22\uc2 Launch \highlight\uc2  Of Generic Diovan Tablets\b0\par\par\uc2 129 \uc2 words\par \uc2 5 January 2015\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2015 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Mylan Inc\uc2 . (MYL) on MOnday announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of \uc2 Novartis AG\uc2 's (NVS) Diovan\u174\'00\'AE Tablets.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for the product, which is indicated for the treatment of hypertension, to lower blood pressure.\par \par \uc2 Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, had U.S. sales of anout $2 billion for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2015 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020150105eb150058y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of \uc2 Novartis\uc2  Diovan tablets\b0\par\par\uc2 69 \uc2 words\par \uc2 5 January 2015\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2015. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Valsartan tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of \uc2 Novartis\uc2 ' (NVS) Diovan tablets. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application, or ANDA, for this product, which is indicated for the treatment of hypertension, to lower blood pressure.\par \par \uc2 Document FLYWAL0020150105eb150050o\par }\page {\par\fs20\b \uc2 Quest nutrition  \highlight22\uc2 launches \highlight\uc2  protein powders.( \highlight22\uc2 New Products \highlight\uc2 )\b0\par\par\uc2 117 \uc2 words\par \uc2 1 January 2015\par \uc2 Nutraceuticals World\par \uc2 NUTW\par 45\par \uc2 ISSN: 1531-0671; Volume 18; Issue 1\par \uc2 English\par \uc2 Copyright 2015 Gale Group. All rights reserved.  \par \par \uc2 Los Angeles, CA-based Quest Nutrition has \b \highlight22\uc2 introduced\b0 \highlight\uc2  new Quest Protein Powders, which are highly versatile and can be added to on-the-go protein shakes, baked goods and a variety of other everyday products, according to the company.\par \par \uc2 Quest Protein Powder delivers 21-23 grams of protein per serving from a proprietary blend of high-quality whey isolate, micellar casein and milk protein. The product is gluten-free, contains 2 grams of sugar or less, and a high protein-to-calorie ratio, according to the company. Quest Protein Powder comes in five flavors: Vanilla Milkshake, Chocolate Milkshake, Strawberries & Cream, Peanut Butter and the cooking-inspired Multi Purpose Mix.\par \par \uc2 Document NUTW000020150129eb110000p\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw198\pich40\picscaley100\picscalex100\picwgoal2970\pichgoal600
47
4946383961C6002800E60000FF7174FFB6C1FFA4A7FFC9D4DADADAFF6A6FFF6168A5A5A58B8B8BFFB6B5FFDBE3B4B4B47B7B7BFF5761FF373D6B6B6BFF96A372
7272828282919191FF0000FF282BFF7584FF3131FF4A51262626FFEDF2ECECECCACACAFF1418FF4244171717FF5258636363FEFEFEF6F6F6C5C5C5FFE2EAFF00
1AF1F1F1FF0030FF2021E8E8E8FFF5FAFFEAECBDBDBD090909FF00003A3A3AFF0D00FFF2F5AAAAAA5B5B5BCDCDCD444444F9F9F9FF00009E9E9ED5D5D5545454
FFD0D2E0E0E0FF0000FF0039313131FFA49BC2C2C2FFDBDCFFE1E2E4E4E4FF9099B8B8B8D0D0D0FFD3DC4C4C4CFFADAFFFC3CD979797FCFCFCFF8181FF8389FF
8A90FFF9FEAFAFAFFFA5B2FF9192FF899AFF687EFF7B8DFF8984FFF9FAFFC9CAFF1332FFC1B9FF8493FF999BFF5971FFBFC5FF8EA6FF2746FFCDC3FFFCFFFFAC
BEFF0000FF9FB1FF0000FF2E1CFF8C86FFA2BFFF0003FF9892FF1E07FFFDFBFF5248FF7F97FFDFDFFFD8D4FF7B7BFF0500FFFDFDFF0000FFE7E9FF3D4FFF948E
FF5D5BFF4970000000FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E332D633031312036362E3134353636312C20323031322F30322F30362D31343A35363A32372020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F702043533620284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969643A3439
3435374342313634353431314534383039454641434334344137384341392220786D704D4D3A446F63756D656E7449443D22786D702E6469643A343934353743
4232363435343131453438303945464143433434413738434139223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E63654944
3D22786D702E6969643A3741443738343836363435333131453438303945464143433434413738434139222073745265663A646F63756D656E7449443D22786D
702E6469643A3439343537434230363435343131453438303945464143433434413738434139222F3E203C2F7264663A4465736372697074696F6E3E203C2F72
64663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9
E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9
A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A69
6867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A29
2827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C00000000C60028000007FF807F
8283833D07113B308A8B4A211239352384939495969795270B114A8B8A368E39482298A5A6A78327073327A8AE981C13080C11349D2DAF82040F1F7EBE7E1F40
40BDBF7E2E07B9C9980819C5194019C4BE1F3ACAD60B39953D30BE3004D6C913C5BF33B92DD27E342D041B1B042D0836BF13E0D6A44E21C50F423D1B45480794
F87241A2DE2B1D2E80547A508C864157376A1C9147EE203A099646E4F343EF613204C5185472C2D08F108FA69CC80B5169A3AF1D285D89ABE8AAE4C0229710FA
4110D3958A66BF6A5842E20B574F4B20FDB0A44482D88793474B3128560ED506A0BF220C12C195903CAD96BA5E22E58AEC9F05E396FE31BB565E55416CFF27C5
954B496C0E17BE1C12EA8A2442846F7BC3CE5D4B6AF0564253699EEA81CE5708C094A67C8049A9DDE013922ADDC8BCB6468B162AE00A3A30CECF831E95667CC8
3669048719075AA0B67443859341488E2C103A68A6AF07A64EDCB8E464C3705DBA49DC16FB67C48C073660D0400015315557574B037B3023F42424454EE44080
2042881D19B4F6C8D164D6831D40B29D9892633C83074044FE9961E3830B17192033085AA57DF0400B6C89A0432B836C30010CFFF532D9117FC0D39E798A6C50
E10EFEB960E01F45D0300E0C08482001033A6C505F13122002C4148370D0447B0C846003104221C1CB7F2E28E19D203370E3070C21E0D523647F24E6CBFF5BA7
ECA0DD2FE9B5C0206E788DE35013DAD1C381760FDCE0D22F1FF0F607634FF638019284F440D1070BF4B0D1074744501A103724354E0E4E3EE9CB014764398888
E3B850C40C551613015958FE460A075502F1A3927E30694A0D85EA09C30347DCD65C0EF8193A260234A053CE0913D020A42F4AC8F3DF38180D62E7931F84B0C0
72826C00C4401CC0259031F5ED502810220268E5781248931F2D0FE8A00222E8B0F60707B54893C14658F992014E245499C19412FC420359904A6ACA118DE969
C30284D4A00F21BEF921A020279CFA9B0E35C80B962024E9590C0C140A22E74B8490D68D2036BD54C3B2FBC28BD5BD9324EA8BB383E430226813149A41FF0F22
50641A21D9FE6254B8C9EC52A99E2EE857E1BAAE16F3EE1F379CEAC25B2D14CAB02013545B263264FAD2449AD2C058B0C937606583243A48A317250EFB01B120
127BCBD9AE7E64A060311238B199134848D32AC865C5C8000CE596C69AC0BF59F7CBCAB6FE0284A67F74EC8BC984A890830D238FF3C106243474802CE3152A92
4B2E5423C808A7DAD04AD1BFA835C9AB4BFFF12A938046FDC714C50493C1E5D52A2108D7A51816513C614F13DA0C9E0ED2EDD984A4ED0B1053C6FC0BDC94C442
F7930890AD1D8F4AFD61930BB9D67AAB2F86FF81B8634815D338E384E4E987424967D009234A74A21FE7989042C0020C2658C3DC4F2243F9EB849CBE67FFEABF
2FAFA120AEBF3D881046C9254404E5EEF0AF2F12D420C4FD4290A0FF02DF005E90EFBF08DEF0725709E42DCE78C9539BE310389241504F2A2E98D9246ED084BA
F1E47BEA1BC4FCDC453EB59DAF427EC31784FE57091DC8CB0F36D860E326E1BF06954F80D2501C210C3843060A427919F843D3CA2695EB744E1020C9C0072D91
345F5C3024661B9F0B3D3888F4F9C1644E6A95250688C25751E6122D14840A5ED88AAC25AE78BF389E0DFF80C36739634A967820269A0623D104E60F50F3058C
30C891F0A94C34AA335F1343483014BE712DFE6AC8005DD03E42A4E80F59FC431E83C7016900A7803624CBAB763608A86540052328DFC626E104065405FF6486
7123E95088C64A286F799218E54BC822191FD60A2BACDB23F802E902745DA2603BDBE0070AA94317606477628A57006F53831812E2049A6AD7CA0491B495E110
277D2AC60E84209C1308612582109F1F6C790A020DE94C951881040AE502A8A8F22513F8921C095104587ED089F7FA970B30759C4138E12E0194C40934E9021A
4C603C028101C62247C8549C0A061ADA80347C890412C04F2822D0E6D244304942B82403826B97318070A3DF48E206B8645B29A20926F9216046E5915706DAF8
07A268E703E8C8000D167080109C90484D10410B2AA78408E8E055287C00034C14018DA11027A4D08126C771AE09CC0E4AF2C364B580B5007512835F0CFFE84F
E56810811EE8C046E8F880121E8004383A630708B867D85CC0130ED060A92E20129A2AA1820780AD6E810202027E94CDD2D0601BC658D5907EC7A3427D600442
3092CC8A1001B0E9EB0336C88124CCB20109D82C03BF1C48613DF68766E00E85043861067872BAC20AF6084D336D95E8A12AC1FAE11B04F85A3432600314F531
B09B8D142A46400012CCA03C0F08010D764003A1E6800453624B4D69E088FF09E108FA2301FB08A08316E42FBAFA83AE084EF019EC1E0130BC15C26F91F58008
48E0006575233B677022042CE07CD5E5807CE7CB81FC4902092DA8C17C855056074580010898C2F97AD002FACE577F23D840810DCC01E96A48074798AFFFFD38
C09911F480001863A710182C5FE446A56B1F0EB188474CE2129BF8C4284E7132CA200529AC40062CD0401E4A5002052860084948020F76BC852DECF8C74398C3
1C8840843CC458065AD0C21D3C629650AAF8C974A1441296908752686109553002140050000380C0030E70C0052A508114A4A003688E819AD1DC01339B99CC17
8873981DE0010F60E0CE2000011F0A500000D4010A55A8C2170490800404C0C73C48429159B0022743F9D1AE90010F0450070CC4000F3C00A425E680874E7BBA
D31DB8009DF960803A64C10D5F088200542D00012CE1D54BA00215D000012BD8DA0B58C08205767D05035CA1CB6000439E1B00860634C000C736800100FFB06B
2878410C10408319A61D806A33610049180211588064487BFB0F65508019A250800BD8E1D33150402958E06B082C610B0AD08014FE200519C8780874D8421712
20802F64A10E05E0C397C55C012E74A00D6DF8B4C217EE6984AB39066C76730A446D670C2CDB0272B035B4BF608428787C0F10104000064087226B40062BD002
1CBE8D1229E4810E0988820130C00586A700031058012AA450021E04400C7598F90552706E86E3A10D31484105E46C673D2B1B00507FC2134CBD86AA5B7DEA4F
807A970DC0070CE881E06766B81DDEA0060758FC0A16C0C215AE00863EF4010C6B7FB618D840F769CB3A0061F0F11018CDF24AAC80054908031AA06000FF0FBC
81E1A106C11304B0852A9F420606A84007161E830A98DDD77210031AF08E6D059440032B904219CA1015119461051A284112981006338841ED427F43D13B0DF1
0E70810B63C8BD1E30D000B4675E0CC097031600606C3E90DACF801EB4A1F3CE832097200F1A90F7E85FC1E2176B8005354EC200C2C0EF2A3C21E00E90BCD82B
E081520B80090AD079259C9C0731F301006B10401778B0EDD0F7DD14A8CF030F121084351460E09327761307027D8605B666055E100559077500E06577F67571
16676466797236671678810457661DF0700967749DD606297079755005EFB6775A800A4E760732407AF7771422B0020A10004B00011600020E10800C77FF7B63
F076CBB6067BB00741900061C0030330005BC00401D06F51600105D00020800160167E64A67453D80153686672B67BC7760558100546206D01C0049F376FB9A0
052CD00502E0782DD87766B87F5FF0043698020C670274F88164E7007100004FF00509C003F1E60AA75706A6377D3D71071AB07A54F0047CE0016A80071D9004
9A26186BC8649AE6687FA0057930004B406E71A00697D6697458874637711ED0007AA87C5B50723146860F917F0AC00361B004410005FFE70115F0899F660263
400493D88B61C10274D00541500702E7003F208A1E48796D5601BB07020DD06775F00450006846508DD6D871D338750DE8841E30741D307B0B478728F0B403E4
8802BBE88BE8580A70C002B1F80558D0007A207EC9388FF4588F78208EE3488EE58802C8D80690988E00790A7F3704B1E8064F3073E1878B1E188A28D0900EF9
900FA98F12B98FA1988CA1C6076A18901A091796580687B87D4BA06500C00771D08D6AF0066F1003E0688F0B67076A467617E001A456075140056130000A2003
1BB9933DA1052FC60244300774400664D005FBF66A41909441F0055FE0064A1904AF9600464906CD3707792003DD960B8100003B}}
\par\par \uc2 Business\par \b \uc2 analysis Plan manager fights back on drug prices Move could set tone for future deals on specialty medication\b0\par\par\uc2 By Jason Millman, The Washington Post   \par \uc2 577 \uc2 words\par \uc2 27 December 2014\par \uc2 South Florida Sun-Sentinel\par \uc2 FLSS\par \uc2 Palm Beach\par 3D\par \uc2 English\par \uc2 Copyright 2014, South Florida Sun-Sentinel. All Rights Reserved.   \par \par \uc2 For the last year, a stream of \b \highlight22\uc2 new drugs\b0 \highlight\uc2  with shocking sticker prices has looked unstoppable. There was Sovaldi, \b \highlight22\uc2 introduced\b0 \highlight\uc2  last December by \uc2 Gilead Sciences\uc2 , priced at $84,000 for a 12-week treatment. Then came Harvoni in October, also from Gilead, priced at $94,500. And this month, drugmaker \uc2 AbbVie\uc2  received \uc2 Food and Drug Administration\uc2  approval for Viekira Pak, which the company priced at about $83,300. All three drugs treat hepatitis C.\par \par \uc2 Now comes a major pushback.\par \par \uc2 This week, the country's biggest drug plan manager, \uc2 Express Scripts\uc2 , said it will drop Gilead's drugs Sovaldi and Harvoni from a list of preferred drugs covering 25 million patients and instead will only put Viekira Pak on its list. \uc2 Express Scripts\uc2  said it has negotiated a significant discount with \uc2 AbbVie\uc2 , perhaps between $20,000 and $30,000 per course of treatment, in return for expanding access to patients and letting primary care doctors prescribe the drug.\par \par \uc2 Insurers and companies like \uc2 Express Scripts\uc2  have been sounding the alarm that the new hepatitis C treatments are at the forefront of a wave of high-priced drugs that, while offering improvements over previous therapies, will strain their budgets.\par \par \uc2 Over the past year, these companies have tried to limit access to these drugs as a result. In many cases, they'd only allow sicker patients to get them, and they limited the types of doctors who could prescribe them.\par \par \uc2 "This negotiation is a vast improvement to the current environment in which a significant number of patients have limited or no access to curative treatment," read a statement from Ryan Clary, executive director of the National Viral Hepatitis Roundtable, which has pushed for widespread access to new hepatitis C medications.\par \par \uc2 Compared to other developed countries, in which governments set prices, there are limited tools for pushing down the costs of brand-name medications in the U.S. Domestic government programs get mandatory discounts (excluding Medicare), and it's up to private payers to try to negotiate discounts with the drugmakers.\par \par \uc2 But will the \uc2 Express Scripts\uc2  deal set the tone for future expensive specialty drugs hitting the market? Some closely watching the industry think it could.\par \par \uc2 "We believe we are in the early innings of a transformation around specialty formulary exclusions and believe this could play out in other competitive specialty categories over time," \uc2 JPMorgan\uc2  analyst Lisa Gill said in a research note, Reuters reported.\par \par \uc2 Steven Miller\uc2 , chief medical officer of Express Scripts, said it will try to strike similar deals, pointing to new advancements expected in treatments for cancer, multiple sclerosis and rheumatoid arthritis.\par \par \uc2 But Dana Goldman, director of the Schaeffer Center for Health Policy and Economics at the \uc2 University of Southern California\uc2 , warns this could come at the expense of the patient since not all will respond to the same treatment.\par \par \uc2 Express Scripts\uc2  says it won't limit access for hepatitis C patients who need Gilead's drugs, but exclusions could still be problematic, Goldman said.\par \par \uc2 "The reality is if you put up barriers for physicians and patients, we know that people won't have as good access," said Goldman, whose own research found that limits on drug availability lead to worse outcomes for psychosis patients.\par \par \uc2 Photo: Express Scripts of St. Louis is the nation's largest manager of insurance drug plans. JEFF ROBERSON/AP   \par \par \uc2 Document FLSS000020141227eacr0002t\par }\page {\par\fs20\uc2 Business\par \b \uc2 Spectrum Pharma Submits NDA For CE-Melphalan - Quick Facts\b0\par\par\uc2 191 \uc2 words\par \uc2 26 December 2014\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2014 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Spectrum Pharmaceuticals Inc\uc2 . (SPPI) announced the company has submitted a \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) to the U.S. FDA for the approval of Captisol-Enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. The company is also seeking approval for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.\par \par \uc2 Spectrum Pharma expects \uc2 FDA\uc2  review to take approximately 10 months. The company said it plans to \b \highlight22\uc2 launch\b0 \highlight\uc2  the drug with existing hematology/oncology sales force next year pending approval.\par \par \uc2 Spectrum Pharma gained global development and commercialization rights to CE-Melphalan from \uc2 Ligand Pharmaceuticals Incorporated\uc2  (LGND) in March 2013. Spectrum assumed the responsibility for the pivotal clinical trial and was responsible for filing the NDA. Under the license agreement, Ligand received a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2014 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020141226eacq001xi\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Ligand partner Spectrum announces submission of NDA for Melphalan\b0\par\par\uc2 115 \uc2 words\par \uc2 26 December 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Ligand (LGND) announces that its partner Spectrum (SPPI) has submitted a \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application to the \uc2 FDA\uc2  for Captisol-enabled Melphalan HCl for injection for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Spectrum is also seeking approval for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. According to \uc2 Spectrum Pharmaceuticals\uc2 , the Captisol-enabled Melphalan NDA was filed under a 505b2 application and Spectrum expects \uc2 FDA\uc2  review to take approximately 10 months. Spectrum plans to \b \highlight22\uc2 launch\b0 \highlight\uc2  this drug with its existing hematology/oncology sales force next year pending approval. \par \par \uc2 Document FLYWAL0020141226eacq0012x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw189\pich40\picscaley100\picscalex100\picwgoal2835\pichgoal600
47
4946383961BD002800F7FF00FF6767FF0000FF5252FF0606FF0101FF0E0EFF0202FF1010FF1717FFFEFEFF0B0BFF1C1CFFF7F7FFB4B4FF5454FF4545FFC6C6FF
7D7DFFFFFFFF9393FF3838FF7272FF2626FFC9C9FF8888FFDEDEFFF2F2FFF4F4FF1616FF6B6BFF0A0AFF0505FF4D4DFF2C2CFF4F4FFFF3F3FF1818FF8080FFDF
DFFFFDFDFF2222FFC4C4FF4242FF2929FFF0F0FFEBEBFF0303FF0404FF3434FFADADFF0F0FFFF5F5FFE0E0FF2A2AFF4B4BFF1A1AFF3D3DFF1919FF1212FF9292
FF8D8DFF6565FFEAEAFFE1E1FF7B7BFFF6F6FFFCFCFF2D2DFFF1F1FF5959FF3E3EFFF8F8FFE2E2FF0808FF0909FF0D0DFF1515FF0707FF2727FFA2A2FF5A5AFF
F9F9FF7E7EFF3A3AFF1111FFD2D2FF2020FF1F1FFFE4E4FF7676FFBDBDFF1313FFFBFBFFC7C7FF1B1BFFA1A1FFEEEEFFA6A6FFDCDCFF6060FF0C0CFF2424FF7C
7CFFB6B6FF2B2BFFB0B0FFE3E3FF6161FFD1D1FF2121FF2323FF5353FF6C6CFFC2C2FF6262FFEFEFFF5757FFFAFAFFE6E6FFC5C5FFA0A0FF3535FFA7A7FF1414
FF1D1DFFACACFFECECFFB9B9FF5050FF5E5EFF9797FF3737FF8383FFE5E5FFDBDBFFCCCCFFEDEDFF5151FF6969FF5D5DFFE7E7FFD0D0FFD4D4FF4040FF8686FF
5B5BFF8E8EFFB7B7FF5555FFB5B5FF4141FFCDCDFF4949FFD5D5FFA5A5FF4E4EFF7F7FFFE9E9FF6D6DFF9090FFAAAAFF5F5FFFC0C0FF4848FF2525FF9D9DFF2F
2FFF7373FFAEAEFF3030FF3131FF7474FF3333FF6F6FFFBBBBFF7171FFCFCFFF7777FFD9D9FFDDDDFFD7D7FFDADAFFE8E8FF7A7AFFD6D6FF4A4AFF6868FF5656
FF3636FF1E1EFF9A9AFF9191FF8A8AFF6363FF8989FF7979FFA9A9FF6A6AFFABABFFB8B8FF4C4CFFA3A3FFCECEFF9C9CFFBFBFFFBEBEFF3C3CFF5C5CFF3B3BFF
7070FF6E6EFF9999FF9494FF3939FF2E2EFF3232FF3F3FFF9F9FFF8484FF9595FF8181FFD8D8FF4343FFD3D3FFA4A4FFCBCBFFBABAFF5858FFCACAFF2828FF9E
9EFFB2B2FF4646FF4747FF8B8BFFAFAFFFC3C3FF8787FFBCBCFF8C8CFF4444FF6464FF9696FF7575FF8282FF9B9BFF9898FFB3B3FF7878F8F7F7FFB1B1FA4747
FC7C7CFED9D9FFC8C8FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A45374239373346443531423531314536383342314337334644453946314437322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A4537
423937334645353142353131453638334231433733464445394631443732223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A4537423937334642353142353131453638334231433733464445394631443732222073745265663A646F63756D656E744944
3D22786D702E6469643A4537423937334643353142353131453638334231433733464445394631443732222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000BD00280040
08FF00FFFD93606BDBA21C0512A6F2C548A0C38710234A9C48B1A2C58B181F76D383E7C9932FE782083CE1AE6336654204DA42D5F149291A09324A4C60A894C7
52B862420CD2A0E3173D8E3016084094A803812C96147D41C961A558020450FA54CBA1B8183140B99220449A003A9A540A8BCAA9DBBF23A8FAC43016450890A8
4094FD4B104713D6187EFE352216A3CFBA14C71AD0291A408E26665C044E1A165500355902B934001583582321B33A08D0B580B0B57F3FA6100E90E51F2C0E45
A9101A782650D43569A240CC14E64D5439E136FC9BD183309411FF3401E114E15DA61A450DC0A9A4161C8413732B19EB2B6A28E1A3127D38284A42CB3F108479
C0FF208C814104C20F3464E84CD4C0840345115C3041817009118421FCEB50744005812A10B643022DD8505401D4FCF3CA00458D71435104A4F110230F16F508
2045C94094077010509437AE10C6811A239052940559C047D414FF54D14651140840980846148543503F84405825128047541E970C5154182758575424913141
D8384570D7CC77E18D575479E71595DE7AC9BD17DF7CF515755F7EFFC0D1DF7FFF0458D4800516758030FFD843D82E5E40D8004473C8315A0079FC93012F7702
F04F0A84B971C93F83A4760A1545B1188E91A424425812DA204714141A8CB042510A9C2210381E8C06433F12C972061EC93C014B0613D901C11D9930201345AE
28FF50540E2944F10D04833ED4421C5D1CF12A442D5C90822C22FD6AEC43B5A490C20F1375F2431C10D471AC445C0053D407403C34C19D013048980B294C2BAE
B80C1CB2CC2E35E89198B851BC419801A0086446A7442D91C93F412842182F4189BB416F45FD16518E984A21D468D8097141175D40D0851A92108602254AA486
C4188F52E021615EC84AD82F8816758529A309E32351FAF147D400A338C16D00BC2C4218029128459412D958F0B23C4010464217B06C3CEB1CAF103685814519
6126519B88A1735198B04258075512F586049E100606184F13D54718457930271CDE060086914609B401268F3C828D25520C4654775016251E79E6A1A71E7B01
B8FFA76200F2D1671F7E45A53C268002128834513A5870451B28A0E0862724C8F9900476BCFC0535DC2EB10D3384114002299147FEC02D460E60050A90476EDB
CB016823C13F26E8489402FF616145514EE8409427AE32821AEC44A912451C84955DBC184D4E99B7957B67F937B72F80B238B703BC2290080614E5C006098872
A70B45A131492F9643D4051AA3F92090F8845DD1C83F5CF47CED68D3D451236115B7574A058479C606D84186A28CC20FECBB9DC1FE51070016C5143418970425
F2870F1445071798A00637C8416395E04ED94889434E6088DDC18E04E4804E0757C8428784A30C8479010B04D28038FDC810024903FF6031AE7FF90638102198
02FF3162C3A2C80109FFD0829288F28240B4B0858A7841517E21AD7141A209C981C33F4E6086D1848B06FB238A1966272EDEFC3022B52B0A198671B0EB20C566
62FC07289457943DC88201422A0A344633087ADC691E0D205E006E11854B15EE1F00208C25AEF0322B24A082DC6AC32CC4E0B100A0A16B3BB05DF1C0E00A3E8C
C61B2738046142A00628BC0C103364811BB845804F1C21188409C41CE28045A23C8008920AC00782211AA22CE00CFF4843F788120CB405003B11E984A388C281
3BFC631C51228C24EA60ADA280600319405F7BB444941C54C107610CC0970EA9B26EC54220B9204C32FEB101C205A0005FF8C72DCA16881C106601F870841888
80FF8BD061A08BA329C0249C5194052CC28244E1031634608DA294211A1A228A25FEA10613066010182A8A22F49084A27C820B603064003C308D146833007010
42D68862032C18139910410425B8E39D9305E06ECEAB5A00AEC437BF6D49705E7267000CB732322D2D00685A9C126A20002B94CD41E913C8088AF12D6F8D22A3
A37941114057140E5C0307F6240A8AFEA603011821A20188D1CB0A800A810831004B68C53F9641AF02B4829101288328FEF1D23712A608CD0B00DD6C8A53A250
496F58DAE6DF02D725A28C1365FB395C99129726A224E1090319C11C5840844B6C21AA0269442AEEE4813A30825B24F8C71D08638543E08B052C980303BE30CC
00FF5443AA9B25C206ECF43219408606B9544069FE1188DA5A5642841A4D13CC51889916C5053D9011519810867F7CB028BE20684E11DB536E06E00629288476
89C209A186EB19923D2A064ED0094C10E65E66A8A42E3C491402CC0922EE306E00F0F18F3984E24ECE24C71E8A5283E7ACA128BD68C5DF72F18F42AC9228D088
0461D630832C084D0CB670D9ED38219004E095282EE007445250003AFA9210B249002E78D151C2C8E014B32B60518611049DDEB216DDFD9B0B069C2171FCE31E
15224A192A20C56E254220C9F05D51683117134C815E45D90227122086BF11C01811D9C02608638A2A08440F7C0B802EC0E09030944168BEC432BE08415FC2E4
41FF0D12F86FC066F00F0D074009B7C8630014200D87B060944F14D724101A001D9023D0884EB4B18E400454746D0BBE52F4ABCE40681DE847D298CE3444AE1B
002B7C818C1091001B9679A772E843D3A8BE88202A491487C421AC01C0841D0422885A12A51EA036D606E46C350D44840630ACEF3C30B281420972103A49F5B8
7C90EB63D9A1A1C9898340EC11B2BC064502DB2A8A158ED143804D0A880F79AB021668114B8C860CD578460E6A3B805B28FB5840D04112180409D98C6B17E4DB
A64062D1BE7FD842BA4401445EFCE5ED00082C889A5400872F62CC553864780178413CDE6D2C3310DA17132406C409F0807F44C1A60190C73F68D1B501984382
66FF0C18B81DC2800406A0091868A3F7FCCA44100C84104CE81F0164700D3D080405084000076ED0820A6091004C98C408E8601D0560A31387580007820E8937
D0CB0316A081102CC184A023C09959E83A0716308E2990C0D611DFC2147423080E40F900A688C13F665183A93321161718028322D0E6B4FE23EFA341522184B6
075CF8A10308C8F70B1030062CE8C40E165862C47B110D211CA1E00E38410250E0010528E00A8570B90736C18AA0EFC1086C18390AA6CE8144F4F51F445881EC
57E0842FF880D5A3294617D221486EF1A114C61C8D0CCE7054A276AB652FC3C11F247FA745B00101F72BCA3602411834FCA1129F250C05C0A00EC220A39A2FEB
83FF04A8DA5B36E862C21A9004A1EB6108918A3391CC14C43F7CD1E200F4E1F51109C27688F28127F8001E84D10036B50662004B4531047FA00E68E553F59206
87602245610658355491B5323D70157A561831E00B5B0662920006BC4514ABF022A3B1076E80077810435DB00E77720341C06B1F60092870416C60076D660140
805621600777D03F016004FA722476008178C20023904B4A9006970065198403F9E60588807F10A11DB3F22484252544210C4760631B800439B62519D058E224
54C6E71F88732609E007E9441407F009FF200DF5170A411600522042B087661D5070B7F30B1F5603F643143720067E20526395287AF16017456A015001E7C744
A9FF8705E5901CC460087A960E09706044D10A4420850F4185735353D1B45DD093587DE35D8C353860524E66385968585980237FAB2063010055F5054C0E8108
A3C03152D369A3A54BD5B03104100A6AC06555F00361548844F108B4E3726A5514372079DC901234A0491F0009FF9082448102E6F0341E800B7C85300E3103E2
288E48B00B345537445158017058A3F88544718A41958AE94559D7C32D505044F6F51051C003AC0404A7C02D4AA00DF0033B39B00AD5C62D43A088C933090231
8D98922D7A007D01C0713664044CF67A2C807674105883158A86F53CB6143D8AF55362F85814A88A46458F84410D88600258800448800529907D13795F0E8105
3EFF981C62204A77220355803CA971068C400330F90388B00CF98627B340038500936AE00318937C4141037AA6001D301038D01FC3F424DFE846FF3002701400
80758E578837362692A5B8585C828AE4348FADB838AAF10FFE300A388003D8300C12599310410300381A6DF00FCA504445910A7F421865C00EFFE0007589038B
2005B29827B54007750984EEE233B248248860670A1001FB4647A4608BC60402D0C1025016001BE98C7B457D45010CBBF89167498A0C0838B0A006D5C0964411
41D1E09644210809E0036B180064300DFF10067FA36EA0351011331A6BF00F8CE05EA3F10EAA25346E90410F7022ABF037CAC8068898071D4814DEC0008F1065
5CFFB0019A49269D109601B00FF92010EDD07BDD72064118002E6003BF908185B052AEC95DD2A346E81009104787DD190030B0067939009AC28A443106273003
F04714C5D0002120349FD035F908115F709001700F5BC40DCAD502FF70092EB705592009249856C4D9550D10019544077F18008AF00318507F705005C1B54033
800E2EC6990EF10DA5C92D95007BC8003B29C000BD989FEDB89FB0630144E047A3919403A0456F686B21A01B473081A3D1087E606536E910DDD04BCC64023484
36988005026102B0E697EE13066846188B900051491445C00041106465800409B74027000A84710D12710EADA00A57B0057BB007D65003E7106902410B664001
2BE9500EAA900BCBB02E9ED01802800A75A00794CA0D41D009D1D518BFA06401B0003B900EBC207B6121105F000D16B002E8D00C201815BBE086FF8008F140A9
CCE010B30009CE50034EC00AC8000E31610863D0186FE05A11710C948A0173201086100D949A0C552410C7B00830E0044E4001EDE00A0F31030D000D14B0AA0F
50011E7A048240A992E02BD3D018944008AFD01845E07303A10CC9810C14371177909407907AF5BAAF2B5434C7C5AF1001498C9341005BB0D3020C0580762290
6C052BB08546B0061BB1324108A3618D12FB95DF50051A9B09C572B11E4B1155A009A5D005B5A042101110003B}}
\par\par \b \uc2 CareFusion; CareFusion  \highlight22\uc2 Launches \highlight\uc2  New Innovations For Enhanced Medication Management Across Multiple Care Settings\b0\par\par\uc2 1,411 \uc2 words\par \uc2 25 December 2014\par \uc2 Computer Weekly News\par \uc2 COMWKN\par 235\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Computer Weekly News via via VerticalNews.com   \par \par \uc2 2014 DEC 25 (VerticalNews) -- By a News Reporter-Staff News Editor at Computer Weekly News -- At the 49(th) Annual American Society of Health-system Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, CareFusion (NYSE:CFN) \b \highlight22\uc2 announced new\b0 \highlight\uc2  innovations to expand the capabilities of its enterprise-wide medication management solutions for use in hospitals and outpatient settings.\par \par \uc2 With a record-setting audience of more than 500 people at its annual CareFusion Insider event, company executives \b \highlight22\uc2 introduced\b0 \highlight\uc2  multiple new innovations and partnerships to enhance enterprise-wide medication management across an integrated delivery system, including hospitals, ambulatory care settings, long-term care facilities and behavioral health centers. The company also \b \highlight22\uc2 introduced new products\b0 \highlight\uc2  to support greater transparency to a patient's medication adherence before and after receiving care in a hospital.\par \par \uc2 "We are committed to providing health systems with an optimized platform of enterprise-wide medication management, through internal innovation and collaboration agreements that provide a best-in-class experience for clinicians and their patients," said Tom Leonard, president of the Medical Systems segment for CareFusion. "Throughout any step in the medication use process at multiple care settings across a health system, CareFusion provides comprehensive solutions and analytics to help clinicians provide safe and efficient patient care."\par \par \uc2 The company unveiled its new Pyxis((R)) Mini system that is smaller in size than a traditional medication dispensing cabinet, but fits the unique needs of outpatient settings such as ambulatory care centers, long-term care facilities and behavioral health centers. The Pyxis Mini system fits on a table top and is operated through a desktop or laptop computer. It has less than 50 percent of the capacity of a Pyxis MedStation((R)) ES system, but provides the same security and access to critical medications closer to patients. The Pyxis Mini system leverages the existing Pyxis((R)) ES platform, using the same server, CUBIE((R)) pockets, inventory management and data systems as other technologies built on the Pyxis ES platform. This enables Pyxis ES customers to leverage their investment in one platform to have centralized medication management across all of their hospitals, ambulatory and long-term care settings. To date, the Pyxis ES platform has been installed in more than 280 hospitals and health systems.\par \par \uc2 To support medication adherence, the company announced a collaboration with Health Care Systems to enable new capabilities for CareFusion's MedMined((R)) Surveillance Advisor to provide hospitals with a list of a patient's medication regimen over the past year upon admission. The reports would help clinicians reconcile a patient's current medications with any new medications needed during his or her hospitalization. In addition, MedMined Surveillance Advisor also has the ability to provide an alert to hospital clinicians if patients do not fill a new prescription within a set period after discharge. Clinicians can select an adherence window between two and 30 days after discharge to receive a notification. This capability will help clinicians know if patients are following their instructions for the prescribed medications needed after the patient leaves the hospital.\par \par \uc2 CareFusion also announced an agreement with Medacist to further extend the company's commitment to detect and deter diversion. Under the agreement, CareFusion customers who use the company's Knowledge Portal for Dispensing will be able to run RxAuditor diversion software. RxAuditor is recognized as the leading medication diversion software in the industry.\par \par \uc2 Building on its leadership in infusion pump interoperability, the company demonstrated its interoperability solutions for the Alaris((R)) System with the electronic medical records systems from Cerner and Epic. The company currently has 5 live interoperability sites with Cerner and 3 live sites with Epic.\par \par \uc2 The company also demonstrated new technology that can potentially help reduce hospital re-admissions by simplifying a patient's prescribed medication regimen as they transition home. More than 30 percent of patients don't fill their medication prescriptions, and more than half of patients do not take their medications as prescribed. The new Rowa Dose system(1 )takes patient-specific prescriptions of multiple medications and creates dose-specific packages to support medication adherence. Each dose (e.g. morning, afternoon and night) of a patient's medications would be contained in a package(s) that designate the date and time they should be taken. Prior to discharge, a clinician would provide the patient-specific dosages and explain that one pouch always corresponds to one administration time, which is designed to help improve medication use at home.\par \par \uc2 To support safe and efficient infused medication delivery, CareFusion highlighted two new aspects of its offering to extend beyond its industry-leading interoperability capabilities. The Pyxis((R)) IV System, which was demonstrated at last year's ASHP Midyear Clinical Meeting and Exhibition, is now live at Avera McKenna Hospital & University Health Center in Sioux Falls, S.D. and Wesley Medical Center in Wichita, Kan. Avera McKenna and Wesley Medical Center use the system to accurately and efficiently compound infused medications for their hospital. The Pyxis IV System leverages their investment in the Pyxis Pharmogistics((R)) inventory management software and extends it to their IV room to automate the compounding process. Extending inventory management directly to the IV preparation process helps improve the accuracy of IV compounding, reduce errors and minimize waste.\par \par \uc2 "Our goal was to implement an IV workflow software that would enhance patient safety and efficiency at the same time," said Melissa Goff, PharmD, MBA, pharmacy operations manager at Avera McKennan Hospital & University Health Center. "We selected the Pyxis IV system primarily based on our previous work and integration with the Pharmogistics inventory system. Adding the Pyxis IV system allowed us to only manage one interface and integrate the medication production process."\par \par \uc2 To help providers save time and improve medication safety from the pharmacy to the operating room (OR), CareFusion and Kit Check will collaborate to provide an integrated solution for medications stored in automated dispensing cabinets and/or trays and kits. CareFusion will integrate the kit and tray management and anesthesia check solutions with the CareFusion SmartWorks platform, enabling medication tracking for central pharmacy and the OR through RFID based technology.\par \par \uc2 "Our collaboration with Kit Check is another example of combining two leading technologies into a simplified solution for our customers," said \uc2 Rusty Frantz\uc2 , senior vice president and general manager of Dispensing Technologies for CareFusion. "By combining the benefits of both technologies, we can help hospitals improve safety and save time when managing all medications used within the Pharmacy and the OR."\par \par \uc2 CareFusion also demonstrated its Sedation Analytics offering through its Knowledge Portal for customers who have CareFusion ventilators and infusion pumps. The Sedation Analytics application combines data from CareFusion mechanical ventilators and the company's Alaris((R)) System infusion pumps to identify variability from the ICU sedation protocol at the hospital. A key strategy for sedation optimization is the use of daily spontaneous awakening trials (SATs), also known as sedation vacations, which are planned interruptions to continuous sedative infusions. Spontaneous breathing trials, which happen during a sedation vacation, help clinicians determine if the patient is ready to be weaned from the ventilator. The Sedation Analytics application can measure compliance with the hospital's protocols for sedation vacations and spontaneous breathing trials, and can detect increases in sedation over a specified limit.\par \par \uc2 CareFusion announced a new development to help in safe medication delivery that demonstrates how the centralized management feature of the Pyxis ES platform can extend to third-party components. The first third-party product to integrate formulary management comes with the company's long-standing collaboration with Codonics. The Pyxis((R)) Anesthesia ES system is currently offered with Codonics Safe Label system to automate medication management and syringe labeling in the OR and Procedural area. CareFusion now has exclusive rights to synchronized formulary management with the Codonics system. Any formulary items that are added or deleted in the central Pyxis ES server are communicated to Pyxis MedStation ES systems, Pyxis Anesthesia ES systems and now Codonics systems. The centralized formulary management saves valuable time and creates a safer, more standardized approach to formulary management.\par \par \uc2 CareFusion will be demonstrating these and many other technologies from Dec. 8-10 at the Anaheim Convention Center for the ASHP Midyear Clinical Meeting and Exhibition in booth 617.\par \par \uc2 Keywords for this news article include: Hospital, Software, Anesthesia, CareFusion, Technology, Pain Medicine, Investment and Finance.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document COMWKN0020141219eacp0003c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 BioDelivery Sciences Files 8K - Other Events >BDSI\b0\par\par\uc2 241 \uc2 words\par \uc2 24 December 2014\par 17:20\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 BioDelivery Sciences International Inc\uc2 . (BDSI) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 24, 2014.\par \par \uc2 On December 23, 2014, \uc2 BioDelivery Sciences International, Inc\uc2 . (the "Company") issued a joint-press release with \uc2 Endo Pharmaceuticals Inc\uc2 . ("Endo") announcing the submission to the \uc2 U.S. Food and Drug Administration\uc2  of a New Drug Application (the "NDA") for Buprenorphine HCl Buccal Film (the "Product") for the management of severe pain. The NDA was a joint submission by the Company and Endo who are developing the Product pursuant to a worldwide license and development agreement between the Company and Endo. A copy of such press release is attached as Exhibit 99.1 hereto.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312514453715/d842894d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312514453715/d842894d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312514453715/0001193125-14-453715-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312514453715/0001193125-14-453715-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 BioDelivery Sciences International, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US09060J1060"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US09060J1060}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 24, 2014 17:20 ET (22:20 GMT)\par \par \uc2 Document DJDN000020141224eaco002aa\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Effective Internal Communications Part of Successful New Pharmaceutical Product  \highlight22\uc2 Launches \highlight\b0\par\par\uc2 301 \uc2 words\par \uc2 24 December 2014\par \uc2 Biotech Week\par \uc2 BIWK\par 355\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014, Biotech Week via NewsRx.com   \par \par \uc2 2014 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- When a pharmaceutical company is gearing up for a \b \highlight22\uc2 new product launch\b0 \highlight\uc2 , effective brand and communications leaders focus not only on external communications but also internal disease state communication and education directed at employees.\par \par \uc2 Internal communications about products nearing \b \highlight22\uc2 launch\b0 \highlight\uc2  can help pharmaceutical companies as they build a credible external message regarding \b \highlight22\uc2 new products\b0 \highlight\uc2 , especially first-in-class therapies for new or socially sensitive conditions. Communications teams must overcome numerous hurdles to inform employees adequately about a disease state that a new medical product will treat.\par \par \uc2 A \uc2 Best Practices, LLC\uc2  benchmarking report, Best Practices for Internal Communications Regarding Brands & Disease State, examines how companies communicate at the brand and disease state levels in order to educate employees internally and build a consistent external message surrounding new products.\par \par \uc2 Effective internal disease state communication requires a structured approach, including clear education objectives, tight processes for message control, and prepared responses to product questions that employees may encounter in social situations.\par \par \uc2 The study found that for all employee groups except sales and manufacturing, most companies start communicating internally before filing a new drug application. Sales communications often are delayed to prevent pre-approval selling.\par \par \uc2 This study was produced from in-depth surveys of 32 top biopharma companies and a series of executive interviews. It will enable marketing and brand team leaders to implement the type of well-timed and well-targeted communications strategies essential for cementing both the medical and commercial framework for a new product's market entry.\par \par \uc2 Keywords for this news article include: \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document BIWK000020141219eaco00078\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw226\pich40\picscaley100\picscalex100\picwgoal3390\pichgoal600
47
4946383961E2002800F7000091A2D21D61AEEFF0F8005BAA6681C0C4CCE81460ADF8F8FC3468B2DADEF0125FADACB8DEC7CEE9758CC79EACD88599CE5A8BC3E8
EAF64871B7DEE2F28D9ED0F3F4FA8094CB2D66B1FCFCFE99A9D6E7E9F5889BCFB2BCE05576BA456EB62163AF6A84C2A0AED9788FC8BCC5E45F7DBEC0C8E6CAD0
EAF4F5FB014EA21860AE6C86C32C61AE0A5EAC7088C4D4D9EE9CAAD796A6D54485C08295CC005DACF1F2F9397EBDCCD2EBD0D6EC3066B1607EBE6883C1386AB3
2964B0C2CAE7EDEDF75A7ABC7C91C92562AEC8CFE93168B2406DB54C73B83E6CB40058A8BBC3E395A4D4F0F1F9F6F8FCE0E3F3EDEEF88FA0D2638CC5BEC7E5B8
C1E3B5BFE2D5DAEFD2D8EDA8B5DCD9DDF07990C8B0BBE0E3E6F45778BC4A72B8A6B2DBD2D7EDE4E7F4F8FAFDCFD5EC5879BC5376BAE1E4F34282BF426EB64180
BD427EBCC8D0EAFEFEFEF5F8FBD6DBEFB6C0E27E92CAE5E8F55478BB4E74B98A9CD0AAB6DD1A5FADA4B0DA0D5FAD3D82BF5174B9BFC8E63A6BB44681BE627EBF
4670B76380C06E88C4054DA2DCE0F28497CD055EACC1CAE6BDC6E52263AFA2AFDA738AC6F5F7FBF0F5FA5175BA7C92CA0A4CA1748BC60E5CABABB8DE5B7BBD0A
5CAB7289C54169B20057A80054A60053A50056A80056A70051A4F2F6FB0055A70055A64183BF0052A4005CAB788EC7004FA30052A5DCE0F195A6D5FBFCFEF6F7
FBFAFAFDF2F3F9E2E5F45275BAF7F7FBEEEFF8F2F6FA2764B0C6CDE8F2F3FAB4BEE14182BEF3F7FBEAECF6EBECF7034EA2DDE1F1D8DCEFEBEDF7ACB7DDB9C2E3
FAFBFDADB9DE95A5D43C6BB4F6F6FBC3CBE8FAF9FC416EB6FBFBFD2563AFC4CBE7BBC4E4CDD3EBDADDF0A9B6DDB0BADFABB7DEA6B3DCA5B2DBB6BFE1D7DCEFA7
B4DC97A7D55073B8EAECF7DEE1F24E7DBD6480C0416DB55D7CBE4181BD5C7CBD96A4D34183BE607CBD11499FF3F5FB4B6FB67187C3909ED0085DAC436FB6065A
AA5176BA5175B9EEF3F9A7B3DB95A8D40059A9F1F6FAD9DEF0FCFCFDA5B4DBFDFDFE93A3D3EBF1F8637ABCF1F3FA557DBDAFBBDFE5EAF55573B894A5D47389C5
597ABC045BAAFFFFFF0058A921F90400000000002C00000000E20028000008FF00C9F51B48B0A0C18308132A5CC8B0A1C38710234A9C48B1E24381FF326ADCC8
B1A3C78F20438A1C49B2A4C9932853AA5C597220CB973063CA9C49B3664D973673EADCC9B3674F9C3E830A1D4A5428D0A248932A5D2AF228D3A750A3FEEC27B5
AAD5AB2F9D62DDCAB5EB3FAD5EC38A5D0A76ACD9B353D1AA5DBBB32CDBB7704DBA8D4BB72EC7B976F3C6C5ABB7AF5ABE7E038B052CB8F056C255295D5A4CE9A4
E2C62B296DAA44B91226C886432A5E7C097347B09C2C59E284A9B4E98FA6535FDE7829B5E78C98448BBEC49192A5509406E8BE14AA92E64AA132E9E6146AD3A6
4CC8932B4F2E2A23254F982EC041A74842804CBE35DA96CD9DB676EEE02BBDFFFE175BF4269095928B5ECEDE136D4CC97D3F4F4EDB52724EFF3685B2A45BB7A7
F31E69C58E076F745046001F2498A028967897D1001728A860218EB8F70F25C51492602103784609025A882186161760E25C259FEC210D1651B488853461B033
5E7E9C6C61813352ECA28B3446EC000428400629242822E8400926971080C514A89C608A0F4238B183258D51624088228AD8011C823478E10C6F6429E6963378
B68911216AC1C3788D656301284090708D08430A29C221C56C32C49B226CC1490A4482B24821FFECD1062816F0210A0E6D44D3621448BC8000807751559B0CA5
D0904B2A6E68E0A91B5D0050CE009D65148712A9A412012D11B89145081260FF52C91E59A4E20514AF7DE8C50927DC528E6F9B7C620113ABF863ECB1FEC45266
479C4860022AC81AAB8203D1566B6C159EE4510031D6FAD3840C32FE334014AB28D1E40907C0E2C6023B984849062728418329A61CB0CA01A6FCBA1126AE8081
4A051310612247980C3386B4C578D1EDB11684220817C60E220A250F180B4E009584D184B12450404BB54A8861498096B236AEB1A754B3062E599C72EC0D3948
C6091F07F8734A173D74A184B1AB5C53C9002EFB238283CE0D4087B1058867C93026F813CF180B3400820E1B20E18F211D727449113BFB63853A873CC0863F16
B0720B033DE06185B14ABCD24330C9F8734D1F0EA8A003087D6C0046B5CE0CFFB009257B18EB83210E18E303DBE888878DB1A558D14501361C2C46761A7122C2
B16B0441B946A184E04F2ABF540283B15EBC1DCC206B1C7BCC0C9678606C044658528EB119B0B3C907B8F883C4D1FEA0D24B033A88F0CC186F8CFC59C91BD9C2
4DC4AECC5007027DBC3001CA4EB0630936ACF893C50A8CB0A3C82BAFF36149CDFE6C335E2516183B426F9050E38F30717C9089259489928916905C581B15C61A
12C47E9EC8C41B64D0880F882214DFA047C42A618B5028C0092AF0473436B1850C0021009C185DB41CC08E1A196B1928C8842724400863754110989883B1A690
820114C71500E0037E5823016411C26F1CF10405FCE1025770421AC67A4003FF43810273F4C258072887253E110B63C9E00F3930961642A3859D956014FE5845
0BE65709D16C010103AB944742410A63C9E112A4E184282A7181231A0B089520C2CEC610002465020758F4870CC667AC98752413E250DF1FF210017F1CA00F9C
98E14646D3914B0CA16627E0C1E644310051FCED1F96204129FCC1804FD4C711A9EB010B3660AC510460056B8B560B2C11417F48E13C94C8840776260C1D7822
05C662C011684309F1B0A3917088963EF4A7914C38C11FB8B8C00F8318464B04617AFE08442C2FA73B51E8C21FAFA8A327E2F0B92AE4321398E925A5C4D81132
1AAB17E1720E27D8B1006301C3158540C6E73E30305B3C8376FF00461FC7E3FF891618EB188CE04010393123D410A166ABE081229DB34812C483939EFC4726A8
C90003C8C058F128033B7A502D64D4A195AFCCC82678E00263492213B8F4870006B0114A8CE712C1AC052E36E98F2B8451A2C7BC05022A01447F6CE0A6A29087
B190F1894AFC220BFEF0023A4AEA045160620623F047012EEA8F2928607321018B39FD81CE5C29207BFE9087019A960A7A5E481451F5070030D1857D76A49F1F
C4062CFC818C148C732497C001F9A2C183FF7C24930FEDE46266300863BD420115F3C70406C0875C582B1B2005502526514853F4411429F5C7004A4334AD0553
09122800E3BCE189621E73143BED692FC679893CD0940897A8C4318C650C25FF34A108A39140CD0ED14A7F38C00099B82BC9C65846AEA6B3A5DC54EC0584304F
1365A20327F047053A60093CB89523A20081B1B000046325211429A104734B69810F40A7238085686C8B00D6571840123488852248204F6B852070AE84652500
60AC60FCE3129935400A52F009E301D358457045028CD584709416A7FE402D4F8DC5813F84E2C2E7B94461FD4181D0F4D61F42B80C2502914516F0600A2F0302
0F3271D3E311F79CC7D5C8266AE80F0D1441B4A92804272E1186839DE21004E5A83FFCC8114B686193AF78813FC091030377C4A52ED5DA0E14762C266480083B
6E68603DE989DEBA570B7130E643BB2584C5B9B21297A803B5FC61021CE027FFB3C918C528AC0004276B04A6C63A4728B6500B6351C1871096704F59610213D8
A0071240337E99E0C93AF4D9581BC8C43F04913B2C1C2163D0AAB2211050AAE196B3B85DEDC826CCAC84064021C25B7840D334D08B58B954C8445EA4188AA581
92A2E20758D5C8003AA00210F063A1FFE0442162F18568456307944BAF60E16A58034082093CE0C182BB450323182B164540C209E231085090EA429985052A68
E08F6648FAC97930962ABAD802F26181CBA74D2DE3C0018E038003120DBA40659B7C09CFF94309C570E90E8CB587F778A004D13D561A1C3084D59093235B0D35
C1D2FDEF469CDA053AA880B11A608B815102D6E3B104248CE506FEC102DF1FFFD94477D90C5EAD6D02127428E4B1601186192A9BCBFE6CB616B88A892D80F504
1CA0405A6147613F182B1793408176321B0631DCC1022F3877473EA16EDF6CF3584E8865BC270C6238A8220CBED8827828E10B63A90337AA301613F0B35F7F44
A0E1B0E1441FEEB1B16369400CC2D52AA8632C521AD7E2071CD5C005D2A73D04CCF0E31CE367CEA161357F0041EA1CA9C40E0E668296D7668D79B8C2B4FDE106
C363D2A1EA15850E8EC58014ECDC1F710805081EDAB04994C0B0D6F6070738D14E3607004094C86C2F2BE189AC79640655BF102578E78F063062EB3D8D0576E8
97354BFC609356B8001B916884F330C11FBE88B273C0598E405C5FED85788DFFDE613C1E4C50950963FDF71D36D144BA16C35D42064167FFC1EC1EF474178AF1
C848F9577990F4F24FCE702C91F6795B165B12F031AE3400A7E70F2090090D000A9EB00532E70F19F00BC6220577044D0E9035B9772C2CC5501F017CFEB06E19
710906706AFE000C454062827681B80719973000A2E50F2A100A8D208028A00AA620370FD65295B009018005C7D2029D357EC6F51A2688546A957E21230AFAF6
4F91801FE0E30F4E205CF5A702D1150F90D01CA276622C371298C00228F802E075738B31008D270F05337390001D39A001C8020714F74A96900DE4E30B04F50F
99F581222182249811953004D3060663D382F935463BC45503F07AC6620228FFE0395DF001C27567828080005084C8C3397BE71997600910632C0810004D1332
3F080941C30CB6D37E37E0701AC16C36F00933D805C5006CF9E185426079FF956BFF100AE3E05D65087A822551FBE0349142078FB60A7B80029B9058C66203E4
3087E761096D702C22201E7BF8642DE6879B6309D32000281361F27688B55109AEB03134D00215600AD1150192C05C2FF06089E41195C0888780892FE60F0BF0
5F50761E7130661450091FC05CA4D84BA4642C1480092BE70F6D402550460947B066C7F007D3500FB4B5535096119C40523C1451FF350461D0200DC909018006
FFA608BE6186FA3385C87200DE100A040046405033F190039E107BB1004B98FFB066A570059C60001ED890F9B703C4F40FDA5864A3772C86280504D590981009
17E00951602C1FF30A19200C35362F5A303294200689D619505609D8406E4D10700FB711A1900414F609FD21081DC000C7220575600946D0674A6092175209EA
702C818003B7C03881C002BAF1093C505CC567099BA00341E30332F0019F20238D41040B960029E07101200050400229C002E460007C3083EA603CA2900D9B24
049F30309B500670782C02400294B07A4C500694000AA71008964102C67203D9914228E80FA0E093C6C298FD31035B300286808B82107C04338DA5B45365E70F
23F0096A39009F6000D9F00A0D100AB6792C21A0004AF839FA630951840561FFC002E4690087808040D0625F918917C209CA602C02200572C00CBDB079ACE004
8E202B1E5033A7A0032D971BD7642C0E700DDDD90451500523B083C6927D22F506D0A09A05200D322003BD20730960006174098D57012E00068FE69C01001999
D04AE0900F5C981F1ED09D54D00C503066A890005DA002E7B109D4C40A060020405842027A2CB7A20CF4393D07400006B6091D2045B9D6184AE60F09300499D0
7EF1E002F2F90825002DB7902703B00B6C13067FE04D9036439C80007DE90FB9B006567038C60200DF761731D0096CDAA666E007C5B23050700567200B9D5003
CDE90F83B0057AC0A6DA10036E692CBB700528662DD4B00EDA60A76C7A0610FF000F99D62D4C0001DAD0A664B066D5F208DD30A99D4006807A2C78600764E0A6
10D034DDF20E1960069B6A0D2525A03510AA9D600610E00E0B832C1110038A4A067610A06CA007AEDAA6AF1A0337C0794F600FC5B6302370069DA00D4F903A09
60AB100008C6F2048A2A0B7A3036D5020BFA200B9AEAAB9D10039AF0ADE0AA09AD9006B36A48AD00AEE9102DA5B004E03A0BE4632CA6C02DD6520A6A70AEE1DA
0A883066DD8201B310AE9AA0A0D57200F6FAADADA0AFF1000EFEDA0AEF5A2D69B004E73A0BF5A0AF079008FDFAADB3C00BE56A2CC2A006E1DA0EC5CA0B89E0AF
E0DA0A18EB0FF8D0350B73021CAB09B3506C34F0052C5BB2F310AE8800B0C808120F152BB2DF1A10003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of Vivelle-Dot\b0\par\par\uc2 274 \uc2 words\par \uc2 22 December 2014\par \uc2 Drug Store News\par \uc2 DRSN\par \uc2 English\par \uc2 \u169\'00\'A9 2014, Lebhar-Friedman, Inc. All Rights Reserved.   \par \par \uc2 PITTSBURGH \u8212\'20\'14 Mylan has announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of \uc2 Novartis\uc2  ' Vivelle-DOT.\par \par \uc2 Mylan received final approval from the \uc2 Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.\par \par \uc2 "The approval of Mylan's Estradiol Transdermal System USP represents our seventh U.S. transdermal product launch and strengthens the company's growing portfolio of women's health products. We look forward to continuing to meet patient needs in this space as we strive to provide the world's 7 billion people access to high quality medicines,\u8221\'20\'1D said Mylan CEO \uc2 Heather Bresch\uc2  .\par \par \uc2 Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (twice weekly), had U.S. sales of approximately $262.5 million for the 12 months ended Sept. 30, according to \uc2 IMS Health\uc2  .\par \par \uc2 Currently, Mylan has 285 ANDAs pending \uc2 FDA\uc2  approval representing $111.3 billion in annual brand sales, according to \uc2 IMS Health\uc2  . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ended June 30, according to \uc2 IMS Health\uc2  . {\field{\*\fldinst{HYPERLINK "http://www.drugstorenews.com/article%2Fmylan-launches-generic-version-vivelle-dot?utm_term=DSN204811"}}{\fldrslt{\cf2 \uc2 Read more...  }}}\uc2 . \par \par \uc2 Document DRSN000020150211eacm0003j\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  First Generic Version Of Vivelle-DOT - Quick Facts\b0\par\par\uc2 265 \uc2 words\par \uc2 22 December 2014\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2014 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - \uc2 Mylan Inc\uc2  . (MYL) Monday announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of \uc2 Novartis\uc2  ' Vivelle-DOT.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.\par \par \uc2 Mylan CEO \uc2 Heather Bresch\uc2  said, "The approval of Mylan's Estradiol Transdermal System USP represents our seventh U.S. transdermal product launch and strengthens the company's growing portfolio of women's health products."\par \par \uc2 Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), had U.S. sales of around $262.5 million for the 12 months ended September 30, according to \uc2 IMS Health\uc2  .\par \par \uc2 Currently, Mylan has 285 ANDAs pending \uc2 FDA\uc2  approval representing $111.3 billion in annual brand sales, according to \uc2 IMS Health\uc2  . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ended June 30.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2014 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020141222eacm00461\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of Vivelle-DOT\b0\par\par\uc2 155 \uc2 words\par \uc2 22 December 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, which is the generic version of \uc2 Novartis\uc2 ' Vivelle-DOT. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis. Currently, Mylan has 285 ANDAs pending \uc2 FDA\uc2  approval representing $111.3B in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 . \par \par \uc2 Document FLYWAL0020141222eacm001xx\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Robaxin(R) Injection\b0\par\par\uc2 388 \uc2 words\par \uc2 22 December 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 111\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com   \par \par \uc2 2014 DEC 22 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin((R)). Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Mylan's immediate shipment of this product supports the growth of the company's portfolio of more than 100 injectable products in the U.S.\par \par \uc2 Methocarbamol Injection USP, 100 mg/mL, had U.S. sales of approximately $15.1 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 286 ANDAs pending \uc2 FDA\uc2  approval representing $111.6 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $29.5 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Mylan Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020141219eacm00023\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Aldeyra Therapeutics\uc2  Files 8K - Other Events >ALDX\b0\par\par\uc2 189 \uc2 words\par \uc2 18 December 2014\par 08:50\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Aldeyra Therapeutics Inc\uc2 . (ALDX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 18, 2014.\par \par \uc2 On December 18, 2014, \uc2 Aldeyra Therapeutics, Inc\uc2 . issued a press release announcing that it has submitted an Investigational New Drug application to the \uc2 United States Food and Drug Administration\uc2  to conduct Phase 2 clinical testing of NS2 for the treatment of noninfectious anterior uveitis.\par \par \uc2 A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1341235/000119312514446163/d839605d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1341235/000119312514446163/d839605d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1341235/000119312514446163/0001193125-14-446163-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1341235/000119312514446163/0001193125-14-446163-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 18, 2014 08:50 ET (13:50 GMT)\par \par \uc2 Document DJDN000020141218eaci001ww\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Advaxis Files 8K - Other Events >ADXS\b0\par\par\uc2 229 \uc2 words\par \uc2 17 December 2014\par 07:30\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Advaxis Inc\uc2 . (ADXS) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 15, 2014.\par \par \uc2 On December 15, 2014, the Company announced that the \uc2 U.S. Food and Drug Administration\uc2  has cleared its Investigational New Drug application to conduct a Phase 1/2 clinical study to evaluate the combination of ADXS-HPV (ADXS11-001) with \uc2 MedImmune\uc2 's MEDI4736, in patients with advanced, recurrent, or refractory human papillomavirus ("HPV")-associated cervical cancer and HPV-associated head and neck cancer. The clinical trial is expected to begin patient enrollment in early 2015.\par \par \uc2 Exhibit No. Description\par \par \uc2 99.1 Press Release dated December 15, 2014.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315214004184/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315214004184/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315214004184/0001493152-14-004184-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315214004184/0001493152-14-004184-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Advaxis, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US0076242082"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US0076242082}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 17, 2014 07:30 ET (12:30 GMT)\par \par \uc2 Document DJDN000020141217each001k1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Relypsa\uc2  Files 8K - Other Events >RLYP\b0\par\par\uc2 231 \uc2 words\par \uc2 15 December 2014\par 08:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Relypsa Inc\uc2 . (RLYP) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 15, 2014.\par \par \uc2 On December 15, 2014, \uc2 Relypsa, Inc\uc2 . announced that the \uc2 U.S. Food and Drug Administration\uc2  had accepted for filing the New Drug Application (the "NDA") for Patiromer for Oral Suspension ("Patiromer FOS") for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood. The NDA is supported by eight clinical trials, including a Phase 3 program that was conducted under a Special Protocol Assessment, a long-term treatment trial that evaluated the safety and efficacy of Patiromer FOS in patients for up to one year, and an onset-of-action study that evaluated the time to potassium lowering action.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1416792/000119312514441953/d837699d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1416792/000119312514441953/d837699d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1416792/000119312514441953/0001193125-14-441953-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1416792/000119312514441953/0001193125-14-441953-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 15, 2014 08:01 ET (13:01 GMT)\par \par \uc2 Document DJDN000020141215eacf001ht\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of Hikma Maple's Robaxin injection\b0\par\par\uc2 107 \uc2 words\par \uc2 11 December 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. Mylan received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Methocarbamol Injection USP, 100 mg/mL, had U.S. sales of approximately $15.1M for the 12 months ending September 30. \par \par \uc2 Document FLYWAL0020141211eacb001er\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Robaxin(R) Injection\b0\par\par\uc2 392 \uc2 words\par \uc2 11 December 2014\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) today announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin(R) . Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Mylan's immediate shipment of this product supports the growth of the company's portfolio of more than 100 injectable products in the U.S.\par \par \uc2 Methocarbamol Injection USP, 100 mg/mL, had U.S. sales of approximately $15.1 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 286 ANDAs pending FDA approval representing $111.6 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $29.5 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/mylan-launches-generic-robaxin-injection-300008428.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/mylan-launches-generic-robaxin-injection-300008428.html}}}\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020141211eacb0004n\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Announces  \highlight \highlight22\uc2 Launch \highlight\uc2  Of First Generic Version Of Orapred ODT - Quick Facts\b0\par\par\uc2 223 \uc2 words\par \uc2 11 December 2014\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2014 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - Generic drugmaker \uc2 Mylan Inc\uc2 . (MYL) today announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity.\par \par \uc2 This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions. It is also indicated for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions.\par \par \uc2 Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, had U.S. sales of around $19.9 million for the 12 months ended September 30, according to \uc2 IMS Health\uc2 .\par \par \uc2 According to \uc2 IMS Health\uc2 , currently, Mylan has 286 ANDAs pending FDA approval representing $111.6 billion in annual brand sales. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $29.5 billion in annual brand sales, for the 12 months ended June 30.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2014 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020141211eacb00462\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw388\pich38\picscaley100\picscalex100\picwgoal5820\pichgoal570
47
49463839618401260070000021F904010000FC002C0000000084012600870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0073081C4890E00F81070FE648281047C187391C368448B1A2C58B032546C488
5121438F1C438AB4A870E1C893284D964CC9122443950861A65938E687C234206926AC990367CF85337FD44CF831E8D09E0F8CDAFCF9234D52A03A4DFA0C8AE3
60D58D3E22FEB8FA33A840AF5B23567510312BD98656C3660D5B756B58B70EDD2EAC1A3747561C641DE2D06BF7ECD60712F9EEDD48416C5FAD7CA3E21CCA732D
4C981F117A8C4C19B2E5981F2B27BC7A57ABDD8D9C3D77BE7B30EBE7814B377F866BF2AADCB497334715BA13E8C1993889D2F6D9B4E9429B407C067FA0E6A09A
DF0B75CC3C9E06C818203DA13B2F12BDE70FE7D77F1C2F1E5C47D3EEBD95DFFFD658B7605D1F0F6A8E71ECF0418E0A19DD5F7DE003877BC039DCC7BC5852E3DC
827FFDE05E5E02E5755005ED65E55E619E9D25917EA9DD66924A1A858598409DB135D146A77DE690690499661564FEA1B6D15B1B4E68D0442BA918A28939F567
626B324EF82186A755B813486FC0A812194241379373C9F994C31850DD94DA188BD126216D501DE71B1009E186831A5929F55B4DE269F7570E0EC03622436314
C193540D2526D10F33F8479E7D28A2E8986708719523872266A4278B81E9A9A14D645236D39A27FAA0C36AFB016A1710E7A195A85D258919116E26AD65678BA9
C574E98AE57944A84B6DEDA72288276A5ADA8A980D34157491F9541358BDA9FFB498753461D7A44DCFE9B65C0E459051411A3C018AE46E506AC79470B8397926
43822D8503B014E2FAD256F065852060F081E943B50F2C7521A21B7ABAE28111C1471E82F949842E83EE1D549843F00938D79868525AE77F33C6756389DE4E68
A18A99CE98694E9221D76F5957ED3B6268745926A1A80D5BC89588A1F9A816C06095298694D62149E591124A47EB41C1D904A44E3AF800244FCB35E5DD514D3D
D0E30F4072F75D4D40484925CD8036C92A90DE490C30A045D854746F80129DB4D136BDC1B4D34B331DF50F4514A12F8E2F9976238778BD882ED70DE72774605E
A17119A102C5EB59A402A38D1C4C8EBD8A5C552C7B8B62877EBA28EA6300AEFF1D138276FB8B990C3196FAEFDE8ED55699C141DDE65B8FCCC53413754BE59643
70BF31341553CFA50122B4C276BC259154A681D3E95036E8EFD43DB3EEA54DCDC10EE8CE482F4DFBC12DDE8929570DF35592690E72DD1A6AC1A269E94419BEA8
12BD1C8E387C7F3B166FD2B015DA78EA4B73755BA05BF855FC6F5D750D9B629F20F9E7BCBF9D4E146C953D1D375BD067CE262D638E5B1754714C5A17644291D3
06F3915F41887A2404AB97D1AC3DA8894BD26E77BBDCD42E6A69F855EB76969BD83D505C428B917D360298F3F18E43C2FB4198D2B590EE698E6F0AC95646AAA5
BC47B1ED6E85F3568F4E6730C1A5EA5E764B1F0EBC231FB1EDCD3535D15E0EFFB3879598804835E519489E54322CF1C14E80B379D5E4064840C79D6C5A81EACA
4B7882244AA5CE288F6959979C851E52FDA638B24BA3ED9286469CDC6E8D51A312EDB816990AD5053602290C7AF4529A6EA5AF791BDC900F82453767D18B2C98
3248124FB5C4D3B0E72B506A9CDC2233278025AA4F097B4C62E62411AFE0704605E214AA42C3BC1D21474A60D1C9FFDC6732E0144C95FEEB4A540492BF6921E9
2751111FB4C0C8392285483E4BB3A01A2AB040D72D245E6E6C5D84D4E8C012BA2871846A4F9FC2A51F0E39C03E8901CD67CC35A3990C0F4EFB9958027F87234B
DE10949409963A61D22873DAF05B5761E1B814B21619315253C034A2A3C675FF4798148F3723139264704206A8E0E65000C5A54241264B9A34749001641900FD
D545590AC5434A944CD48002074DC0A18215D44E11D49086A265AE381CED281A89E940670D0F448BAC1E0EBE862FF091B38323D4D3D67853998929C4355C918B
DE9EF710B9B8A663038B955251782F1A49845404A310680846D58CBE725E97FCE97EFE89A625B9844B9EF4E484BCF9933138C42BEAA1895E06A594B4FE400C13
826BE57A32C09810323F7B440DEBDEB08C7DD46319D0D88726D4A08950E480AFD1A88732A2E15765C0216AA0A84734E8110D7D2C43133691A0A2F6D92E01AD09
6D6E9217364BD22E106A2D2C79D1DE69FE25B11E0A043FFA914F35ADD2AEA0FF96505F2A1C48526EB3DBBAFA6845AAFD92BCD8C6220291273FADD19E134513CA
B374289B0DC18F28E994CA9B8CAC78F19B101769E310B301B28BD38CA836AF72A641C50CAE383853856E79D11445AA373E81C33E94E1D137684213CB00EC3216
0207650836131EF5AF267E9386BE82221370504326FABA5FE0586E5A974A835FB0BA959C92250D3DEA21F7AA225D6902A5472CDAC81BDE4095E5CD945652F9C1
0CB98934BC2AD19BF5AB926F7A62262891D874A6438DE706D22311F9E6C18E52D241FC88109C48A4389C31DD52F4B39632CD53AADA711A026CA240591DF35517
2519A548FA91677D14A839F0EEB3C6AA09189B19C3A683A80FD24052D32129FF4B3349AB43CA7C1031E00AC7387E585646E39AECFC40BE98CDD41BFC0B8AA5BC
611F94B3495F05F483C5722C2199986FB7224825E822E601A088866934A18CA8C6651FA0D607882D3426E9E60714A0DE07283638A8FE82BA1E70F84F1AF60187
193C4013D0A0276353BD8CBAC817D4D1C804421230EB37B887AF1216C81B18BB9037D4631F5212CAAE19DBE98D448318029AF524B487EA7D24761FB0C2D1A181
9D89763D60C1DE3C3459D5E05F504383AC3DD9C71B66B0E7392B23D93F48C0B8410D870428A4BFC906C5326625DF245D3B3F70A8479C91428C5413C3ACC0F208
92D0BB6BC1F2250D9A902CA81B1C6F6FEF63196AE0097D4B338607B47BBEB4FF5CC8C9410D40DAC24BC7B7D34734BAB5B46ED9D7260ED004B4890928C1FE40E7
505B5A05E41BEB584DA8020C5288031AAE0387A0DA9B1B9C29602C2B9050809B9EE5BC8A1E673D60F9767A4DF4D8874002EB1484D40314D7D4F94FBDCD240C9B
E4D6D096C1A231A40350B349E75ED139B81D4009501BBB8B1F7F831A3E1A13C666C2DF8255551A1AAE09A7856B206A00770E801E1104E81C0EEE29B67B2A3089
686822BD8B76CD3E28A1DA8568221AEEB34B62DDE35FB9E200EFF969784272BE0F3205F6F3C59E50A441918349CC3752BA4400637BA4F301D7E4F5FAD0C41846
DC9319FC601FC4207126D2E090315C7BE1C56733CA6FA38C657C14C315159EFF8E96A2F6CCB9EECFB5CF5C0E68FD03681083E64B13C83EF4017FE63D353F3A97
88DA276C21C176864E1C944D09A00FFBE00032607903761578870309B07ECAA011DD176F09287FA08000E6910399500F3F80009107077C046A9A400194100D25
17119C9678CAE05F1C7368C2D63C024180FBE07C82A55A709706FEC64E07E27B6AE00063907802215FD47758D0B6110907622938100ED0815127104F77165C07
260A756BD130288B754B932776A8F16CCBD01416671733305F0C387909787CDE9425FB90096D9203FEE51448027B39005720436B32602269405FD3B30FD03003
02715FAAB20CCA00429B312043E663B9B10CD14060E72784418703F25504B3FFF6582D6534396007B5B759D0431008D05762537ECF2510ED367219C5367D2258
53F651FF025848E85FF49179F2D683334316DEA60C99566E0D215F6F8003A82625E92158B4D683D477109A10597F180DF2B583024106DE460CB208620E2158D0
B00C0E90783F05847B531291F7060E006864E10091E68133608B9D046C2048645C9700A6011F9CA60681D157F33560DA830391966AFB400FBCA57361F615DDA7
0C0F176C0D518E6F90095CE619760640F62815F216173AE787D140096B316BD0E779336167CB000A03F9885A215766A586F3D57DCA771056481A5A913415A00F
CAC0522C155B02F131872642EE61042CA76E3C573AD9C188E0B65B5A052277FFF100C9B00FFA47829FE447F8C5604E612862812E1AE100B376787A076D0E9015
47F85A0DA7877BC17570E09303318F9B400C8DF7764B296F58537BCA500FCB567693070DA7376B62E0950282067E050AA1400CBAB87E24056ECBF00938027798
573045218F7F5815DF086DF611694EB11591A70994C057CA302C483983391259C616132788721C567C240558DEC4776247175CB76C193733F126610D377FE107
403E90003B19846350779430173A475F86D91332306B97A509D3F71597754B2C486F56781BCB70769BA00C8E0775C1E3178A2258142093CF278FB49603145009
CAC9720F508CF0F503BFE20302726846903497E41ED491039BC093EE8177F4FFA153F98100FE9606C9D710C1E32E9F9100F39500388000E809758B95033D3003
0D1058E3F9001590827E98470BB10F9B8000F7A11033A076F6784D34B10F25B771C7810314608FCB605940009857718611315BEBA70902E05FC1564D70A78E30
05138756669E447B66A56F72281099100D93609EEBE781B42458076022A7473D6042A007507CFA815F4E6172F590326F688F1ED97E9A9000C4C05893404BCFA7
0916988D957824CF2221F6F800762698B494714271623F719065370648590F9A603547327F09507269307DC37270E9A58762C019423A9EB6F131A620760E0404
B2080A9A50A79DA662020A07C9000A1266132D5A6EB3934C15500C3C993477FF915B61A1A2A0E07C24E95C6F4039F1669737708DEDB2956992513A970949E86D
C6287F8798037DC55E38F097FE97111F3701C7B7103E407BF2F78725D48370209FF3E7183A37062AF888FAF18491B1A115E09ED2C89A0C5A5A7B738D0D68223E
B00FA720208ACA101D681397574285E9526A2896FAA18457386FB1BA8033A00CEFF65AF987240E808C9F17795E29061510AE89279B6F864B032900A0E614BE47
0C0EC1AE67A94A49B10F9580A60EE5875DE04D6B28848B0A7AF7761066A2506A3250074174DDB2330FE000135B7C02A2738531AC3C77101FB728496364DE1626
D7611EA4B61127877A04D1B112C18E204810D1500C61E11E3909262CEB6DC9FFE610FB3683833129F5CA22CF39607BA80F3B58AD9F81856A0872031169390084
B3A68E0AF19C41F803E939032C481070376A70931F91C63113F200A1096A2D88B3304880CAE020395B6D933785751158A9A609CE856EEE2170834A93EFF166C9
07189106B4EBF100350B6E3635110E096A7F487339A08C9F271003E97BE5467DDE9406F48059046175A9461075A89C9EB941D24516D6B9347EB5B9B0031D55E9
73B4E74068741075B09C1F0B1F4F878895D2425F51669E715620C183B4D974FF41622AE25C62A160F6825C7A489BDB531046425B6DA60601695D024152045174
01F416A8743939566424A506B8FBAB0931038F566456B5123F201EFB611A49FF4158605A10D38B521DC2666C3626EA454B1D855C3A7613A9870364F00666A510
CADBBC73D145B0AB10ECD5446CB2B483453700E4660C018739764B63A664197956B08B4BC0F2516A300921D75E78D221C0719DF3952D80B26CDD57684B2B6F9A
B534FEF55811A273A1B0B1D8FA18E3894DAA6527A5821709804847B93DC7455BF059C17BF10016E81FEFE2BE39D55CEA57270791533FC5BD101148A7711F3E34
6402613510624958F74E517C2F8844C550582280312004117544611F84431735A2A0363210DE9528F59B26AE05AB3C31906C611F7285511EF92CBB154083843D
40915D5CB4C5928321A6B61145503236017782E58840300CD0576098F500A7FFAB33F0B533FE450C09F6677DF5800F84101D84365AF51FC4F55AACB55A8E542E
E9821F22942239422D3A05538B8424EB61C49E9C40CCFA282FA211898335A09127D342612ED436A0E4CAC475CBA9923BC16A2159B2439A2C3C121549A6A215AA
5CA46FF824E193BF9362575081B8B3C4C64DA45017B3C299F7B1D43906920B6C85D69F985501197834B9314715707AF2286A342747FD02221A86AC666429ACF1
19A4521E48CC47DA242F76C164D58403E768555F33CBC475449F6530684331C16C22E95347B0BCC51A644EA7B21A2E9C49A715BBE58355D9A4196305571255C7
7DF28BE9A51364E010648A267655A4024C1B4F312C6F15CDE30151B8423775FFC1B87A1C18C644016CF606CC5B3447637E219C34553162632A366A8447F44C27
6CF3C3D5F45AAEAC35FF31A217481EFC7CCF6FA11F8BD424351443243BC6A2882A2EE14E7A9316A012D6E564460FC14991523D8263C74E45CAEB017198E1C2B3
513DAE974AEB2110DE85BC3D8194017415DE354919493DBA44139FB327D8A451CA9459E6A71BDC7C7EF0112F17DC3A7B32C600A8D4FAE22DEC3164FE81D550E8
21433C8813211161A2BBF7372104ED305D162D7DB319112DCC03E17CD5B3D6B75C5538292A5D5CCCFB245496FD123A62C1A9D248A4714B5E415EDA2B3D5671C6
ED251459B13E05611ACBA2CC01D45665E55064B584B475A87E76418FBD33B4FF53BA2D15DE474D6A44863D5B432317E822D1A4214DF5D98601A0978D1E9A22C4
50B4395A0275F30D128F643D6D5DD6C3731912BD378FC1DB7CB367F3AD4F95E43080685507BD106FBC1A59E15D96724B206236CC7C51573128B8945EFED36475
E691669C1E0C4523CB2C3AF092D80A1447E7771D91E840E79C4CBD413B6FC44EBA15273EE41F47141633612D7C3161BD23A7880227A055C453C54444C11431D6
3C257B4EE85D38608D194EBE149B6DCB03EE22F6F410FD04424A3430AB435421C9A471834B56C81420C31568B0125922DDAF61173C1154EA71543F60363321E1
6B7C5111A7120339DAB83D9D8B8D3AA5FBB16F144C53833A1F835C8DF2595859EDCB78733EA496D8F2F14124E4D9FF97D8B4BCD5646EE751EC3CB0413E31F53C
ED24E06BDD5545F5496D4DDF66BDDF47F53661EDDBA8ADC761717C54F616636612E8C5CC4C6A67857DD8ECF513B3BE1A842D386636565FC1E1FF01B421D8D416
536304732AE8B2C32B670447D9D152E607DC3744E00913EAE21217A636B38401DAE70D265837221D36DD3B1230D8B3D0B53D548133237992EAB2B1D5FD74478D
62C45BA35578C4E5665D1EA6D174599472FC2B71A502751725D3EDFD137BAD562D9756624EEB0F7310651C84A6E14D72B68A74C22FE874F17C3310A9C91F9AF4
1F9A3BDA9EA210B5F58E58F51EE4D3101A8C40A8C22073E2201DF4DF5B51636134C5135D8DAE2CC4391154F79E2AE5912CB96C4366BDE54AEDC9E9CE440E45F3
E384D199F4D78D61D8734156AA111504FFF488621A064EC75913CDEC65C023BE63F066217E11365A7E387D332FF777F5067E4F177237555ECAFFBCCCDFA16415
A4A2D0F6611632E23B064120870351B8B15DFA6CCB3742E4ADCBDFF1DEDFB7EC185A02DDAA35F702832F5425CBFB544939B1D962E1D6D6553923AD35E2A35636
616799EFEBAD116725E1158D7B24272D144DE44469AED5F7585615802494FE54923ED73CCF2C18914D2502111AE6101FFFC29B8E2FC11D5D19A1214BAFE72601
1F265421B5B55A45A1E8302FF497DDCB21E6D658E62A4E824B5CAD7E465C55E544E08B5E3CA983DB7CD2E8520AFE50D26471A1DCAAD4CC54BF1A796EE1632671
75EC505981EB3D81CF6465E10C1BBBDA34A2008123478E1F0207FE189810218E823F1CF8788043A08F8439280E642890420E860E081EFC8810FFE4C790233F32
4C68502447830337E678C051A4C00A1823B20C6910C74D9518098EF92132A8C99525491E3D8950A851994D1BE64833308DD21F40A7023D28B020D18414958244
C9B422CA8B5B093EC02A542BCA855F732A9C1955EBC131238B8A59D9B6AED0BA1CA30EDC2B304DCB815EA172952AB52AC2BE1663EE34F898A3648273B362DCDA
B3A2E3C91039C21CE871EC678B9515E6102D9072D9B0864B3FA0581335C598A43D869D38F0C14CD10E964A66FB312AC2E10251329C7952F9D68BA68F5F5EBA99
EAE2E1048953B5FE9669D8E4DC2B17056F383AD2B04D7B9ADDBA728C8F31BE7388A99CF6231A8B7D115E2C5BB5BE5EC553E1039DEB07BC7EBAFF0F2B90A2A2E8
AF856492282597C0FA8822EED6AA2D870A9EC3ECB3E04A7BC9B4C57C0AEE2B8A74D0ACA5E61C5C4942877422C9339F92C3C922AD20C88840E13E5C0EA4AFD2CB
CEA8BCF242B1C7C3AA230EAA07AE5ACCC0A596F4512D92B0330F48928A78D2C78474782AA1A80094EBA331041B8DBEBA8E3C48A4A8D2A88BBDA608AC2B8D13F9
2A32070013530A87A806FC6B321C6A8AC93317299250B9CDC00222A3E6047A08A69D10BA2D870E098228C0D2567A4E25B6026CA9A19D287220A30AABC4813540
5143493687BA22CDC606DD023239F47C1234C5D3EA1C2A48A5869BEA071D8603EA87A9B8DAF049EFAA8C754DA5943CE922E3222C2CA98250122A8344FFAAF201
08ACDCFC5040FDAAC2610C034B230941902E02AAAE72BD1C884AA8BEF2F6302F7D882A20003B}}
\par\par \b \uc2 Bennet, Hatch Propose a Streamlined Pathway for Approval of Antibiotics; The PATH Act is needed to spur the innovation of new antibiotics and give patients with unmet medical needs access to important antibiotics faster"; Sen. Orrin G. Hatch (R-UT) News Release\b0\par\par\uc2 419 \uc2 words\par \uc2 10 December 2014\par \uc2 Congressional Documents and Publications\par \uc2 CONGDP\par \uc2 English\par \uc2 (c) 2014 Federal Information & News Dispatch, Inc.   \par \par \uc2 Washington, D.C. -- U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) today \b \highlight22\uc2 introduced\b0 \highlight\uc2  a bill to create a \b \highlight22\uc2 new drug\b0 \highlight\uc2  approval pathway to streamline access and encourage innovation and development of potentially lifesaving antibiotic drugs for patients, particularly Veterans who have encountered antibiotic-resistant bacteria while overseas.\par \par \uc2 "Antibiotic-resistant bacteria pose serious and unique challenges to health care professionals," Bennet said. "This bill will allow new antibiotics that show promise combating these bacteria to reach patients more quickly and save lives. It will also encourage bioscience companies to invest in innovative research to develop these lifesaving drugs."\par \par \uc2 "By addressing antibiotic-resistant bacteria, we can make major strides in preventing a significant number of illnesses and deaths in the United States," Senator Hatch said. "I am excited to build on the progress we have made. The PATH Act is needed to spur the innovation of new antibiotics and give patients with unmet medical needs access to important antibiotics faster."\par \par \uc2 "Superbugs"--or bacteria that are substantially resistant or unresponsive to any existing and available antibiotic--are an increasingly urgent public health threat, both at home and abroad. While antibiotic resistance continues to cost tens of thousands of lives in the United States each year, less than ten new antibiotics have made it to market since 2000. Antibiotic-resistant bacteria is also a significant concern to our troops, affecting more than a third of returning Iraq and Afghanistan veterans, according to the Department of Defense.\par \par \uc2 In an effort to address some of the significant regulatory obstacles facing antibiotic development and hindering patient and veteran access, the Promise for Antibiotics and Therapeutics for Health (PATH) Act would permit the \uc2 Food and Drug Administration\uc2  (FDA) to accelerate an antibacterial drug's approval for an identifiable, limited patient population upon determining that the drug treats a serious or life-threatening condition and addresses an unmet need. In addition, the bill requires a drug's label to include special designation from FDA indicating their intended use in limited, high-risk populations approved under this pathway. The bill also calls for further guidance and potential expansion to other appropriate therapeutic areas.\par \par \uc2 Read this original document at: {\field{\*\fldinst{HYPERLINK "http://www.hatch.senate.gov/public/index.cfm/releases?ID=3e3ad4d1-8a4d-423c-8ca6-9aec59beef8f"}}{\fldrslt{\cf2 \uc2 http://www.hatch.senate.gov/public/index.cfm/releases?ID=3e3ad4d1-8a4d-423c-8ca6-9aec59beef8f}}}\par \par \uc2 Document CONGDP0020141211eaca0008g\par }\page {\par\fs20\b \uc2 Melanomas; SU2C-supported research discovers why patients respond to a life-saving melanoma drug\b0\par\par\uc2 401 \uc2 words\par \uc2 8 December 2014\par \uc2 Cancer Vaccine Week\par \uc2 CNVW\par 40\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Cancer Vaccine Week via NewsRx.com   \par \par \uc2 2014 DEC 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Work supported by the Stand Up To Cancer (SU2C) - \uc2 Cancer Research Institute\uc2  (CRI) - Immunology Translational Research Dream Team, \b \highlight22\uc2 launched\b0 \highlight\uc2  in 2012 to focus on how the patient's own immune system can be harnessed to treat some cancers have pioneered an approach to predict why advanced melanoma patients respond to a new life-saving melanoma drug. This \b \highlight22\uc2 new drug\b0 \highlight\uc2 , pembrolizumab (Keytruda), was recently approved by the FDA. These findings are reported in Nature online November 26, 2014, ahead of print in the journal.\par \par \uc2 Over a two-year study, researchers including Dr. Antoni Ribas of \uc2 UCLA Jonsson Cancer Center\uc2  and co-leader of the CRI-SU2C Immunology Dream studied 46 patients with advanced melanoma treated with pembrolizumab. These patients had tumor biopsies before and during treatment. The researchers analyzed those biopsies and classified them according to whether the patient responded or not to pembrolizumab. The study then used the biopsy findings to predict the likelihood whether patients would likely to respond to this treatment\par \par \uc2 According to the press release issued by \uc2 UCLA Jonsson Comprehensive Cancer Center\uc2 , a protein known as PD-1 puts the immune system's brakes on, preventing T cells from attacking cancer cells. Pembrolizumab removes the brake lines, freeing up the immune system to kill cancer cells. Keytruda was the first PD-1 immunotherapy drug approved by the FDA in September 2014.\par \par \uc2 "The work of Dr. Ribas, his colleagues and the SU2C-CRI Immunology Dream Team is so important, bringing tangible benefits to patients struggling with advanced melanoma and providing the means to assess why some patients are responsive to this breakthrough drug," said \uc2 Phillip A. Sharp, Ph.D\uc2 ., chairperson SU2C Scientific Advisory Committee, and MIT Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge. "Not only has this research validated a pathway to determine which patients may be responsive to pembrolizumab, we anticipate it will significantly inform development of better drug combinations that are more effective, less costly and with fewer side effects for even more patients with melanoma and other cancers."\par \par \uc2 Keywords for this news article include: Cancer, Oncology, Melanomas, Immunology, Hemic and Immune Systems, \uc2 Entertainment Industry Foundation\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document CNVW000020141205eac80000y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 EPIRUS Biopharmaceuticals\uc2  Files 8K - Other Events >EPRS\b0\par\par\uc2 248 \uc2 words\par \uc2 5 December 2014\par 16:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 EPIRUS Biopharmaceuticals Inc\uc2 . (EPRS) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 05, 2014.\par \par \uc2 On December 5, 2014, \uc2 EPIRUS Biopharmaceuticals, Inc\uc2 . (the "Company") announced the addition to its pipeline of a preclinical product candidate, BOW070, a proposed biosimilar version of Actemra(R) (tocilizumab) marketed by \uc2 Genentech\uc2 /Roche. Actemra (tocilizumab) is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis. According to EvaluatePharma(R), global sales of Actemra in 2013 were $1.1 billion. The Company is in the comparability phase of development of BOW070.\par \par \uc2 The addition of BOW070 will continue to build the Company's pipeline of biosimilar product candidates (BOW015 (a biosimilar version of Remicade(R) (infliximab)) and BOW050 (a biosimilar version of Humira(R) (adalimumab))) in the synergistic therapeutic category of immunology and inflammation.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1135906/000110465914085111/a14-25707_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1135906/000110465914085111/a14-25707_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1135906/000110465914085111/0001104659-14-085111-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1135906/000110465914085111/0001104659-14-085111-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 05, 2014 16:31 ET (21:31 GMT)\par \par \uc2 Document DJDN000020141205eac5003vv\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Cannabis Science (CBIS) Readies To  \highlight22\uc2 Launch New Products \highlight\uc2  In California With Apothocary Genetics\b0\par\par\uc2 632 \uc2 words\par \uc2 5 December 2014\par 07:33\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Cannabis Science (CBIS) Readies To \b \highlight22\uc2 Launch New Products\b0 \highlight\uc2  In California With Apothocary Genetics\par \par \uc2 PR Newswire\par \par \uc2 COLORADO SPRINGS, Colo., Dec. 5, 2014\par \par \uc2 COLORADO SPRINGS, Colo., Dec. 5, 2014 /PRNewswire/ -- \uc2 Cannabis Science, Inc\uc2 . (OTCQB: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.\par \par \uc2 "All that's left now is to finish work on the packaging and the labeling, and that should only take a matter of days," said Mr. Raymond C. Dabney, Director, President & CEO and Co-Founder of \uc2 Cannabis Science Inc\uc2 . "The products and the formulation are there. We're ready to launch in California and we're excited, as I'm sure many self-medicating patients are."\par \par \uc2 The California launch was made possible by a renegotiation of the Cannabis Science agreement with Apothecary Genetics Investments LLC. The new agreement enabled Cannabis Science to purchase and license two northern California production farms with a combined total of 51 acres. The purchase included all related equipment for cannabis cultivation and production for the state's substantial medical cannabis market and gives Apothecary Genetics the right to sell Cannabis Science formulations throughout the State of California.\par \par \uc2 "Apothecary Genetics is state licensed and regulated, and now with our new licensing agreement we can proceed with the commercialization of our medical cannabis formulations throughout the State," said Mr. Dabney.\par \par \uc2 Mr. Dabney said the company will provide more information about the release of its products and where they will be available in the coming days.\par \par \uc2 About \uc2 Cannabis Science, Inc\uc2 .\par \par \uc2 Cannabis Science, Inc\uc2 ., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.\par \par \uc2 Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. \uc2 Cannabis Science, Inc\uc2 ., does not undertake any duty nor does it intend to update the results of these forward-looking statements.\par \par \uc2 Cannabis Science, Inc\uc2 .\par \par \uc2 Raymond C. Dabney\uc2 , Director, President & CEO, Co-Founder\par \par \uc2 raymond@cannabisscience.com\par \par \uc2 Tel: 1.310.650.3788\par \par \uc2 Chad S. Johnson, Esq., Director, COO, & General Counsel\par \par {\field{\*\fldinst{HYPERLINK "http://www.cannabisscience.com"}}{\fldrslt{\cf2 \uc2 www.cannabisscience.com}}}\par \par \uc2 info@cannabisscience.com\par \par \uc2 1.888.777.0658\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/cannabis-science-cbis-readies-to-launch-new-products-in-california-with-apothocary-genetics-300005429.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/cannabis-science-cbis-readies-to-launch-new-products-in-california-with-apothocary-genetics-300005429.html}}}\par \par \uc2 SOURCE \uc2 Cannabis Science, Inc\uc2 .\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.cannabisscience.com"}}{\fldrslt{\cf2 \uc2 http://www.cannabisscience.com}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 05, 2014 07:33 ET (12:33 GMT)\par \par \uc2 Document DJDN000020141205eac5001kp\par }\page {\par\fs20\b \uc2 INTERPHEX; INTERPHEX and Pharmaceutical Processing Announce Launch of INTERPHEX Live\b0\par\par\uc2 673 \uc2 words\par \uc2 3 December 2014\par \uc2 Biotech Week\par \uc2 BIWK\par 343\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014, Biotech Week via NewsRx.com \par \par \uc2 2014 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- International Pharmaceutical Expo (INTERPHEX), the premier pharmaceutical and biopharmaceutical event dedicated to innovation, technology and knowledge, and sponsored by the \uc2 Parenteral Drug Association\uc2  (PDA), announced the launch of INTERPHEX Live. INTERPHEX Live is a daily Show, taped from the floor of INTERPHEX, presenting reviews, interviews and lively discussion of the latest, cutting-edge pharmaceutical and biopharmaceutical technology. The broadcast will feature nearly two dozen presentations and panel discussions on a wide range of industry and technically complex topics.\par \par \uc2 "On behalf of INTERPHEX and Pharmaceutical Processing, we are proud to offer even more value to our INTERPHEX visitors and exhibitors by launching INTERPHEX Live. This new, technology-focused three-day live event, presented right on the show floor, will enable industry professionals to gain valuable insights in a fun and entertaining format," said Ed Several, Senior Vice President and General Manager, INTERPHEX. "Both attendees and exhibitors will have the opportunity to view the presentations and panels live via our show floor studio, as we record for "on-demand" viewing after the show on both the INTEPRHEX and Pharmaceutical Processing websites. In addition, we will broadcast throughout the show floor and, following the show, distribute through the Pharmaceutical Processing Daily e-Newsletter and INTERPHEX Connector e-Newsletter."\par \par \uc2 Several continued, "We believe this new, live event will enhance the overall show experience, making INTERPHEX 2015 a must attend event. Please view our promotional video clip to learn more."\par \par \uc2 "INTERPHEX Live will feature the best and brightest thought-leaders in the industry discussing the latest trends, state-of-the-art technologies and covering the hot button issues in today's market," said Mike Auerbach, Pharmaceutical Processing's Editor in Chief and INTERPHEX Live host. "I will be speaking with a number of subject matter experts on topics such as biopharmaceutical processing, solid dosage manufacturing, parenteral processing, regulatory and compliance, inspection and packaging, supply chain, facility design and management and more," added Auerbach. About INTERPHEX INTERPHEX (International Pharmaceutical Expo), sponsored by \uc2 Parenteral Drug Association\uc2  (PDA) is the single source for complete biopharmaceutical manufacturing solutions to safely and cost effectively process all dosage forms for life-enhancing drugs. It brings over 12,000 global pharmaceutical and biotechnology professionals together with 600+ suppliers via 300,000sf of event space through a unique combination of exhibition, education, workshops, partnering opportunities, and networking events. INTERPHEX offers annual national and international industry events and educational opportunities around the world. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.INTERPHEX.com"}}{\fldrslt{\cf2 \uc2 www.INTERPHEX.com}}}\uc2  and follow INTERPHEX on \uc2 Facebook\uc2  , \uc2 LinkedIn\uc2  and \uc2 Twitter\uc2  (@INTERPHEX.) IPX Blog continues the learning beyond the show floor and INTERPHEX Connector is the new twice-weekly email industry insight and news briefing. About Pharmaceutical Processing Since 1984 Pharmaceutical Processing has provided industry professionals with news and information on the cutting-edge technologies and services for the pharmaceutical, biopharmaceutical, nutraceutical, and medical device markets. Pharmaceutical Processing engages pharmaceutical and biopharmaceutical manufacturing professionals daily, weekly, and monthly with relevant industry news and technology solutions that solve critical issues, delivering it in the formats that meet their business and professional needs. From formulation to manufacturing to packaging, Pharmaceutical Processing provides comprehensive coverage on the latest technologies and best practices being used in today's marketplace. Pharmaceutical Processing reaches more than 28,000 direct request publication subscribers, 24,000 e-newsletter recipients daily, and more than 40,000 unique website visitors monthly. {\field{\*\fldinst{HYPERLINK "http://www.PharmPro.com"}}{\fldrslt{\cf2 \uc2 www.PharmPro.com}}}\uc2  About PDA The \uc2 Parenteral Drug Association\uc2  (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of it's nearly 10,000 members worldwide.\par \par \uc2 Keywords for this news article include: Drugs, Therapy, INTERPHEX, Technology, Biopharmaceuticals.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document BIWK000020141128eac30007t\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Perrigo \highlight22\uc2 Launches \highlight\uc2  Generic Pennsaid\b0\par\par\uc2 149 \uc2 words\par \uc2 2 December 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.  \par \par \uc2 Perrigo\uc2  announced it has received final approval from the \uc2 Food and Drug Administration\uc2  (FDA) for Diclofenac Sodium Topical Solution, the generic version of Mallinckrodt's Pennsaid.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/perrigo/manufacturer/11484/"}}{\fldrslt{\cf2 \uc2 Perrigo }}}\uc2  announced it has received final approval from the \uc2 Food and Drug Administration\uc2  (FDA) on its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Diclofenac Sodium Topical Solution, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mallinckrodt-inc/manufacturer/234/"}}{\fldrslt{\cf2 \uc2 Mallinckrodt's }}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/pennsaid/drug/3597/"}}{\fldrslt{\cf2 \uc2 Pennsaid }}}\uc2 .\par \par \uc2 Diclofenac Sodium is a nonsteroidal anti-inflammatory drug (benzeneacetic acid derivative) indicated for the treatment of sign/symptoms of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/arthritisrheumatic-disorders/category/83/0/"}}{\fldrslt{\cf2 \uc2 osteoarthritis }}}\uc2  of the knee(s). Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/osteoarthritis-patient-information-fact-sheet/article/222374/?DCMP=OTC-MPR_Related-Links"}}{\fldrslt{\cf2 \uc2 RELATED: Osteoarthritis Patient Information Fact Sheet }}}\par \par \uc2 Diclofenac Sodium Topical Solution is available as a 1.5% 2/2 strength. Shipments of this product have begun.\par \par \uc2 For more information call (866) 634-9120 or visit {\field{\*\fldinst{HYPERLINK "http://www.perrigo.com/"}}{\fldrslt{\cf2 \uc2 Perrigo.com }}}\uc2 .\par \par \uc2 Document MPRMPR0020141203eac200005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 ZO Skin Health, Inc.  \highlight22\uc2 Introduces \highlight\uc2  Three  \highlight22\uc2 New Products \highlight\b0\par\par\uc2 848 \uc2 words\par \uc2 2 December 2014\par 07:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par New Lash Enhancing Serum for Fuller, Thicker Lashes That Won't Change Eye Color \par  \par Clinically-Proven Acne and PIH Treatment and Prevention That Minimizes Post Acne Scarring \par  \par Post Procedure Recovery System Accelerates the Renewal Process \par  \f28 \par \par \uc2 \f2 IRVINE, Calif., Dec. 2, 2014 /PRNewswire/ -- ZO Skin Health, Inc, a privately-held aesthetics company, has \f28 \b \highlight22\uc2 \f2 launched\f28 \b0 \highlight\uc2 \f2  three \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  developed by Zein Obagi, MD which are all highly potent and clinically proven.\f28 \par \par \uc2 "Dr. Obagi is a world-renowned scientist and dermatologist and his research, products and philosophies have advanced the skincare industry. These three new groundbreaking products are technologically advanced, science-backed and highly potent. ZO(R) Skin Health continues to pioneer the future by offering our customers unique aesthetic products proven to help improve their skin health and improve skin's appearance," said James Headley, President and CEO of ZO Skin Health, Inc.\par \par \uc2 Ossential(R) Lash Enhancing Serum has been created to visibly improve eyelash length and volume. Our clinical study showed that in just four weeks 4 out of 5 subjects noticed longer, thicker lashes. What's particularly exciting about this new serum is that it will not cause a change in eye color, which makes it safer for everyday use and unique from other lash serums currently on the market.\par \par \uc2 AkneBright(TM) Acne Spot and Pigmentation Treatment is a fast-acting targeted treatment for rapid relief of acne lesions and prevention of post-inflammatory hyperpigmentation. AkneBright(TM) uses the power of encapsulated salicylic acid to prevent the formation of new pigmentation. It contains potent broccoli extract, sunflower seed oil and glucosamine to calm and soothe redness. Clinically proven Manuka Honey is used to help prevent post acne scarring and is a natural microbial long known and clinically proven for wound healing. It has also been proven to stimulate tissue growth in wounds in just 7 days by over 60%.\par \par \uc2 The third breakthrough product is the ZO(R) Medical Post Procedure Recovery System(TM). This three product system, including Pomatrol(TM) Soothing Ointment, Surfatrol(TM) Antiseptic Powder Solution and Regenacell(TM) Epidermal Renewal Creme is designed for use after chemical peels, laser resurfacing or any combined ablative treatment. The three products in this kit contain a highly effective, unique variety of proteins and growth factors. It is clinically proven superior in accelerating wound renewal and skin recovery rates by up-regulating the re-epithelialization process of cell rejuvenation. The product is available only through physician offices.\par \par \uc2 About ZO Skin Health, Inc.\par \par \uc2 ZO Skin Health, Inc. develops and delivers innovative skincare solutions that optimize skin health around the globe. Utilizing cutting-edge science and Dr. Zein Obagi's extensive clinical experience creating treatments and regimens for healthy skin, ZO Skin Health, Inc. provides comprehensive skincare programs for physicians and their patients. Committed to advancing effective treatments for healthy skin, ZO Skin Health, Inc. supports physicians' practices through skin health seminars and clinical training, and patients through a variety of educational programs. As a result, ZO Skin Health, Inc. is focused on providing products and protocols that bridge the gap between therapeutic treatments and daily care that allow patients to experience continuously healthy skin regardless of their age or unique skin condition. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.zoskinhealth.com"}}{\fldrslt{\cf2 \uc2 www.zoskinhealth.com}}}\uc2 .\par \par \uc2 About Zein Obagi, MD\par \par \uc2 Researcher, innovator, scientist, published author, lecturer and board-certified dermatologist, Dr. Zein Obagi has achieved international renown as a leading authority on skin rejuvenation. He is the ZO Skin Health, Inc. founder and medical director and is responsible for the development of new skincare treatments, protocols and products to achieve and maintain healthy skin.\par \par \uc2 Over twenty years ago, Dr. Zein Obagi pioneered the concept of skin health and conceived of, and brought to market, a line of medical grade skincare products -- the original Obagi Nu-Derm(R) System -- that transformed aging skin. Dr. Obagi founded WorldWide Products, which produced and marketed the original Obagi Nu-Derm(R) System. At that time, Dr. Obagi merely intended to challenge the norms of traditional skincare. Instead he shattered the status quo. Today his ideas about skin health are no longer surprising; they have become mainstream. Subsequently, WorldWide was purchased by \uc2 Obagi Medical Products, Inc\uc2 ., a company with which Dr. Obagi no longer has any affiliation, but which retained his family name (Obagi(R)) as their trademark.\par \par \uc2 ZO Skin Health, Inc. and Dr. Obagi have no business relationship with \uc2 Obagi Medical Products\uc2 , and \uc2 Obagi Medical Products\uc2  does not sell or endorse using any ZO(R) product. "ZO" is a registered trademark of ZO Skin Health, Inc. "Obagi" and "Obagi Nu-Derm" are registered trademarks of \uc2 Obagi Medical Products, Inc\uc2 .\par \par \uc2 Find us on \uc2 Facebook\uc2  at ZO Skin Health by Zein Obagi, MD.\par \par \uc2 Follow us on \uc2 Twitter\uc2  @ZO Skin Health.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20140121/LA49259LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20140121/LA49259LOGO}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/zo-skin-health-inc-introduces-three-new-products-300000925.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/zo-skin-health-inc-introduces-three-new-products-300000925.html}}}\par \par \uc2 SOURCE ZO Skin Health, Inc.\par \par \uc2 /\par \par \uc2 Document PRN0000020141202eac20002w\par }\page {\par\fs20\b \uc2 Precision Spine, Inc\uc2 . Precision Spine(TM) Plans to  \highlight22\uc2 Introduce New Products \highlight\uc2  at \uc2 North American Spine Society\uc2  Meeting in San Francisco\b0\par\par\uc2 422 \uc2 words\par \uc2 30 November 2014\par \uc2 Medical Devices & Surgical Technology Week\par \uc2 MDST\par 275\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Medical Devices & Surgical Technology Week via NewsRx.com   \par \par \uc2 2014 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- \uc2 Precision Spine, Inc\uc2 . announces it will be attending the 29th annual \uc2 North American Spine Society\uc2  Meeting, November 12-15, 2014, in San Francisco, CA. The company focus on product development will be highlighted at the NASS meeting with the introduction of several new and expanded product offerings.\par \par \uc2 Precision Spine's President, \uc2 Rich Dickerson\uc2  said, "We are pleased with the progressive growth we are seeing as a result of our continued focus on providing innovative, effective and efficient solutions for the surgical treatment of spine conditions. This year we will be introducing the MD-Max(TM) ULIF System which is a versatile, minimally invasive retractor access/fixation system that is designed to enable surgeons to achieve results that are the same as, or better than, those attributed to the 'gold standard' classic open approach. The system's surgical approach is designed to be minimally disruptive while providing maximum access to the operative site to help to reduce blood loss and optimizing OR time. Its goals to improve patient mobility and reduce dependence on pain relief medications contrast with percutaneous approaches that can create surgical trauma by puncturing muscle.\par \par \uc2 "Compatible with our MD-Max ULIF System, we are also introducing the Extended Tab SureLOK(TM) C System featuring breakaway tabs at 10mm increments to permit improved access and an open tulip design for facilitating easier rod insertion. Also being introduced is the expansion of our ShurFit(TM) PLIF line of convex and lordotic interbody spacers, which are available in 0, 5, 10 and now, 15 degree variations with an aggressive tooth pattern designed to minimize potential for expulsion, a large graft window to enhance the opportunity for successful fusion and a large contact area to optimize vertebral support. These new products further complement a growing array of cervical and thoracolumbar spinal technology solutions from Precision Spine." About \uc2 Precision Spine Precision Spine, Inc\uc2 . is a privately held company headquartered in Parsippany, NJ with manufacturing facilities in Pearl, MS. Precision Spine is dedicated to providing innovative, quality spine products that are designed to help treat serious orthopedic medical conditions in a cost effective manner. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.precisionspineinc.com"}}{\fldrslt{\cf2 \uc2 www.precisionspineinc.com}}}\uc2 .\par \par \uc2 Keywords for this news article include: \uc2 Precision Spine Inc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document MDST000020141121eabu0006l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Avanir Pharmaceuticals\uc2  Files 8K - Other Events >AVNR\b0\par\par\uc2 201 \uc2 words\par \uc2 28 November 2014\par 06:02\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Avanir Pharmaceuticals Inc\uc2 . (AVNR) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 26, 2014.\par \par \uc2 On November 26, 2014, \uc2 Avanir Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  has issued a Complete Response letter to its New Drug Application for AVP-825. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/858803/000119312514427420/d829841d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/858803/000119312514427420/d829841d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/858803/000119312514427420/0001193125-14-427420-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/858803/000119312514427420/0001193125-14-427420-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Avanir Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=P479&isin=US05348P4019"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=P479&isin=US05348P4019}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 28, 2014 06:02 ET (11:02 GMT)\par \par \uc2 Document DJDN000020141128eabs0015b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 INTERPHEX Announces Launch of New INTERPHEX Exhibitor Awards for 2015\b0\par\par\uc2 800 \uc2 words\par \uc2 24 November 2014\par 09:30\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved. \par \par \uc2 -Recognizing Cutting-Edge Technology and the Outstanding Efforts of Companies that Support Pharmaceutical and Biopharmaceutical Development and Manufacturing-\par \par \uc2 \f2 \par NEW YORK--(BUSINESS WIRE)--November 24, 2014-- \f28 \par \par \uc2 International Pharmaceutical Expo (INTERPHEX), the premier pharmaceutical and biopharmaceutical event dedicated to innovation, technology and knowledge, and sponsored by the \uc2 Parenteral Drug Association\uc2  (PDA), today announced the launch of INTERPHEX Exhibitor Awards for 2015. The INTERPHEX Exhibitor Awards program recognizes cutting-edge technology and value-added solutions that enable biopharmaceutical development and manufacturing companies to achieve business and production goals and objectives.\par \par \uc2 "With our media sponsor, Pharmaceutical Processing, we are pleased to announce the launch of this exciting new program, INTERPHEX Exhibitor Awards," said Ed Several, Senior Vice President and General Manager, INTERPHEX. "Winners will be recognized and awarded for showcasing innovative technologies and/or new strategies and services that have significantly contributed to the industry. To win an INTERPHEX Exhibitor Award, the exhibit/booth must excel in each criterion, rise above fellow exhibitors and competitors, and clearly reflect excellence in pharma and biopharma development and manufacturing."\par \par \uc2 "The INTERPHEX Exhibitor Award Judging Panel has a very difficult task selecting which exhibit is most deserving of an INTERPHEX Exhibitor Award," stated Mike Auerbach, Editor-in-Chief, Pharmaceutical Processing. "The competition will be judged by a highly esteemed group of pharma and biopharma industry experts chosen for their dedication to development and manufacturing excellence and depth of industry experience."\par \par \uc2 Winning exhibitors will be announced at INTERPHEX 2015 in New York, New York on April 21, 2015. Submissions for the INTERPHEX Exhibitor Awards program will be accepted through February 15, 2015. For additional details and criteria, please visit {\field{\*\fldinst{HYPERLINK "http://www.interphex.com/For-Exhibitors/Exhibitor-Award-Program/"}}{\fldrslt{\cf2 \uc2 www.interphex.com/For-Exhibitors/Exhibitor-Award-Program/}}}\uc2 .\par \par \uc2 The INTERPHEX Exhibitor Awards will be issued in the following categories:\par \par \uc2 The Best in Show Award recognizes accomplishments and display in the use of knowledge, innovation, and state-of-the-art technologies to achieve extraordinary levels of quality, production goals and objectives; ultimately transforming critical and affordable life-enhancing ideas to finished drug products.\par \par \uc2 The Judges may recognize the incredibly strong showing of knowledge, innovation, and state-of-the-art technologies on the INTERPHEX show floor by awarding an Honorable Mention Award.\par \par \uc2 The Best in Green Technology recognizes an especially noteworthy technology judged on the basis of substantive significance, innovation and sustainability.\par \par \uc2 The Best New Product/Service Award is given to the exhibitor that encourages, develops and features the very best in new products or services showcasing knowledge, innovation, and state-of-the-art technologies leading to significant business, economic or manufacturing benefits for the pharma and biopharma industries.\par \par \uc2 The Editor-in-Chief of Pharmaceutical Processing awards the Editor's Choice Award, which is based upon his/her view of the best in exhibiting in Knowledge, Innovation and Technologies within the pharma and biopharma industries.\par \par \uc2 The Judges recognize outstanding achievements in cutting-edge technologies with the Best Technologies Innovation Award.\par \par \uc2 About INTERPHEX\par \par \uc2 INTERPHEX (International Pharmaceutical Expo), sponsored by \uc2 Parenteral Drug Association\uc2  (PDA), is the single source for complete biopharmaceutical manufacturing solutions to safely and cost effectively process all dosage forms for life-enhancing drugs. It brings over 12,000 global pharmaceutical and biotechnology professionals together with 600+ suppliers via 300,000sf of event space through a unique combination of exhibition, education, workshops, partnering opportunities, and networking events. INTERPHEX offers annual national and international industry events and educational opportunities around the world. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.INTERPHEX.com"}}{\fldrslt{\cf2 \uc2 www.INTERPHEX.com}}}\uc2  and follow INTERPHEX on \uc2 Facebook\uc2  , \uc2 LinkedIn\uc2 , \uc2 Twitter\uc2  and \uc2 YouTube\uc2  . IPX Blog continues the learning beyond the show floor and INTERPHEX Connector is the new twice-weekly email industry insight and news briefing.\par \par \uc2 About Pharmaceutical Processing\par \par \uc2 Since 1984 Pharmaceutical Processing has provided industry professionals with news and information on the cutting-edge technologies and services for the pharmaceutical, biopharmaceutical, nutraceutical, and medical device markets. Pharmaceutical Processing engages pharmaceutical and biopharmaceutical manufacturing professionals daily, weekly, and monthly with relevant industry news and technology solutions that solve critical issues, delivering it in the formats that meet their business and professional needs. From formulation to manufacturing to packaging, Pharmaceutical Processing provides comprehensive coverage on the latest technologies and best practices being used in today's marketplace. Pharmaceutical Processing reaches more than 28,000 direct request publication subscribers, 24,000 e-newsletter recipients daily, and more than 40,000 unique website visitors monthly. {\field{\*\fldinst{HYPERLINK "http://www.PharmPro.com"}}{\fldrslt{\cf2 \uc2 www.PharmPro.com}}}\par \par \uc2 About PDA\par \par \uc2 The \uc2 Parenteral Drug Association\uc2  (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its nearly 10,000 members worldwide.\par \par \uc2 Document BWR0000020141124eabo0007t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw254\pich40\picscaley100\picscalex100\picwgoal3810\pichgoal600
47
4946383961FE00280070000021F904010000FC002C00000000FE002800870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF006FC418184320C14999060A3440ECD38A82033329336870E00A34FB32662476
63854031622016DC9770A0818C992E6A24F970E1A4956E5AC6589169A54D942B00001033490C3462041512E4026D924C8535358A396A514C3D37042BCE941832
AAC51B186DA211BAE26546313A0D28D3487185186529AD8A8C2126E93E655133D6334853233100375612630051E54D9B3AC5A0D179A3914E37F506EBACF9EE86
4E0035EB19D689702BDE7A5A1F679AFB98D85BB031921A76BA124D4E005E4B6B1EFBF72B5EB431F0EE038BDAF14EDACAA0D18E8186F60A8D996CB74D0880613D
DF6E888931805A19E1493A63B8619E5AA332DA00DC64740E192880ACDE0130FFF00C6D301A65CAA367A2ED73DF4FE690F7D5831E1A9A46E86735426B743A7F6B
8D0FBD15DB4B99EC9491633760B6CF3BCCF9B7CF6031B0A6CC43F6D944DB27F211A6A0736E0D26964DB14578533D2156D85A81009818DB7CF1E1B64F6C637117
43468AB5B70F74A891151F5CE22958201A24CE084D602419F8976333BA96977B3AB186A2182BD555240049D6A85474156E9599941AC5F6E17F1AC58722464362
34E1652805A62034B6B1B6CF0DA46596E33ECCADC01A741286E8A67B217A66D327B12508268EA5C5501E0019F5F920009EA584977DC43027E29B3A65B5CF5D63
65C29C010A92789E010412E99CA52B29C39CA0DCF9590F7519E168298769CAFF76A986AE0160E757496E479B5B892E06A6460C5DDA60A2509248658577BD7625
A3F2DD788389C0114929B36FFEB65D6CF1E9C7459337F138696B38FA49D20DC44C92A46D9E45DAA84E5CC4882D86FB4CF612666CD674A688F68164EABA3B6106
E75FDEDAA75852D06C6BE88DD23299148A499A6A2B6BD841A9DB491AADAA532336A1FB6B4606BC336556FF7A0B5C83AC71F6E159EBEDB9D1B0B3F95A8F47D156
BA92B1DF5A17A282ADD558614AD72D19624D40D584E29267524BDB4B8D68C705D09242F3CE596E9C75EBD05F096A937714839694B1B7BA4159C5D91A6564A454
42FC988821ADA42961A5E614DAC6FBF480939199BCE4AD9339DDE0E6B69C02FF4A8C3293407B6D7198B1F79601968644B2CDC5C15BAA9E6086170366D7415377
46DB32AB1B86C98A98EC9287C607EA839EDD5BA432E85D9729DB3756A75F88EE65EE96C63842B99D94281235ABB2B3C1E96B4826A655F64AD8F2BAF1DA5921EB
98EDBB5BCDA64EC23ADE2D6D9EC1F72C315CC2091ACE2F3E7C93777AFFAA1895E2EAE798015B6F1458BEBECAB7EB3E46AE2C9B692A4F499AE0D6196C9F66DBD9
F652ED1A71485200D8326AE9865C24D392527C1703C74D845B70430973CEF3382AA12169B5C3195856D0838194EF2617EA9E6C3425219080057DF9235FB72455
BF9B604B6633A39E4DD6B6026278A87C83F1085878E5105BF50000EDBAC993FFF0A79740D58347D412614DAC9411062D8C30E98981B8E6E2142F958B0BD6118C
62CA87AD0FFECA51CC1BDC63C618BEB7D82627C1FA4FB232510AB3D8CA86D67A0B6450E40BE20DEF6A90DB986DDAA7A3B7E9658C3A29DF7174721AC4D8055B39
6140FD3EC7BD6E79894954F20A34B005A531E9A72BB17ACC973272C0024EE206CF6A2203109213E6192B5B1104231ED124C7F8EDC360F54889F4BE7731731508
5482018E9D9225374E7A6996EE915423FF83A33BF62A891989C90803A91AC838A78E2333D052FEF2A45F4DB25F45CB44858A87300060AC8928EC6625F938172B
ECA38D7819882EEB41B625F5AA66C78B0DA9F8C4BBCFB9C936FBF01B98AE89FF95B304062B1AD112A05C199B1A7E2F502D6C4DB2E674CC59FAE254F2F1929BDE
C716139DE92405AA5F35C184C48C30A07DA7FC1F0CDD833B220D6927ACE9640181781F03D8278F0F4425DCD616C64BC12E565C581368943117F44CA28583B495
360B2A45B908C4A6DE7B0BDF4A860633E57136F3AC5BF0A2B3A6CC7DD05186E29141E533B0372D315DF011964FDDF4A4FAC5722CDE21CA29C5D5A6457DA742B0
EAE68C383329DD580B45B27AD3E4789446118AABA95FCCC93C1F5846479571AD24195742730880B1D826572715C31EF3644C0660B19D1ECBC8772C8445EB20C9
8E7E8C19694EE827DD7C0D3D2FB257DEA0815A34B8734AAFE5A463B0C84FD7FFF831A6FC625E5CA9B60F34B2B56199CB556C40D219318A8B0B35156283A0E52D
05B533A52E6A556CD5F6985A39082F3DF15FFF5498A8BC28437F9CF40B700E76A56FD9C678CF6D59C7B2F4B56B31CD5626922C75596997D3FC0D49ABCB16CD68
34D2557905AB07BAE35C72C55BF8F1C6B5D232995B4612B9916E2450A25D495BBB3B4CF55189BFA8844E529868AC2F39074A0E9B94735CE7B5F241876202E2EE
7DB0D43D3B21C493D11A4B0F39D5BF306E74BE4EBDF0EEBCC223AFB86A43D422609FD0E019F9A204C22CC9CA107BB555F8D92EA164ABE9F36C04C6891627B377
29E38896273FB72C0559482ED81DBD06E29B226C9E77092358D4CCCC520566FF2C037B1B8A24199B7419314D614C968D34C2A0861534A03BB10F775813652765
8B61AE411FB96693AB9625094F839BD4CFD284919078713D81D9CC764CD3BEDDF8B84E3FB54C72CD979DDBE1EB961E53C6F836C330842C65B30CCB04A6191AAB
B67C62A7DB21CE77DC941E2A2D312C523CE5593E393C34D42913BDCECA1177E3C51F9EE77DDB590C47685DA37219E93AD1190B74F216CB15F4B54009E2919F8A
F953477D87185E73E6615C08C8AC8C8F32E97E0C4200394678AEC430A58DC1877C812DF415333AF47E0C1AFEDD6E9BD8123E288DD9D9C6F2BC31D6843668B8E6
184F0319ECD0DB761217F84D2623549B609B8FE37D8CEE62CA3FFF7D628C7E8D82CB0DD61648BC1232E044028B172348F39ADBFCE638CFB9CE77CEF39EFBFCE7
400FBAD0874EF4A21BFDE8484FBAD297CEF4A63BFDE9508FBAD4A74EF5AA5BFDEA58CFBAD6B7CEF5AE7BFDEB600FBBD8C74EF6B29BFDEC684FBBDAD7CEF6B6BB
FDED708FBBDCE74EF7BADBFDEE78CFBBDEF7CEF7BEFBFDEF800FBCE0074FF8C21BFEF0884FBCE217CF78B40704003B}}
\par\par \uc2 Markets\par \b \uc2 Sanofi\uc2 \u8217\'20\'19s Diabetic Headache -- Overheard\b0\par\par\uc2 197 \uc2 words\par \uc2 23 November 2014\par 19:17\par \uc2 The Wall Street Journal Online\par \uc2 WSJO\par \uc2 English\par \uc2 Copyright 2014 Dow Jones & Company, Inc. All Rights Reserved.   \par \par \uc2 It may be tough for \uc2 Sanofi\uc2  to shake off the drag of diabetes. The French drug maker, which unceremoniously sacked its chief executive last month, last week laid out its pipeline, pledging to \b \highlight22\uc2 launch\b0 \highlight\uc2  18 \b \highlight22\uc2 new products\b0 \highlight\uc2  by 2020. They could deliver cumulative sales of \u8364\'20\'AC30 billion ($37.6 billion) over each drug\u8217\'20\'19s first five years, not adjusted for the risk of bringing the drugs to market.\par \par \uc2 But diabetes still looms large in \uc2 Sanofi\uc2 \u8217\'20\'19s plans, even as mounting price competition in the U.S. casts a shadow over its growth outlook. Toujeo, \uc2 Sanofi\uc2 \u8217\'20\'19s latest insulin expected to \b \highlight22\uc2 launch\b0 \highlight\uc2  next year, accounts for over one-fifth of its pipeline-sales outlook, according to \uc2 Credit Suisse\uc2 .\par \par \uc2 That raises concerns about how successful \uc2 Sanofi\uc2  will be in switching patients to Toujeo from its current product Lantus, and how the new insulin will be priced and marketed. \uc2 Sanofi\uc2 \u8217\'20\'19s five-year earnings-per-share growth of 9%, notes \uc2 Citigroup\uc2 , is close to the sector at 10%.\par \par \uc2 But assume flat sales in the diabetes business continue after 2015, with higher costs as drugs are launched, and that falls to 5%. Quite a crash.\par \par \uc2 Document WSJO000020141124eabo002j9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Cook Medical\uc2  Expands Percutaneous Stone Extractor Line with  \highlight22\uc2 Launch \highlight\uc2  of Perc NGage(R) and Perc NCompass(R)\b0\par\par\uc2 378 \uc2 words\par \uc2 24 November 2014\par 08:05\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par BLOOMINGTON, Ind.--(BUSINESS WIRE)--November 24, 2014-- \f28 \par \par \uc2 \f2 Urologists now have new options for stone extraction devices when performing percutaneous nephrolithotomy (PCNL), as \f28 \uc2 \f2 Cook Medical\f28 \uc2 \f2  is launching the Perc NGage(R) and Perc NCompass(R) nitinol stone extractors today. The \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  complement the Perc NCircle(R), which has been on the market since 2002 and was the first nitinol extraction device for percutaneous procedures. \f28 \uc2 \f2 Cook Medical\f28 \uc2 \f2  was the first company to incorporate nitinol into its stone extraction devices.\f28 \par \par \uc2 The two extractors are designed specifically to remove stones and stone fragments when physicians are removing kidney stones percutaneously. The design of the extractors mimics the original NGage and NCompass, which are indicated for ureteroscopic stone removal procedures.\par \par \uc2 Because every kidney stone is different, the method for extraction varies from stone to stone. The different wire configurations of each extractor are useful in various scenarios. For example, the Perc NGage can grasp and release a stone, while the Perc NCompass has a 16-wire configuration.\par \par \uc2 "These products were developed for physicians who needed, in PCNL procedures, the same options that they currently have with our ureteroscopy extractors," said Jean-Marc Creissel, vice president and global leader of \uc2 Cook Medical\uc2 's Urology division. "We are pleased to be able to meet that product need and fill out our percutaneous extraction offering. Now physicians can apply the technology they master to an additional procedure."\par \par \uc2 The Perc NGage and NCompass are available to urologists in global markets where \uc2 FDA\uc2  clearance and CE Mark are accepted.\par \par \uc2 About \uc2 Cook Medical\par \par \uc2 Since 1963 \uc2 Cook Medical\uc2  has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family-owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at {\field{\*\fldinst{HYPERLINK "http://www.cookmedical.com"}}{\fldrslt{\cf2 \uc2 www.cookmedical.com}}}\uc2 , and for the latest news, follow us on \uc2 Twitter\uc2 , \uc2 Facebook\uc2  and LinkedIn.\par \par \uc2 Document BWR0000020141124eabo0004u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 INTERPHEX and Pharmaceutical Processing Announce Launch of INTERPHEX Live\b0\par\par\uc2 672 \uc2 words\par \uc2 17 November 2014\par 09:30\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved. \par \par \uc2 The premier, technology-focused 3-day video/talk show event presented live on the show floor during INTERPHEX 2015, April 21-23\par \par \uc2 \f2 \par NEW YORK--(BUSINESS WIRE)--November 17, 2014-- \f28 \par \par \uc2 International Pharmaceutical Expo (INTERPHEX), the premier pharmaceutical and biopharmaceutical event dedicated to innovation, technology and knowledge, and sponsored by the \uc2 Parenteral Drug Association\uc2  (PDA), today announced the launch of INTERPHEX Live. INTERPHEX Live is a daily Show, taped from the floor of INTERPHEX, presenting reviews, interviews and lively discussion of the latest, cutting-edge pharmaceutical and biopharmaceutical technology. The broadcast will feature nearly two dozen presentations and panel discussions on a wide range of industry and technically complex topics.\par \par \uc2 "On behalf of INTERPHEX and Pharmaceutical Processing, we are proud to offer even more value to our INTERPHEX visitors and exhibitors by launching INTERPHEX Live. This new, technology-focused three-day live event, presented right on the show floor, will enable industry professionals to gain valuable insights in a fun and entertaining format, " said Ed Several, Senior Vice President and General Manager, INTERPHEX. "Both attendees and exhibitors will have the opportunity to view the presentations and panels live via our show floor studio, as we record for "on-demand" viewing after the show on both the INTEPRHEX and Pharmaceutical Processing websites. In addition, we will broadcast throughout the show floor and, following the show, distribute through the Pharmaceutical Processing Daily e-Newsletter and INTERPHEX Connector e-Newsletter."\par \par \uc2 Several continued, "We believe this new, live event will enhance the overall show experience, making INTERPHEX 2015 a must attend event. Please view our promotional video clip to learn more."\par \par \uc2 "INTERPHEX Live will feature the best and brightest thought-leaders in the industry discussing the latest trends, state-of-the-art technologies and covering the hot button issues in today's market," said Mike Auerbach, Pharmaceutical Processing's Editor in Chief and INTERPHEX Live host. "I will be speaking with a number of subject matter experts on topics such as biopharmaceutical processing, solid dosage manufacturing, parenteral processing, regulatory and compliance, inspection and packaging, supply chain, facility design and management and more," added Auerbach.\par \par \uc2 About INTERPHEX\par \par \uc2 INTERPHEX (International Pharmaceutical Expo), sponsored by \uc2 Parenteral Drug Association\uc2  (PDA) is the single source for complete biopharmaceutical manufacturing solutions to safely and cost effectively process all dosage forms for life-enhancing drugs. It brings over 12,000 global pharmaceutical and biotechnology professionals together with 600+ suppliers via 300,000sf of event space through a unique combination of exhibition, education, workshops, partnering opportunities, and networking events. INTERPHEX offers annual national and international industry events and educational opportunities around the world. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.INTERPHEX.com"}}{\fldrslt{\cf2 \uc2 www.INTERPHEX.com}}}\uc2  and follow INTERPHEX on \uc2 Facebook\uc2  , \uc2 LinkedIn\uc2  and \uc2 Twitter\uc2  (@INTERPHEX.) IPX Blog continues the learning beyond the show floor and INTERPHEX Connector is the new twice-weekly email industry insight and news briefing.\par \par \uc2 About Pharmaceutical Processing\par \par \uc2 Since 1984 Pharmaceutical Processing has provided industry professionals with news and information on the cutting-edge technologies and services for the pharmaceutical, biopharmaceutical, nutraceutical, and medical device markets. Pharmaceutical Processing engages pharmaceutical and biopharmaceutical manufacturing professionals daily, weekly, and monthly with relevant industry news and technology solutions that solve critical issues, delivering it in the formats that meet their business and professional needs. From formulation to manufacturing to packaging, Pharmaceutical Processing provides comprehensive coverage on the latest technologies and best practices being used in today's marketplace. Pharmaceutical Processing reaches more than 28,000 direct request publication subscribers, 24,000 e-newsletter recipients daily, and more than 40,000 unique website visitors monthly. {\field{\*\fldinst{HYPERLINK "http://www.PharmPro.com"}}{\fldrslt{\cf2 \uc2 www.PharmPro.com}}}\par \par \uc2 About PDA\par \par \uc2 The \uc2 Parenteral Drug Association\uc2  (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of it's nearly 10,000 members worldwide.\par \par \uc2 Document BWR0000020141117eabh00099\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Inovio Pharma Files 8K - Termination Of Definitive Agreement >INO\b0\par\par\uc2 301 \uc2 words\par \uc2 17 November 2014\par 16:35\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Inovio Pharmaceuticals Inc\uc2 . (INO) filed a Form 8K - Termination of a Definitive Agreement - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 14, 2014.\par \par \uc2 On September 9, 2013, \uc2 Inovio Pharmaceuticals, Inc\uc2 . (the "Company") enter into a Collaboration, Option and License Agreement with F. Hoffman-La Roche Ltd, \uc2 Hoffman-La Roche Inc\uc2 . (the "Agreement"). On November 14, 2014, the parties partially terminated the Agreement with respect to the development of INO-5150, the Company's DNA immunotherapy targeting prostate cancer, as well as the research collaboration in prostate cancer under the Agreement. All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to the Company. The Company plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.\par \par \uc2 The Company and Roche will continue to collaborate and co-develop the Company's DNA immunotherapy (INO-1800) against hepatitis B virus under the existing license under the Agreement.\par \par \uc2 The Company issued a press release on November 17, 2014, and the Company incorporates by reference the text of that press release into this Form 8-K current report.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1055726/000119312514415209/d822715d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1055726/000119312514415209/d822715d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1055726/000119312514415209/0001193125-14-415209-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1055726/000119312514415209/0001193125-14-415209-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 17, 2014 16:35 ET (21:35 GMT)\par \par \uc2 Document DJDN000020141117eabh003o6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 ZS Pharma Files 8K - Other Events >ZSPH\b0\par\par\uc2 248 \uc2 words\par \uc2 17 November 2014\par 08:23\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 ZS Pharma Inc\uc2 . (ZSPH) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 17, 2014.\par \par \uc2 On November 17, 2014, \uc2 ZS Pharma, Inc\uc2 . (the "Company") issued a press release announcing that it presented detailed results from HARMONIZE (ZS004), its second positive Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, at the late-breaking Clinical Science Special Reports Session of the \uc2 American Heart Association\uc2  Scientific Sessions. Hyperkalemia is a life threatening condition characterized by abnormally high concentrations of potassium in the blood (serum K + >5.1 mEq/L). The press release also announced that the study results were simultaneously published in The Journal of the \uc2 American Medical Association\uc2 . A copy of the press release, which includes additional detail on the HARMONIZE (ZS004) results, is filed as Exhibit 99.1 hereto.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1459266/000119312514414314/d822124d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1459266/000119312514414314/d822124d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1459266/000119312514414314/0001193125-14-414314-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1459266/000119312514414314/0001193125-14-414314-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 17, 2014 08:23 ET (13:23 GMT)\par \par \uc2 Document DJDN000020141117eabh001j7\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: BioLife Solutions  \highlight22\uc2 Launches \highlight\uc2  Two  \highlight22\uc2 New Product \highlight\uc2  Packaging Options for BloodStor(R) and CryoStor(R) Freeze Media\b0\par\par\uc2 1,011 \uc2 words\par \uc2 17 November 2014\par 06:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 BioLife Solutions \b \highlight22\uc2 Launches\b0 \highlight\uc2  Two \b \highlight22\uc2 New Product\b0 \highlight\uc2  Packaging Options for BloodStor(R) and CryoStor(R) Freeze Media\par \par \uc2 Single-Use Syringes and Bulk Dispensing Bags with Sterile Dockable Tubing Offer Improved Aseptic Processing of Clinical Cells and Tissues\par \par \uc2 PR Newswire\par \par \uc2 BOTHELL, Wash., Nov. 17, 2014\par \par \uc2 BOTHELL, Wash., Nov. 17, 2014 /PRNewswire/ -- \uc2 BioLife Solutions, Inc\uc2 . (\uc2 NASDAQ\uc2 : BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced it has launched two new improved packaging options for its BloodStor and CryoStor cryopreservation freeze media products.\par \par \uc2 Current aseptic processing methods predominantly rely on repeated access and dispensing from media containers, via pipetting from the open mouth of the bottle, which carries an increased risk of contamination. Emerging best practices supported by the \uc2 International Society for Cellular Therapy\uc2  (ISCT) and the \uc2 Foundation for the Accreditation of Cellular Therapy\uc2  (FACT) include optimization steps to build and maintain sterile, closed system processing operations to reduce the risk of bioburden introduction to the biologic payload in storage and freezing containers.\par \par \uc2 Sterile, Single-Use Syringes\par \par \uc2 BioLife's BloodStor 55-5, a generic 55% DMSO/5% Dextran cryopreservation freeze media formulation used in cord blood banking, is now available in sterile, single-use syringes with a fill volume of 8ml, supporting manual and automatic processing of cord blood units. CryoStor, BioLife's proprietary cryopreservation freeze media product, widely utilized in regenerative medicine development projects and clinical trials, is now also available in single-use syringes with a 10ml fill volume. Sterile, single-use syringes support improved aseptic processing by enabling a direct luer connection to the biologic freezing bag; supporting manual or automatic dispensing with the use of a syringe pump. Biocompatible materials include a proprietary cyclic olefin polymer syringe body, FluroTec(R) film coated plunger, and polymethylpentene tip cap. Additional product information can be found here {\field{\*\fldinst{HYPERLINK "http://biolifesolutions.com/cgmp-biopreservation-media-products/polymeric-syringes/"}}{\fldrslt{\cf2 \uc2 http://biolifesolutions.com/cgmp-biopreservation-media-products/polymeric-syringes/}}}\uc2 .\par \par \uc2 Bulk Dispensing Bags\par \par \uc2 Supporting high volume processing operations, BioLife has also launched one-liter bulk dispensing bag options for BloodStor and CryoStor. In addition to reduced packaging, bulk bag containers include traditional spike and luer connectors and also a tail of weldable/dockable tubing, enabling sterile connections to the final freezing container outside a laminar flow hood.\par \par \uc2 After extensive research and testing, BioLife selected the Thermo Scientific CX5-14 film for the bag product contact material. PharMed(R) BPT tubing from \uc2 Saint-Gobain\uc2  was also selected due its robustness and compatibility with dimethyl sulfoxide (DMSO), a primary cryoprotective agent (CPA) in the formulations of BloodStor and CryoStor. Additional product information can be found here: {\field{\*\fldinst{HYPERLINK "http://biolifesolutions.com/cgmp-biopreservation-media-products/process-friendly-one-liter-bags/"}}{\fldrslt{\cf2 \uc2 http://biolifesolutions.com/cgmp-biopreservation-media-products/process-friendly-one-liter-bags/}}}\uc2 .\par \par \uc2 Aby J. Mathew, PhD\uc2 , Senior Vice President & Chief Technology Officer at BioLife Solutions, commented on the introduction of these new packaging options for BioLife products by stating, "Our active involvement with customers and industry organizations such as ISCT, AABB, and IBC Life Sciences enabled our team to respond to the need for new packaging alternatives that support improved aseptic processing of clinical cells and tissues. We strive to support the continuous evolvement of best practices in the development and commercialization of cell and tissue therapies."\par \par \uc2 A 2013 visiongain Translational Regenerative Medicine market research report forecasts that the regenerative medicine market comprised of cell and gene therapies and tissue-engineered products will grow to more than $23 billion by 2024. BioLife estimates that the Company's biopreservation media products are now incorporated into the collection, storage, shipping, freezing, and/or patient administration processes of at least 130 customer clinical trials or novel cell-based regenerative medicine products and therapies.\par \par \uc2 About BioLife Solutions\par \par \uc2 BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol(R) and CryoStor(R) platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit {\field{\*\fldinst{HYPERLINK "http://www.biolifesolutions.com"}}{\fldrslt{\cf2 \uc2 www.biolifesolutions.com}}}\uc2 , and follow BioLife on \uc2 Twitter\uc2 .\par \par \uc2 This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the \uc2 Securities and Exchange Commission\uc2  from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. \par \par \uc2 \f2 \par  \par Media & Investor Relations \par Daphne Taylor \par Senior Vice President, Chief Financial Officer \par (425) 402-1400 \par dtaylor@biolifesolutions.com \par  \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 BioLife Solutions, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 /Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.biolifesolutions.com"}}{\fldrslt{\cf2 \uc2 http://www.biolifesolutions.com}}}\par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 November 17, 2014 06:00 ET (11:00 GMT)\f28 \par \par \uc2 Document DJDN000020141117eabh0011n\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Loestrin 24 Fe(R)\b0\par\par\uc2 416 \uc2 words\par \uc2 17 November 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 87\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com   \par \par \uc2 2014 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of \uc2 Warner Chilcott\uc2 's Loestrin 24 Fe((R)). Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.\par \par \uc2 Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate had U.S. sales of approximately $24.4 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 287 ANDAs pending FDA approval representing $112.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use and this risk increases with age. Women who use oral contraceptives should be advised to not smoke. Consult your physician prior to beginning oral contraceptive use.\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Mylan Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020141114eabh0001w\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Cutting Costs & Delivering Growth While Managing a Multi-Product Pharmaceutical Franchise\b0\par\par\uc2 215 \uc2 words\par \uc2 17 November 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 54\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com   \par \par \uc2 2014 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- In today's marketplace, launching multiple products for a common therapeutic area is costly and challenging - as is managing a portfolio of products in the same therapeutic area. While many leaders would consider having a rich pipeline to be a "good problem," many realize that it can be costly to \b \highlight22\uc2 launch new products\b0 \highlight\uc2 , especially when it comes to hiring and training a new sales force to promote the products.\par \par \uc2 According to recent research, companies can most effectively cover promotional demand for new \b \highlight22\uc2 launches\b0 \highlight\uc2  by hiring more sales reps and leveraging existing pod structures. It is now more important than ever to effectively train reps and efficiently deploy them to high-impact promotional opportunity areas and territories.\par \par \uc2 The related research report, "Best Practices in Launch Optimization: How Promotional Efficiency can be leveraged to Support Multiple Products & Indications," provides leaders with metrics and insights they can use to evaluate and improve the management of their pipelines and portfolio assets.\par \par \uc2 Keywords for this news article include: \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020141114eabh0000s\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Five Prime Therapeutics\uc2  Files 8K - Other Events >FPRX\b0\par\par\uc2 234 \uc2 words\par \uc2 14 November 2014\par 16:15\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Five Prime Therapeutics Inc\uc2 . (FPRX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 13, 2014.\par \par \uc2 On November 13, 2014, \uc2 Five Prime Therapeutics, Inc\uc2 . ("FivePrime") issued a press release announcing that it plans to present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R), during the 2014 \uc2 American College of Rheumatology\uc2  and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting, to be held November 14 to 19, 2014 in Boston, Massachusetts.\par \par \uc2 A copy of the press release is filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1175505/000119312514413243/d821296d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1175505/000119312514413243/d821296d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1175505/000119312514413243/0001193125-14-413243-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1175505/000119312514413243/0001193125-14-413243-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 14, 2014 16:15 ET (21:15 GMT)\par \par \uc2 Document DJDN000020141114eabe004k1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: VBI Reports Third Quarter 2014 Financial Results and Provides Update on CMV Vaccine Development\b0\par\par\uc2 936 \uc2 words\par \uc2 14 November 2014\par 16:05\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 VBI Reports Third Quarter 2014 Financial Results and Provides Update on CMV Vaccine Development\par \par \uc2 CAMBRIDGE, Mass., Nov. 14, 2014 (GLOBE NEWSWIRE) -- \uc2 VBI Vaccines\uc2  (\uc2 Nasdaq\uc2 :VBIV) ("VBI") has filed operational and financial results for the three- and nine-month periods ended September 30(th) , 2014 on Form 10-Q with the \uc2 U.S. Securities and Exchange Commission\uc2  ("\uc2 SEC\uc2 "). The Quarterly Report on Form 10-Q is available on the \uc2 SEC\uc2 's website at {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov}}}\uc2  and on VBI's website at {\field{\*\fldinst{HYPERLINK "http://ir.vbivaccines.com"}}{\fldrslt{\cf2 \uc2 http://ir.vbivaccines.com}}}\uc2  under "\uc2 SEC\uc2  Filings."\par \par \uc2 "The third quarter was transformative for VBI," said \uc2 Jeff Baxter\uc2 , VBI's President and CEO. "In addition to raising new capital, resulting in a strong cash position, and making our \uc2 NASDAQ\uc2  debut, it marked a period of focused progress across our two vaccine platforms. Our lead candidate, an innovative eVLP-based CMV vaccine, VBI-1501A, has progressed in line with our target milestones. Over the next twelve months, we plan to prepare several batches of VBI-1501A for toxicology studies and for our Phase I clinical trial, which is scheduled to start in Q4 2015."\par \par \uc2 VBI is developing a prophylactic vaccine to prevent Cytomegalovirus (CMV) infection. CMV is a leading cause of prenatal developmental delays. Based on strong preclinical data, VBI has initiated work for GMP manufacturing of its lead candidate for use in formal preclinical and Phase I trials. Phase I data is expected in 2016, at which time VBI expects to demonstrate safety, tolerability, and also immunological proof of concept in humans.\par \par \uc2 Third Quarter Highlights \par \par \uc2 \f2 \par    -- Completed initial listing on \f28 \uc2 \f2 NASDAQ\f28 \uc2 \f2 . \par  \par    -- Consummated two equity private placements for gross proceeds of $16.25M. \par  \par    -- Obtained a senior secured term loan facility for up to $6M, of which VBI \par       was able to draw down $3M in the third quarter. \par  \par    -- Developed and scaled-up methods for the manufacture and purification of \par       VBI-1501A with GMP sub-contractors. \par  \par    -- Engaged regulatory advisors and continued preparation of documents \par       supporting the IND filing of VBI-1501A. \f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 VBI Vaccines, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 VBI Vaccines, Inc\f28 \uc2 \f2 . ("VBI") is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI's eVLP vaccine platform allows for the design of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus. VBI's lead eVLP asset is a prophylactic Cytomegalovirus ("CMV") vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI's second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.\f28 \par \par \uc2 \f2 Website Home: \f28 {\field{\*\fldinst{HYPERLINK "http://www.vbivaccines.com"}}{\fldrslt{\cf2 \uc2 http://www.vbivaccines.com}}}\par \par \uc2 \f2 News and Insights: \f28 {\field{\*\fldinst{HYPERLINK "http://www.vbivaccines.com/wire/"}}{\fldrslt{\cf2 \uc2 http://www.vbivaccines.com/wire/}}}\par \par \uc2 \f2 Investors: \f28 {\field{\*\fldinst{HYPERLINK "http://ir.vbivaccines.com/"}}{\fldrslt{\cf2 \uc2 http://ir.vbivaccines.com/}}}\par \par \uc2 \f2 Forward-Looking Statement Disclosure\f28 \par \par \uc2 \f2 This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of VBI. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to VBI cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, VBI will not obtain appropriate or necessary governmental approvals to market these or other potential products, VBI may not be able to obtain anticipated funding for its development projects or other needed funding, and VBI may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and VBI does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.\f28 \par \par \uc2 \f2 More detailed information about VBI and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in VBI's filings with the \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2  (the "Commission"). VBI urges investors and security holders to read those documents free of charge at the Commission's Web site at \f28 {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov}}}\uc2 \f2 . Interested parties may also obtain those documents free of charge from VBI. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, VBI undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise. \f28 \par \par \uc2 \f2 \par CONTACT: Company Contact \par  \par          \f28 \uc2 \f2 Jeff Baxter\f28 \uc2 \f2 , President and CEO \par          Phone: (617) 830-3031 x125 \par          Email: ir@vbivaccines.com \par  \par          Investor Contacts \par  \par          \f28 \uc2 \f2 Robert B. Prag\f28 \uc2 \f2 , President \par          The Del Mar Consulting Group, Inc. \par          Phone: (858) 361-1786 \par          Email: bprag@delmarconsulting.com \par  \par          Scott Wilfong, President \par          Alex Partners, LLC \par          Phone: (425) 242-0891 \par          Email: scott@alexpartnersllc.com \f28 \par \par \uc2 \f2 14 Nov 2014 16:06 ET *VBI Reports 3Q 2014 Fincl Results And Provides Update On CMV Vaccine Development\f28 \par \par \uc2 \f2 (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)\f28 \par \par \uc2 \f2 November 14, 2014 16:06 ET (21:06 GMT)\f28 \par \par \uc2 Document DJDN000020141114eabe00489\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Puma Biotechnology Files 8K - Other Events >PBYI\b0\par\par\uc2 312 \uc2 words\par \uc2 13 November 2014\par 16:17\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Puma Biotechnology Inc\uc2 . (PBYI) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 13, 2014.\par \par \uc2 On November 13, 2014, \uc2 Puma Biotechnology, Inc\uc2 . (the "Company") issued a press release announcing top line results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the treatment of first-line HER2-positive locally recurrent or metastatic breast cancer (NEfERTT trial) and scheduling a conference call to be held November 13, 2014 at 2:00 p.m. PST (5:00 p.m. EST) to discuss the NEfERTT trial results. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 In addition, in order to correct an inadvertent omission, the Consent of Independent Registered Public Accounting Firm, which was filed as Exhibit 23.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the \uc2 Securities and Exchange Commission\uc2  on March 3, 2014, has been amended to include a reference to the Company's Post-Effective Amendment No. 2 to Form S-1 on Form S-3 (No. 333-178308). The amended consent is attached to this report as Exhibit 23.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514411184/d823203d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514411184/d823203d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514411184/0001193125-14-411184-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514411184/0001193125-14-411184-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 13, 2014 16:17 ET (21:17 GMT)\par \par \uc2 Document DJDN000020141113eabd004di\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Provectus Biopharma Files 8K - Regulation FD >PVCT\b0\par\par\uc2 247 \uc2 words\par \uc2 13 November 2014\par 06:34\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Provectus Biopharmaceuticals Inc\uc2 . (PVCT) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 13, 2014.\par \par \uc2 On November 13, 2014, \uc2 Provectus Biopharmaceuticals, Inc\uc2 . (the "Company"), issued a press release (the "Press Release"), announcing that the protocol for the phase 3 study of PV-10 as a treatment for melanoma is now available online at {\field{\*\fldinst{HYPERLINK "http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6"}}{\fldrslt{\cf2 \uc2 http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6}}}\uc2 . A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 Pursuant to the rules and regulations of the \uc2 Securities and Exchange Commission\uc2 , the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be "filed" under the Securities Exchange Act of 1934.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312514410192/d823317d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312514410192/d823317d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312514410192/0001193125-14-410192-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312514410192/0001193125-14-410192-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 13, 2014 06:34 ET (11:34 GMT)\par \par \uc2 Document DJDN000020141113eabd001xv\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Medgenics Files 8K - Other Events >MDGN\b0\par\par\uc2 236 \uc2 words\par \uc2 12 November 2014\par 17:19\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Medgenics Inc\uc2 . (MDGN) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 12, 2014.\par \par \uc2 On November 12, 2014, the Company posted to its website at {\field{\*\fldinst{HYPERLINK "http://www.medgenics.com"}}{\fldrslt{\cf2 \uc2 www.medgenics.com}}}\uc2  an updated slide presentation containing additional clinical data from the ongoing MDGN-201 clinical trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients using TARGTEPO (tm) (formerly known as EPODURE (tm) BioPump (tm))." A copy of this slide presentation is attached as Exhibit 99.2 and incorporated by reference herein. The slide presentation is available in the Investor section of the Company's website.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1138776/000114420414067293/v393988_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1138776/000114420414067293/v393988_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1138776/000114420414067293/0001144204-14-067293-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1138776/000114420414067293/0001144204-14-067293-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Medgenics, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US58436Q2030"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US58436Q2030}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 12, 2014 17:19 ET (22:19 GMT)\par \par \uc2 Document DJDN000020141112eabc004lr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Encision  \highlight22\uc2 Launches \highlight\uc2  Its AEM EndoShield(TM) Burn Protection System\b0\par\par\uc2 554 \uc2 words\par \uc2 12 November 2014\par 07:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 BOULDER, Colo., Nov. 12, 2014 /PRNewswire/ -- \uc2 Encision Inc\uc2 . (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  its AEM EndoShield(TM) Burn Protection System ("EndoShield").\par \par \uc2 "We are pleased to \b \highlight22\uc2 introduce\b0 \highlight\uc2  the EndoShield burn protection system, our disposable monitor in a cord, to physicians and hospitals," said \uc2 Greg Trudel\uc2 , Encision's President & CEO. "EndoShield is leading edge technology that integrates our patented AEM(R) Technology into a disposable smart cord and eliminates the need for a separate AEM Monitor. Our customers appreciate the advancement of the technology, the ease of use, and the freedom from capital expense constraints. Our \b \highlight22\uc2 new device\b0 \highlight\uc2  will increase the proliferation of advanced AEM monopolar energy and save patients and healthcare providers from the tragic outcomes of stray energy burns."\par \par \uc2 "Like our other AEM instruments and monitors, EndoShield eliminates the risk of stray energy burns from capacitive coupling and insulation failure in laparoscopy. We believe in our AEM Technology so much that we offer a 100% hold harmless guarantee for stray energy burns to any patient, physician or hospital that uses the AEM system. No other company in the world offers this type of guarantee because no other technology eliminates stray energy burns to the patient. We are excited to bring this technological advancement to fruition and to take AEM Technology one step closer to becoming the standard of care for patient safety in laparoscopy."\par \par \uc2 Encision Inc\uc2 . designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM Technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, CO, the company pioneered the development and deployment of Active Electrode Monitoring, AEM Technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit {\field{\*\fldinst{HYPERLINK "http://www.encision.com"}}{\fldrslt{\cf2 \uc2 www.encision.com}}}\uc2 .\par \par \uc2 In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the \uc2 Securities and Exchange Commission\uc2 . Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2014 and subsequent filings with the \uc2 Securities and Exchange Commission\uc2 . We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.\par \par \uc2 Document PRN0000020141112eabc0003w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Sage Therapeutics\uc2  Files 8K - Other Events >SAGE\b0\par\par\uc2 188 \uc2 words\par \uc2 12 November 2014\par 06:13\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Sage Therapeutics Inc\uc2 . (SAGE) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 10, 2014.\par \par \uc2 On November 10, 2014, the Company issued a press release announcing initial top-line results for its phase 1/2 clinical trial for its product candidate SAGE-547 in patients with super refractory status epilepticus. A copy of the press release is filed herewith as Exhibit 99.2 to this Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1597553/000119312514407567/d817967d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1597553/000119312514407567/d817967d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1597553/000119312514407567/0001193125-14-407567-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1597553/000119312514407567/0001193125-14-407567-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 12, 2014 06:13 ET (11:13 GMT)\par \par \uc2 Document DJDN000020141112eabc001gz\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: \uc2 ICTV Brands Inc\uc2 . Reports Third Quarter 2014 Financial Results\b0\par\par\uc2 3,063 \uc2 words\par \uc2 11 November 2014\par 16:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 ICTV Brands Inc\uc2 . Reports Third Quarter 2014 Financial Results\par \par \b \highlight22\uc2 New Products Launched\b0 \highlight\uc2 ; Conference Call Scheduled for 4:30pm EST\par \par \uc2 WAYNE, PA--(Marketwired - November 11, 2014) - \uc2 ICTV Brands, Inc\uc2 . (OTCQB: ICTV) (CNSX: ITV), a direct response marketing and branding company focused on the health, wellness and beauty sector, today reported financial results for the three and nine months ended September 30, 2014.\par \par \uc2 Third Quarter 2014 Highlights: \par \par \uc2 \f2 \par    -- Adjusted EBITDA of ($162,000), excluding stock-based compensation \par  \par    -- Positive cash flow from operating activities of $89,000 \par  \par    -- Operating loss included $537,000 of non-cash stock based compensation \par       expense, product development and production expenditures associated with \par       new product expansion, and retail marketing initiatives \par  \par    -- Current working capital of $3.0 million, ratio of 2.3X \par  \par    -- Increased cash balance to $1.6 million, from $1.4 million at the end of \par       FY 2013 \par  \par    -- International sales of $4.8 million for the year to date, surpassing all \par       of FY 2013 \par  \par    -- DermaWand continued progress on next-generation device, increasing \par       international expansion and availability in U.S. retail \par  \par    -- DermaWand declared for rollout by Latino Media Services \par  \par    -- DermaWand made available at nearly 4,000 \f28 \uc2 \f2 Rite Aid\f28 \uc2 \f2  locations \par  \par    -- Derma Brilliance clinical study and marketing efforts completed for \par       November launch \f28 \par \par \uc2 \f2 Richard Ransom\f28 \uc2 \f2 , President, stated, "Over my six years at ICTV, I've never been more excited about the future and direction of the Company. While our third quarter results reflect seasonality and a strategic decision to reduce media spend in a historically slow response period, we're confident our investment in new products and sales channels has ICTV positioned to surpass our past successes."\f28 \par \par \uc2 \f2 Business Update:\f28 \par \par \uc2 \f2 DermaWand\f28 \par \par \uc2 \f2 ICTV Brands' flagship product, DermaWand, has continued to make progress on several fronts, including development of its next-generation device, increased international expansion and commencement of U.S. retail rollout. ICTV's design and development team and its Chinese manufacturing partner have made further design changes to be able to deliver an improved and more cost-effective unit. DermaWand successfully tested for launch into 16 Central and South American countries by Latino Media Services. This international relationship expands DermaWand availability to an additional 150 million people. Additionally, in November 2014, ICTV completed its new Spanish language DermaWand infomercial, marking the first time that the DermaWand is being marketed to the US Hispanic community with an infomercial shot one hundred percent in Spanish. Furthermore, DermaWand has commenced its U.S. retail rollout strategy with \f28 \uc2 \f2 Rite Aid\f28 \uc2 \f2  and is now available at nearly 4,000 \f28 \uc2 \f2 Rite Aid\f28 \uc2 \f2  locations. ICTV is in ongoing discussions with several other retailers and expects additional retail partners to carry DermaWand.\f28 \par \par \uc2 \f2 New Product Launches:\f28 \par \par \uc2 \f2 Jidue in September\f28 \par \par \uc2 \f2 Jidue is a facial massager that works through 18 uniquely positioned pulsating nodes, which stimulates the 4 key pressure points around the eye to increase facial blood circulation and lymph flow. It is designed to help alleviate eye fatigue, pain, stress and sinus pain. Initial two-minute spots tests in the United States and Canada were encouraging in September. Presentations to 40 international distributors at the \f28 \uc2 \f2 Electronic Retailing Association\f28 \uc2 \f2 's D2C convention in Las Vegas in September were perceived very favorably and we expect to test Jidue through some of these distributors overseas over the next few months. For more information about Jidue, please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.jidue.com"}}{\fldrslt{\cf2 \uc2 http://www.jidue.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 CoralActives in October\f28 \par \par \uc2 \f2 CoralActives is a new product in the acne treatment and skin cleansing market. CoralActives contains over two times the active acne fighting ingredient, benzoyl peroxide, of the leading brands, while combining the natural anti-inflammatory benefits of sea whip coral extract. CoralActives website was re-launched in September and is now built to allow customers to enroll in an auto ship continuity program. A direct to consumer radio campaign began in October. For more information about Coral Actives, please go to \f28 {\field{\*\fldinst{HYPERLINK "http://www.coralactives.com"}}{\fldrslt{\cf2 \uc2 http://www.coralactives.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Derma Brilliance in November\f28 \par \par \uc2 \f2 Derma Brilliance is a cosmetic system in the growing skin-polishing sector of the skin-care device market. Derma Brilliance constitutes a "razor/razor blade continuity model" led by a hand held rechargeable device and optimized by a consumable micronized diamonds and garnets skin cream formula, both of which are patented. After strong clinical performance results, we just started testing a 30-minute infomercial in the United States. For more information about Derma Brilliance, please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.dermabrilliance.com"}}{\fldrslt{\cf2 \uc2 http://www.dermabrilliance.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 In addition to the products mentioned above, the Company's product pipeline remains as robust as ever.\f28 \par \par \uc2 \f2 Financial Results:\f28 \par \par \uc2 \f2 Revenues for the three and nine months ended September 30, 2014 decreased due to management's calculated decision to lower its DermaWand media marketing spend during a historically slower response period. One of the driving factors was a decrease in the airings of the Spanish language version of the DermaWand infomercial. ICTV is in the process of creating a new version of the Spanish language show, which will air in November 2014. In addition, the Company did not air on live televised home shopping in the first nine months of 2014, but expects to resume airings in the future.\f28 \par \par \uc2 \f2 The Company continues to invest in production and research and development related expenditures. In 2014, ICTV completed clinical trials for the launches of Derma Brilliance and CoralActives, as well as a double blind placebo test in Europe on the DermaWand, with the goal of opening up the DermaWand to additional markets such as Japan and the UK. Furthermore, the Company invested in production expenditures for its skin-care product elastin-rp as well as enhancements to the DermaWand show including new short-form spot for the DermaWand campaign and high-definition enhancements to the long-form infomercial. Additionally, as the Company continues to build the infrastructure to bring its products into traditional retail stores, the Company incurred retail advertising expenditures consisting of promotional advertisements and numerous product packaging initiatives, which were not incurred in the prior year.\f28 \par \par \uc2 \f2 Third Quarter 2014 Compared to Third Quarter 2013\f28 \par \par \uc2 \f2 Revenues for the third quarter ended September 30, 2014 were $6.0 million, compared to $8.3 million for the third quarter of 2013. International revenue to third-party distributors grew by 175% from $655,000 to $1.8 million. Gross profit margin of 68% was realized in the third quarter 2014, slightly down from 74% percent a year earlier, attributable to the higher mix of international sales to total revenue. Operating loss for the third quarter was ($528,000) compared to operating income of $110,000 in the third quarter of 2013. Of note, operating loss for the third quarter 2014 included non-cash stock based compensation expenses and incremental investment (research and development, new production and retail initiatives) of approximately $537,000, which represents a $379,000 increase from the third quarter of 2013. These third quarter 2014 expenses were comprised of stock based compensation expense of approximately $360,000, product development and clinical testing expenditures of approximately $90,000, retail advertising expenditures of $65,000 and new production expenses of approximately $22,000.\f28 \par \par \uc2 \f2 Net loss for the third quarter was ($501,000), compared to net income of $101,000 in the third quarter of 2013. The resulting EPS is ($0.02), as compared to $0.00 in the comparable quarter a year earlier. Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) was ($162,000).\f28 \par \par \uc2 \f2 Nine Months Ended September 30, 2014 Compared to Nine Months Ended September 30, 2013\f28 \par \par \uc2 \f2 Revenues for the nine months ended September 30, 2014 were $23.7 million, compared to $31.2 million for the nine months ended September 30, 2013. International revenue to third-party distributors grew by 66% from $2.9 million to $4.8 million. Gross profit margin of 71 percent was realized in the first nine months of 2014, as compared to 72 percent a year earlier. Operating loss for the nine months ended September 30, 2014 was ($873,000), compared to operating income of $2.0 million in the nine months ended September 30, 2013. Of note, operating loss for the nine months ended September 30, 2014 included non-cash stock based compensation expenses and incremental investment (research and development, new production and retail initiatives) of approximately $1,584,000, which represents a $965,000 increase from the prior year comparable period. These 2014 expenses were comprised of stock based compensation expense of approximately $950,000, product development and clinical testing expenditures of approximately $315,000, retail advertising expenditures of $131,000 and new production expenses of approximately $188,000.\f28 \par \par \uc2 \f2 Net loss for the nine months ended September 30, 2014 was ($858,000), compared to net income of $1.8 million in the nine months ended September 30, 2013. The resulting EPS is ($0.04), as compared to $0.08 in the comparable period a year earlier. Adjusted EBITDA was $86,000.\f28 \par \par \uc2 \f2 Balance Sheet as of September 30, 2014\f28 \par \par \uc2 \f2 11 Nov 2014 16:04 ET \par Press Release: \f28 \uc2 \f2 ICTV Brands Inc\f28 \uc2 \f2 . Reports Third -2-\f28 \par \par \uc2 \f2 As of September 30, 2014, the Company had $1.6 million in cash, compared to $1.4 million at December 31, 2013, and reflects continued investment in expenditures on new product acquisition and development. The Company had working capital of $3,000,000 at September 30, 2014, compared to $2,900,000 at December 31, 2013, which demonstrates our strong short-term liquidity. We have also reached a positive shareholders' equity of approximately $2.4 million, up from $2.1 million at December 31, 2013. In addition, we generated positive cash flows from operations of approximately $89,000 in the nine months ended September 30, 2014, compared to $76,000 in the prior year comparable period.\f28 \par \par \uc2 \f2 Conference Call\f28 \par \par \uc2 \f2 ICTV will hold a conference call to discuss the Company's third quarter 2014 results and answer questions today, November 11, 2014, beginning at 4:30pm EST. The call will be open to the public and will have a corporate update presented by ICTV's Chairman and Chief Executive Officer, Kelvin Claney, President, \f28 \uc2 \f2 Richard Ransom\f28 \uc2 \f2  and Chief Financial Officer, Ryan LeBon, followed by a question and answer period.\f28 \par \par \uc2 \f2 The live conference call can be accessed by dialing (866) 952-1906 or (785) 424-1825. Participants should ask for the \f28 \uc2 \f2 ICTV Brands Earnings Conference\f28 \uc2 \f2  Call. Participants are recommended to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through November 25, 2014. To listen to the replay, dial (800) 753-5212 (domestic) or (402) 220-2673 (international). The conference call transcript will be posted to the Company's corporate website (\f28 {\field{\*\fldinst{HYPERLINK "http://www.ictvbrands.com"}}{\fldrslt{\cf2 \uc2 http://www.ictvbrands.com}}}\uc2 \f2 ) for those who are unable to attend the live call.\f28 \par \par \uc2 \f2 ICTV Brands, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 ICTV Brands, Inc\f28 \uc2 \f2 . sells various health, wellness and beauty products through a multi-channel distribution strategy. ICTV utilizes a distinctive marketing strategy and multi-channel distribution model to develop, market and sell products through direct response television (DRTV), Internet/digital, e-commerce, live television shopping and retail. Its products are primarily sold in the U.S. and available in over 35 countries. Its products include DermaWand, a skin care device that reduces the appearance of fine lines and wrinkles, and helps improves skin tone and texture; DermaVital, a professional quality skin care range that effects superior hydration; and CoralActives, a line of acne treatment and skin cleansing products. \f28 \uc2 \f2 ICTV Brands, Inc\f28 \uc2 \f2 . was founded in 1993 and headquartered in Wayne, Pennsylvania.\f28 \par \par \uc2 \f2 Forward-Looking Statements\f28 \par \par \uc2 \f2 Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2013, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the \f28 \uc2 \f2 SEC\f28 \uc2 \f2  and which may be viewed at \f28 {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 -- Financial Statements follow -- \f28 \par \par \uc2 \f2 \par  \par  \par       ICTV BRANDS INC. AND SUBSIDIARY (F/K/A INTERNATIONAL \par                    COMMERCIAL TELEVISION INC.) \par  \par               CONDENSED CONSOLIDATED BALANCE SHEETS \par                               AS OF \par  \par                                     September 30,    December 31, \par                                         2014             2013 \par                                     -------------    ------------ \par                                      (Unaudited) \par              ASSETS \par CURRENT ASSETS: \par Cash and cash equivalents          $    1,542,480   $   1,370,178 \par Cash held in escrow                        41,351          62,924 \par Accounts receivable, net of \par  allowances for returns and \par  doubtful accounts of $206,644 \par  and $446,307, respectively               578,873         791,292 \par Inventories, net                        2,216,269       1,778,073 \par Prepaid expenses and other \par  current assets                           981,711         733,427 \par                                     -------------    ------------ \par Total current assets                    5,360,684       4,735,894 \par                                     -------------    ------------ \par  \par Furniture and equipment                    64,698          81,507 \par Less accumulated depreciation             (40,252)        (66,712) \par                                     -------------    ------------ \par Furniture and equipment, net               24,446          14,795 \par                                     -------------    ------------ \par  \par Other assets                                    -          21,297 \par                                     -------------    ------------ \par  \par Total assets                       $    5,385,130   $   4,771,986 \par                                     =============    ============ \par  \par  LIABILITIES AND SHAREHOLDERS' \par              EQUITY \par CURRENT LIABILITIES: \par Accounts payable and accrued \par  liabilities                       $    1,949,383   $   1,391,342 \par Severance payable - short-term             40,800          40,800 \par Deferred revenue - short-term             323,109         242,827 \par Tax penalties payable                           -         190,000 \par                                     -------------    ------------ \par Total current liabilities               2,313,292       1,864,969 \par                                     -------------    ------------ \par  \par Severance payable - long-term              16,400          47,000 \par Deferred revenue - long-term              474,274         386,821 \par Convertible note payable to \par  shareholder - long-term                  153,723         393,723 \par                                     -------------    ------------ \par Total long-term liabilities               644,397         827,544 \par                                     -------------    ------------ \par  \par COMMITMENTS AND CONTINGENCIES \par  \par SHAREHOLDERS' EQUITY: \par Preferred stock 20,000,000 \par shares authorized, no shares \par issued and outstanding                          -               - \par Common stock, $0.001 par value, \par  100,000,000 shares authorized, \par  23,269,399 and 21,826,650 shares \par  issued and outstanding as of \par  September 30, 2014 and December \par  31, 2013, respectively                    13,058          11,616 \par Additional paid-in-capital              8,880,548       7,676,177 \par Accumulated deficit                    (6,466,165)     (5,608,320) \par                                     -------------    ------------ \par  \par Total shareholders' equity              2,427,441       2,079,473 \par                                     -------------    ------------ \par  \par Total liabilities and \par  shareholders' equity              $    5,385,130   $   4,771,986 \par                                     =============    ============ \par  \par  \f28 \par \par \uc2 \f2 See notes to condensed consolidated financial statements. \f28 \par \par \uc2 \f2 \par  \par  \par  \par          ICTV BRANDS INC. AND SUBSIDIARY (F/K/A INTERNATIONAL \par                       COMMERCIAL TELEVISION INC.) \par  \par             CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS \par                               (Unaudited) \par  \par                         For the three                For the nine \par                          months ended                months ended \par                    ------------------------    ------------------------ \par                    September     September     September     September \par                     30, 2014      30, 2013      30, 2014      30, 2013 \par                    ----------    ----------    ----------    ---------- \par  \par NET SALES         $ 6,048,043   $ 8,300,312   $23,687,603   $31,155,661 \par  \par \f28 \uc2 \f2 COST\f28 \uc2 \f2  OF SALES       1,906,756     2,146,270     6,940,695     8,597,106 \par                    ----------    ----------    ----------    ---------- \par  \par GROSS PROFIT        4,141,287     6,154,042    16,746,908    22,558,555 \par                    ----------    ----------    ----------    ---------- \par  \par OPERATING \par EXPENSES: \par General and \par  administrative     1,843,469     1,785,146     5,666,266     5,740,604 \par Selling and \par  marketing          2,825,518     4,258,875    11,953,186    14,809,742 \par                    ----------    ----------    ----------    ---------- \par Total operating \par  expenses           4,668,987     6,044,021    17,619,452    20,550,346 \par                    ----------    ----------    ----------    ---------- \par  \par OPERATING INCOME \par  (LOSS)              (527,700)      110,021      (872,544)    2,008,209 \par  \par INTEREST \par  EXPENSE, NET          (1,579)       (5,025)       (6,475)      (17,700) \par                    ----------    ----------    ----------    ---------- \par  \par INCOME (LOSS) \par  BEFORE \par  PROVISION \par  (BENEFIT) FOR \par  INCOME TAX          (529,279)      104,996      (879,019)    1,990,509 \par  \par PROVISION \par  (BENEFIT) FOR \par  INCOME TAXES         (27,759)        4,488       (21,174)       72,533 \par                    ----------    ----------    ----------    ---------- \par  \par NET INCOME \par  (LOSS)           $  (501,520)  $   100,508   $  (857,845)  $ 1,917,976 \par                    ==========    ==========    ==========    ========== \par  \par NET INCOME \par (LOSS) PER \par SHARE \par BASIC             $     (0.02)  $      0.00   $     (0.04)  $      0.09 \f28 \par \par \uc2 \f2 11 Nov 2014 16:04 ET \par Press Release: \f28 \uc2 \f2 ICTV Brands Inc\f28 \uc2 \f2 . Reports Third -3-\f28 \par \par \uc2 \f2 \par                    ----------    ----------    ----------    ---------- \par DILUTED           $     (0.02)  $      0.00   $     (0.04)  $      0.08 \par                    ----------    ----------    ----------    ---------- \par  \par WEIGHTED \par AVERAGE NUMBER \par OF COMMON \par SHARES \par BASIC              23,183,650    21,718,315    22,969,630    21,481,149 \par                    ----------    ----------    ----------    ---------- \par DILUTED            23,183,650    24,252,780    22,969,630    24,660,092 \par                    ----------    ----------    ----------    ---------- \par  \par  \f28 \par \par \uc2 \f2 See notes to condensed consolidated financial statements. \f28 \par \par \uc2 \f2 \par  \par  \par  \par    ICTV BRANDS INC. AND SUBSIDIARY (F/K/A INTERNATIONAL \par                 COMMERCIAL TELEVISION INC.) \par  \par       CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \par    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 \par                         (Unaudited) \par  \par                                       2014          2013 \par                                    ----------    ---------- \par  \par CASH FLOWS FROM OPERATING \par ACTIVITIES: \par  Net income (loss)                $  (857,845)  $ 1,917,976 \par   Adjustments to reconcile net \par   income (loss) to net cash and \par   cash equivalents provided by \par   operating activities: \par    Depreciation                         4,468         8,694 \par    Bad debt expense                 1,318,954     2,381,968 \par    Share based compensation           949,941       379,339 \par    Reduction in tax penalties \par     payable                           (85,933)      (80,000) \par   Change in assets and \par   liabilities \par    Accounts receivable             (1,106,535)   (2,366,445) \par    Inventories                       (438,196)     (160,429) \par    Prepaid expenses and other \par     assets                           (286,978)     (210,804) \par    Accounts payable and accrued \par     liabilities                       558,041    (1,846,059) \par    Severance payable                  (30,600)      (30,600) \par    Tax provision payable                    -      (121,381) \par    Tax penalties payable             (104,067)            - \par    Deferred revenue                   167,735       203,358 \par                                    ----------    ---------- \par    Net cash provided by \par     operating activities               88,985        75,617 \par                                    ----------    ---------- \par  \par CASH FLOWS FROM INVESTING \par ACTIVITIES: \par  Purchase of furniture and \par   equipment                           (14,119)      (10,250) \par                                    ----------    ---------- \par    Net cash used in investing \par     activities                        (14,119)      (10,250) \par                                    ----------    ---------- \par  \par CASH FLOWS FROM FINANCING \par ACTIVITIES: \par  Proceeds from exercise of \par   options                              46,280        96,200 \par  Proceeds from exercise of \par   warrants                            144,583             - \par  Payments on note payable                   -       (30,169) \par  Payments on convertible note \par   payable to shareholder             (115,000)     (137,000) \par                                    ----------    ---------- \par    Net cash provided by (used \par     in) financing activities           75,863       (70,969) \par                                    ----------    ---------- \par  \par NET INCREASE (DECREASE) IN CASH \par  AND CASH EQUIVALENTS                 150,729        (5,602) \par  \par CASH AND CASH EQUIVALENTS, \par  beginning of the period            1,433,102       908,366 \par                                    ----------    ---------- \par  \par CASH AND CASH EQUIVALENTS, end \par  of the period                    $ 1,583,831   $   902,764 \par                                    ==========    ========== \par  \par SUPPLEMENTAL DISCLOSURE OF CASH \par FLOW INFORMATION: \par  Taxes paid                       $     6,585   $   145,530 \par                                    ==========    ========== \par  Tax penalties and interest \par   paid                            $   104,067   $         - \par                                    ==========    ========== \par  Interest paid                    $     7,659   $    17,700 \par                                    ==========    ========== \par  Write off of fully depreciated \par   furniture and equipment         $    30,928   $         - \par                                    ==========    ========== \par  Conversion of shareholder note \par   payable                         $   125,000   $         - \par                                    ==========    ========== \par  \par  \f28 \par \par \uc2 \f2 See notes to condensed consolidated financial statements.\f28 \par \par \uc2 \f2 Contact Information\f28 \par \par \uc2 \f2 ICTV Brands\f28 \par \par \uc2 \f2 Rich Ransom\f28 \par \par \uc2 \f2 Email contact\f28 \par \par \uc2 \f2 484-598-2313\f28 \par \par \uc2 \f2 Kirk Gamley\f28 \par \par \uc2 \f2 Contact Financial Corp.\f28 \par \par \uc2 \f2 Phone: 604-689-7422\f28 \par \par \uc2 \f2 E-mail: Email contact\f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 November 11, 2014 16:04 ET (21:04 GMT)\f28 \par \par \uc2 Document DJDN000020141111eabb0031x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Apricus Biosciences\uc2  Files 8K - Regulation FD >APRI\b0\par\par\uc2 1,048 \uc2 words\par \uc2 10 November 2014\par 17:09\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Apricus Biosciences Inc\uc2 . (APRI) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 10, 2014.\par \par \uc2 On November 10, 2014, the Company provided an update to its corporate presentation. The presentation is currently available on the Company's website and filed herewith as Exhibit 99.1.\par \par \uc2 The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.\par \par \uc2 By filing this Current Report on Form 8-K and furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the presentation attached hereto as Exhibit 99.1. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the \uc2 SEC\uc2  and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the \uc2 SEC\uc2 , through press releases or through other public disclosure.\par \par \uc2 The Company cautions you that the presentation attached hereto as Exhibit 99.1 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to the timing of initial and re-order shipments of Vitaros (R) and initial royalty revenues from the sale of Vitaros in various countries by the Company's commercial partners; the planned launch strategy for Vitaros in the United Kingdom, Sweden, Germany, Belgium and other countries; the planned production of the required 12-month stability data for the Vitaros room temperature device; the planned enrollment in the RayVa (tm) Phase 2a clinical trial of patients with Raynaud's phenomenon secondary to scleroderma; the planned commencement of clinical trials for fispemifene and an approved pathway for RayVa and fispemifene; the size of the commercial opportunity for Vitaros, RayVa and fispemifene and the potential for such products to achieve commercial success; the expected funding under the credit facility of a second term loan subject to initiation of a Phase 2b trial for fispemifene; the planned out-license of Femprox (R) and Vitaros; and the Company's 2014 financial outlook, including cash projections. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of the Company, including, but not limited to: its ability to further develop its product Vitaros for the treatment of erectile dysfunction, such as the room temperature version of Vitaros, and its product candidates RayVa for the treatment of Raynaud's phenomenon and fispemifene for the treatment of secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men, as well as the timing of such events; the Company's ability to carry out clinical studies for RayVa and fispemifene, as well as the timing and success of the results of such studies; the Company's dependence on its commercial partners to carry out the commercial launch and sales of Vitaros in various territories, such as Takeda in the United Kingdom, Sandoz in Sweden, Germany and Belgium, and Majorelle in France, and the potential for delays in the timing of commercial launches in additional countries; competition in the erectile dysfunction market and other markets in which the Company and its partners operate; the Company's ability to obtain and maintain intellectual property protection for Vitaros, RayVa, fispemifene or any other product candidates; the Company's ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; the Company's ability to draw the second term loan under the credit facility when expected, or at all, including the Company's failure to meet the conditions required to draw under the loan and security agreement; the Company's ability to remain in compliance with the terms and restrictions under the credit facility; the Company's ability to access additional capital under the equity facility; the Company's ability to obtain the requisite governmental approval for the room temperature version of Vitaros, RayVa, fispemifene and Femprox; and market conditions. These forward-looking statements are made as of the date of this presentation, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the \uc2 SEC\uc2 's website at {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2  or without charge from the Company.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1017491/000101749114000105/a8-kforcorppres11x10x14.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1017491/000101749114000105/a8-kforcorppres11x10x14.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1017491/000101749114000105/0001017491-14-000105-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1017491/000101749114000105/0001017491-14-000105-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Apricus Biosciences, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US03832V1098"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US03832V1098}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 10, 2014 17:09 ET (22:09 GMT)\par \par \uc2 Document DJDN000020141110eaba004i2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Rock Creek Pharmaceuticals\uc2  Reports Third Quarter 2014 Results and Provides Business Update\b0\par\par\uc2 1,510 \uc2 words\par \uc2 10 November 2014\par 17:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 SARASOTA, Fla., Nov. 10, 2014 /PRNewswire/ -- \uc2 Rock Creek Pharmaceuticals, Inc\uc2 ., (RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company's Form 10-Q was filed with the Securities Exchange Commission.\par \par \uc2 Michael J. Mullan, MBBS (MD), PhD, \uc2 Rock Creek Pharmaceuticals\uc2 ' Chairman and CEO, remarked, "We are advancing the development of our lead drug candidate in the U.S. and the E.U. Consistent with our recent disclosures, we are looking forward to achieving upcoming milestones and commencing Phase I clinical trials in 2015."\par \par \uc2 Business Update\par \par \uc2 Additional pre-clinical studies have been completed in support of both the Company's Investigational New Drug (IND) application and Clinical Trial Application (CTA). The Company is evaluating the additional data both in direct response to FDA's comments on the Company's IND and for incorporation into the Company's CTA. Drug formulations are currently being prepared in line with regulatory standards for clinical trials to begin under the CTA.\par \par \uc2 The basic science associated with anatabine citrate continues to be validated and expanded. As previously disclosed, abstracts outlining four separate preclinical studies evaluating anatabine were recently accepted for poster and nano symposium presentations at the upcoming annual meeting of the \uc2 Society for Neuroscience\uc2 , taking place November 15-19 in Washington, DC. The presentations specifically will focus on anatabine's beneficial activity in animal models of Traumatic Brain Injury, Gulf War Illness and Alzheimer's Disease. All of these studies were independently conducted and presented by the Roskamp Institute, a not-for-profit research organization devoted to understanding neurodegenerative diseases, disorders and addictions. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program.\par \par \uc2 Researchers from the Roskamp Institute recently published a manuscript in "Brain Disorders & Therapy," May 2014, entitled "Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice." The article described how anatabine attenuated tau phosphorylation in vivo animal models which included the molecular activation inhibition of GSK3b, STAT3 and NF-kb as a proposed mechanism of action.\par \par \uc2 Rock Creek Pharmaceuticals\uc2  recently retained a major, national intellectual property advisory and investment bank, as a strategic advisor, to monitor, value and evaluate the growth of the Company's intellectual property (IP) portfolio. Concurrently, the Company continues to take measures to protect existing IP as well as enhancing and developing additional IP.\par \par \uc2 On November 3, 2014, the Company disclosed through an 8-K filing that it had received a notice from the \uc2 NASDAQ Stock Market\uc2  indicating a failure for the Company to attain the $1.00 minimum bid price requirement and was subject to delisting. The Company has appealed the delisting and is taking appropriate steps in pursuit of maintaining \uc2 NASDAQ\uc2  listing. The Company has been granted a hearing in December 2014 with a \uc2 NASDAQ\uc2  Hearings Panel and will advance a plan to remedy the deficiency and request an additional period of time to implement it.\par \par \uc2 Third Quarter 2014 Results\par \par \uc2 The Company recorded a net loss of approximately $10.0 million for the three months ended September 30, 2014, compared to a net loss of approximately $3.4 million for the same period in 2013. The increased net loss for the three months ended September 30, 2014 was primarily due to a discontinued operations charge, increases in stock based compensation, severance costs, directors' and officers' insurance, legal expenditures and research and development expenditures; and was partially offset by decreased loss from the dietary supplement business.\par \par \uc2 General and administrative expenses were approximately $4.3 million for the three months ended September 30, 2014, an increase of approximately $1.5 million from approximately $2.8 million for the same period in 2013. This level of general and administrative expenses was primarily caused by elevated legal expenses, severance agreements, increased Director and Officer insurance, and expenses related to the corporate transition. In the near term, the Company expects decreased \uc2 G&A\uc2  expenses as it implements its office consolidation plan and other measures to reallocate resources to the drug development plans.\par \par \uc2 The Company expended approximately $1.7 million on research and development in the three months ended September 30, 2014, compared to approximately $0.4 million in the comparable period in 2013. The research and development costs in the three months ended September 30, 2014 were directed principally towards additional studies enhancing the Company's clinical regulatory submissions (the IND and CTA), as well as overall drug development expenses associated with consultants, contract research organizations and activities directly in support of the Company's new strategic direction.\par \par \uc2 For the three months ended September 30, 2014, the Company had a basic and diluted loss per share of $(0.05), compared to a basic and diluted loss per share of $(0.02) for the comparable period in 2013.\par \par \uc2 On September 12, 2014, the Company announced that it would no longer market or sell its dietary supplements and cosmetic products in the United States. Accordingly, the Company is primarily focused on drug development in the U.S. and Europe. As a result of this decision, all sales, cost of sales and sales and marketing expenses related to these consumer products, encompassing all of its commercial products on the market, were reclassified to discontinued operations. For the three months ended September 30, 2014, this was a loss of $0.4 million, compared to a loss of $1.5 million in the comparable period for 2013. The decreased loss of $1.1 million was primarily attributable to the reduced promotion of Anatabloc(R) dietary supplement in response to the FDA warning letter received in December 2013. For the three months ended September 30, 2014, the Company also took a charge of $3.6 million consisting of inventory, specialized packaging machinery and other assets specifically related to the dietary supplement business.\par \par \uc2 For a detailed review of the Company's financial disclosures, please refer to the company's current Form 10-Q.\par \par \uc2 About Anatabine Citrate:\par \par \uc2 Rock Creek Pharmaceutical's anatabine citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of anatabine. In addition, the company's compilation of human exposure, safety and tolerability data, derived primarily from human clinical studies and post-marketing data collection of the previously marketed nutraceutical product, has provided important insights for clinical development.\par \par \uc2 About \uc2 Rock Creek Pharmaceuticals, Inc\uc2 .:\par \par \uc2 Rock Creek Pharmaceuticals, Inc\uc2 . is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic inflammatory disease, neurologic disorders and behavioral health.\par \par \uc2 For more information, visit: {\field{\*\fldinst{HYPERLINK "http://www.rockcreekpharmaceuticals.com"}}{\fldrslt{\cf2 \uc2 http://www.rockcreekpharmaceuticals.com}}}\par \par \uc2 Forward Looking Statements:\par \par \uc2 Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the \uc2 Securities and Exchange Commission\uc2 , including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed on August 11, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.\par \par \uc2 Document PRN0000020141110eaba000q8\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Dynavax Files 8K - Other Events >DVAX\b0\par\par\uc2 174 \uc2 words\par \uc2 10 November 2014\par 16:34\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Dynavax Technologies Corp\uc2 . (DVAX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 07, 2014.\par \par \uc2 On November 10, 2014, we issued a press release titled "Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of Heplisav-B TM." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/dvax-8k_20141110.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/dvax-8k_20141110.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/0001564590-14-005412-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/0001564590-14-005412-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 10, 2014 16:34 ET (21:34 GMT)\par \par \uc2 Document DJDN000020141110eaba0044x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Precision Spine(TM) Plans to  \highlight22\uc2 Introduce New Products \highlight\uc2  at \uc2 North American Spine Society\uc2  Meeting in San Francisco\b0\par\par\uc2 400 \uc2 words\par \uc2 10 November 2014\par 16:36\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par PARSIPPANY, N.J.--(BUSINESS WIRE)--November 10, 2014-- \f28 \par \par \uc2 \f2 Precision Spine, Inc\f28 \uc2 \f2 . announces it will be attending the 29(th) annual \f28 \uc2 \f2 North American Spine Society\f28 \uc2 \f2  Meeting, November 12-15, 2014, in San Francisco, CA. The company focus on product development will be highlighted at the NASS meeting with the introduction of several new and expanded product offerings.\f28 \par \par \uc2 Precision Spine's President, \uc2 Rich Dickerson\uc2  said, "We are pleased with the progressive growth we are seeing as a result of our continued focus on providing innovative, effective and efficient solutions for the surgical treatment of spine conditions. This year we will be introducing the MD-Max(TM) ULIF System which is a versatile, minimally invasive retractor access/fixation system that is designed to enable surgeons to achieve results that are the same as, or better than, those attributed to the 'gold standard' classic open approach. The system's surgical approach is designed to be minimally disruptive while providing maximum access to the operative site to help to reduce blood loss and optimizing OR time. Its goals to improve patient mobility and reduce dependence on pain relief medications contrast with percutaneous approaches that can create surgical trauma by puncturing muscle.\par \par \uc2 "Compatible with our MD-Max ULIF System, we are also introducing the Extended Tab SureLOK(TM) C System featuring breakaway tabs at 10mm increments to permit improved access and an open tulip design for facilitating easier rod insertion. Also being introduced is the expansion of our ShurFit(TM) PLIF line of convex and lordotic interbody spacers, which are available in 0, 5, 10 and now, 15 degree variations with an aggressive tooth pattern designed to minimize potential for expulsion, a large graft window to enhance the opportunity for successful fusion and a large contact area to optimize vertebral support. These new products further complement a growing array of cervical and thoracolumbar spinal technology solutions from Precision Spine."\par \par \uc2 About Precision Spine\par \par \uc2 Precision Spine, Inc\uc2 . is a privately held company headquartered in Parsippany, NJ with manufacturing facilities in Pearl, MS. Precision Spine is dedicated to providing innovative, quality spine products that are designed to help treat serious orthopedic medical conditions in a cost effective manner. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.precisionspineinc.com"}}{\fldrslt{\cf2 \uc2 www.precisionspineinc.com}}}\uc2 .\par \par \uc2 Document BWR0000020141110eaba000l1\par }\page {\par\fs20\b \uc2 Mylan Inc\uc2 . Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Viramune XR(R)\b0\par\par\uc2 421 \uc2 words\par \uc2 10 November 2014\par \uc2 AIDS Weekly\par \uc2 CDCW\par 37\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 AIDS Weekly via NewsRx.com   \par \par \uc2 2014 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of \uc2 Boehringer Ingelheim\uc2 's Viramune XR((R)). Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection in adults and in children six to less than 18 years of age((1)). The \b \highlight22\uc2 launch\b0 \highlight\uc2  of this product continues to strengthen Mylan's growing ARV portfolio in the U.S. Mylan has begun shipping product.\par \par \uc2 Nevirapine Extended-release tablets, 400 mg had U.S. sales of approximately $61.9 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 287 ANDAs pending FDA approval representing $112.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Severe, life-threatening, and in some cases fatal liver toxicity and skin reactions have been reported with the use of Nevirapine Extended-release tablets. Monitoring by your healthcare provider is essential during the first 18 weeks of therapy.\par \par \uc2 Keywords for this news article include: HIV/AIDS, \uc2 Mylan Inc\uc2 ., RNA Viruses, Retroviridae, Vertebrate Viruses, Primate Lentiviruses.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document CDCW000020141107eaba0000s\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Avanir Pharmaceuticals\uc2  Files 8K - Other Events >AVNR\b0\par\par\uc2 205 \uc2 words\par \uc2 7 November 2014\par 15:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Avanir Pharmaceuticals Inc\uc2 . (AVNR) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 07, 2014.\par \par \uc2 On November 7, 2014, \uc2 Avanir Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing preliminary feedback from the \uc2 U.S. Food and Drug Administration\uc2  to the Company's New Drug Application for AVP-825 for the acute treatment of migraine. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/858803/000119312514403116/d818409d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/858803/000119312514403116/d818409d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/858803/000119312514403116/0001193125-14-403116-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/858803/000119312514403116/0001193125-14-403116-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Avanir Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US05348P4019"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US05348P4019}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 07, 2014 15:04 ET (20:04 GMT)\par \par \uc2 Document DJDN000020141107eab70043b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Rockwell Medical\uc2  Files 8K - Other Events >RMTI\b0\par\par\uc2 287 \uc2 words\par \uc2 7 November 2014\par 12:13\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Rockwell Medical Inc\uc2 . (RMTI) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 06, 2014.\par \par \uc2 Rockwell Medical, Inc\uc2 . (the "Company") announced that on November 6, 2014, the Oncologic Drugs Advisory Committee ("ODAC") of the \uc2 U.S. Food & Drug Administration\uc2  recommended that the Phase 3 efficacy and safety results for the Company's lead investigational drug, Triferic, support a positive benefit/risk to treat iron loss to maintain hemoglobin in patients with hemodialysis-dependent stage 5 chronic kidney disease. The ODAC voted in favor of Triferic by a vote of 8 to 3.\par \par \uc2 The ODAC reviewed safety and efficacy data from Rockwell's overall clinical program. During the clinical program more than 1,400 patients were treated with Triferic and more than 100,000 individual administrations were given. The results from the clinical trials have shown Triferic to be an effective and highly-differentiated iron delivery therapy with a safety profile similar to placebo.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465914078189/a14-24027_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465914078189/a14-24027_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465914078189/0001104659-14-078189-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465914078189/0001104659-14-078189-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Rockwell Medical, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US7743741024"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US7743741024}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 07, 2014 12:13 ET (17:13 GMT)\par \par \uc2 Document DJDN000020141107eab7003e3\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 DISCOVERY LABORATORIES\uc2  FILES CURRENT REPORT\b0\par\par\uc2 1,096 \uc2 words\par \uc2 7 November 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, Nov. 7 -- \uc2 Discovery Laboratories Inc\uc2 ., Warrington, Pa., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on Nov. 6.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Item 2.02. Results of Operations and Financial Condition.\par \par \uc2 On November 6, 2014, \uc2 Discovery Laboratories, Inc\uc2 . (the "Company") issued a press release highlighting the results of operations for the quarter ended September 30, 2014, and providing a business update. The press release is attached as Exhibit 99.1 hereto.\par \par \uc2 In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 hereto relating to the announcement of the results of operations for the quarter ended September 30, 2014 and all other matters except for those discussed under Item 8.01 below shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filings.\par \par \uc2 Item 8.01. Other Events.\par \par \uc2 On November 6, 2014, the Company issued a press release highlighting the results of operations for the quarter ended September 30, 2014 and providing an update on its development programs. For the fourth quarter of 2014, the Company anticipates operating cash outflows of approximately $11 million, before taking into account any financing activities. The press release also provides certain program updates relating to SURFAXIN(R)(lucinactant) and the Company's AEROSURF(R) phase 2 clinical program.\par \par \uc2 AEROSURF clinical program update: The Company is conducting a phase 2a clinical trial, which is an open label, single-dose study with the primary goal of evaluating the safety and tolerability of aerosolized KL4 surfactant drug product administered in escalating inhaled doses in 42 premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone. In addition, the Company hopes to demonstrate that drug is being effectively delivered into the lungs. If safety and tolerability are demonstrated in the phase 2a clinical trial, the Company will be able to proceed with a phase 2b clinical trial. The design of the phase 2b clinical trial will be informed by the results of the phase 2a clinical trial. The primary objective of the phase 2b trial will be to determine the optimal dose and estimate the expected efficacy margin for the planned phase 3 clinical trial focused on safety and efficacy.\par \par \uc2 The Company is conducting the phase 2a clinical trial at four sites and is currently in the second half of the planned enrollment. The rates of enrollment have been slower than expected. The Company has implemented preparatory activities for the planned phase 2b clinical trial and, through this process, has identified four new clinical sites that will begin enrolling patients in the phase 2a clinical trial beginning in November 2014. The Company expects that these eight sites, based on their experience and knowledge of AEROSURF from the phase 2a program, will be positioned to be transitioned to the next phase of the clinical program.\par \par \uc2 The AEROSURF phase 2a clinical trial is an open-label study, which has allowed the Company visibility into selected outcomes of premature infants participating in the trial. These observations are not predictors of the trial results and may not continue to be accurate for the duration of the trial. The Company's novel capillary aerosol generator (CAG) has performed well in the clinic thus far. Clinically, the infants appear to be tolerating the aerosol well and the clinicians using the CAG report a positive experience and remain enthusiastic about the study. Additionally, they have observed that some infants after treatment with AEROSURF are showing evidence that suggests aerosolized KL4 surfactant is getting into the lung. In both treatment groups we have observed known complications of prematurity expected in this patient population. We have seen numerically more pneumothoraces in the AEROSURF treated group, at a rate within the range reported for this population in the medical literature. Otherwise, the adverse event profile of the AEROSURF-treated group is comparable to the control group. These data have been reviewed with our medical advisors, expert consultants and Safety Review Committee members, and they will continue to do so as the trial proceeds. Based upon the Company's most recent assessment of the clinical trial plan, the Company now anticipates completion of the phase 2a clinical trial in the first quarter of 2015, and completion of the phase 2b clinical trial in the first half of 2016.\par \par \uc2 Item 9.01. Financial Statements and Exhibits.\par \par \uc2 (d) Exhibits\par \par \uc2 99.1 ({\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/ex99_1.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/ex99_1.htm}}}\uc2 ) - Press release dated November 6, 2014\par \par \uc2 Cautionary Note Regarding Forward-looking Statements:\par \par \uc2 To the extent that statements in this Current Report on Form 8-K are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, cash flows, future revenues, the timing of planned clinical trials or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this Current Report are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Such risks and others are further described in the Company's filings with the \uc2 Securities and Exchange Commission\uc2  including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any forward-looking statement made by us in this Current Report on Form 8-K is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/form8k.htm}}}\par \par \uc2 Document INDFED0020141107eab7001bm\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Onconova Therapeutics\uc2  Files 8K - Regulation FD >ONTX\b0\par\par\uc2 338 \uc2 words\par \uc2 6 November 2014\par 09:32\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Onconova Therapeutics Inc\uc2 . (ONTX) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 06, 2014.\par \par \uc2 On November 6, 2014, \uc2 Onconova Therapeutics, Inc\uc2 . (the "Company") issued a press release announcing that ten abstracts related to the Company's products, clinical trials and research were accepted for presentation at the 56th \uc2 American Society of Hematology\uc2  (ASH) Annual Meeting in San Francisco, California, to be held on December 6-9, 2014. All ten presentations are listed in the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 On November 6, 2014, in connection with such presentations, ASH released such abstracts to the public by posting them on its website. The full text of each of the ten abstracts are attached to this Current Report on Form 8-K as Exhibits 99.2 through 99.11 and are incorporated herein by reference.\par \par \uc2 The information in Item 7.01 of this Form 8-K, and the related exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1130598/000110465914077391/a14-23821_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1130598/000110465914077391/a14-23821_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1130598/000110465914077391/0001104659-14-077391-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1130598/000110465914077391/0001104659-14-077391-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 06, 2014 09:32 ET (14:32 GMT)\par \par \uc2 Document DJDN000020141106eab600314\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Heron discloses new P neurokinin-1 receptor antagonist development program\b0\par\par\uc2 160 \uc2 words\par \uc2 6 November 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Heron Therapeutics\uc2  disclosed a development program for a P/neurokinin-1 receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting. \uc2 Heron Therapeutics\uc2 ' lead investigational product candidate, SUSTOL, is an extended release 5-HT3 receptor antagonist being developed for the prevention of both acute- and delayed-onset CINV. \uc2 Heron Therapeutics\uc2 ' new investigational product candidate HTX-019 is a proprietary intravenous formulation of aprepitant, an NK1 receptor antagonist. The HTX-019 formulation is distinguishable from the only IV NK1 receptor antagonist presently approved for the prevention of CINV in the U.S. in that it does not contain polysorbate 80, which may cause hypersensitivity reactions in some patients. Registration of HTX-019 is expected to use the 505(b)(2) regulatory approval pathway for \b \highlight22\uc2 new drug\b0 \highlight\uc2  applications filed with the \uc2 U.S. Food and Drug Administration\uc2 , with potential commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  in 2016. \par \par \uc2 Document FLYWAL0020141106eab6001uv\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Discovery Laboratories\uc2  Files 8K - Other Events >DSCO\b0\par\par\uc2 736 \uc2 words\par \uc2 6 November 2014\par 07:50\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Discovery Laboratories Inc\uc2 . (DSCO) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 06, 2014.\par \par \uc2 On November 6, 2014, the Company issued a press release highlighting the results of operations for the quarter ended September 30, 2014 and providing an update on its development programs. For the fourth quarter of 2014, the Company anticipates operating cash outflows of approximately $11 million, before taking into account any financing activities. The press release also provides certain program updates relating to SURFAXIN(R)(lucinactant) and the Company's AEROSURF(R) phase 2 clinical program.\par \par \uc2 AEROSURF clinical program update:\par \par \uc2 The Company is conducting a phase 2a clinical trial, which is an open label, single-dose study with the primary goal of evaluating the safety and tolerability of aerosolized KL4 surfactant drug product administered in escalating inhaled doses in 42 premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone. In addition, the Company hopes to demonstrate that drug is being effectively delivered into the lungs. If safety and tolerability are demonstrated in the phase 2a clinical trial, the Company will be able to proceed with a phase 2b clinical trial. The design of the phase 2b clinical trial will be informed by the results of the phase 2a clinical trial. The primary objective of the phase 2b trial will be to determine the optimal dose and estimate the expected efficacy margin for the planned phase 3 clinical trial focused on safety and efficacy.\par \par \uc2 The Company is conducting the phase 2a clinical trial at four sites and is currently in the second half of the planned enrollment. The rates of enrollment have been slower than expected. The Company has implemented preparatory activities for the planned phase 2b clinical trial and, through this process, has identified four new clinical sites that will begin enrolling patients in the phase 2a clinical trial beginning in November 2014. The Company expects that these eight sites, based on their experience and knowledge of AEROSURF from the phase 2a program, will be positioned to be transitioned to the next phase of the clinical program.\par \par \uc2 The AEROSURF phase 2a clinical trial is an open-label study, which has allowed the Company visibility into selected outcomes of premature infants participating in the trial. These observations are not predictors of the trial results and may not continue to be accurate for the duration of the trial. The Company's novel capillary aerosol generator (CAG) has performed well in the clinic thus far. Clinically, the infants appear to be tolerating the aerosol well and the clinicians using the CAG report a positive experience and remain enthusiastic about the study. Additionally, they have observed that some infants after treatment with AEROSURF are showing evidence that suggests aerosolized KL4 surfactant is getting into the lung. In both treatment groups we have observed known complications of prematurity expected in this patient population. We have seen numerically more pneumothoraces in the AEROSURF treated group, at a rate within the range reported for this population in the medical literature. Otherwise, the adverse event profile of the AEROSURF-treated group is comparable to the control group. These data have been reviewed with our medical advisors, expert consultants and Safety Review Committee members, and they will continue to do so as the trial proceeds.\par \par \uc2 Based upon the Company's most recent assessment of the clinical trial plan, the Company now anticipates completion of the phase 2a clinical trial in the first quarter of 2015, and completion of the phase 2b clinical trial in the first half of 2016.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/0001140361-14-040377-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114040377/0001140361-14-040377-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Discovery Laboratories, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US2546684034"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US2546684034}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 06, 2014 07:50 ET (12:50 GMT)\par \par \uc2 Document DJDN000020141106eab6002b2\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Loestrin 24 Fe\b0\par\par\uc2 160 \uc2 words\par \uc2 5 November 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan announced that it has received final approval for Norethindrone Acetate and Ethinyl Estradiol Tablets, 1mg/0.02mg and Ferrous Fumarate, the generic version of \uc2 Warner Chilcott\uc2 's Loestrin 24 Fe.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-inc/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced that it has received final approval from the \uc2 Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Norethindrone Acetate and Ethinyl Estradiol Tablets, 1mg/0.02mg and Ferrous Fumarate, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/warner-chilcott-laboratories/manufacturer/11570/"}}{\fldrslt{\cf2 \uc2 Warner Chilcott's}}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/loestrin-24-fe/drug/2507/"}}{\fldrslt{\cf2 \uc2 Loestrin 24 Fe}}}\uc2 .\par \par \uc2 Loestrin 24 Fe is an estrogen and progestin {\field{\*\fldinst{HYPERLINK "http://www.empr.com/oral-contraceptives/article/123837/"}}{\fldrslt{\cf2 \uc2 combination oral contraceptive}}}\uc2  used to prevent pregnancy. The primary mechanism of action is inhibition of ovulation, and other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/examstests-needed-before-contraceptive-initiation/article/300660/?DCMP=OTC-MPR_Related-Links"}}{\fldrslt{\cf2 \uc2 RELATED: Exams/Tests Needed Before Contraceptive Initiation}}}\par \par \uc2 Mylan has begun shipping this product.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020141106eab500007\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw90\pich21\picscaley100\picscalex100\picwgoal1350\pichgoal315
47
49463837615A001500F70000FEFDFEC30122E590A0D66076EFC1CACB2141DB6F83F7DEE30000000028BE5600633A5C77696E6E745C74656D706F726172792069
6E7465726E65742066696C65735C6F6C6B36635C6265656600676966000000009E0200004D005300500068006F0074006F0045006400690074006F0072003300
32004D00610069006E0043006C0061002C79000000005F2D010000002605C2016625E777F8F41200BE1BE777DCF51200D42CF977F8D4F977FFFFFFFF3CF51200
6D89F87700005F2D2C7900002C790000FF00000000000000ECF51200A06AF7770904000000105F2DD8235F2D2C790000FF00000000000000A099010004060403
2CF61200010000002C79000000005F2D010000000300000098F5120070F5120000F61200F4F51200D42CF977F8D4F97767696600B4F512006D89F87700005F2D
2C79000000005F2D0000000004F61200D564F77700005F2D0100000002000000D8F512002C790000FF00000000000000A09901004CF61200D42CF97700105F2D
FFFFFFFFCCF512002966F77754F61200D42CF97770D2F977FFFFFFFF1CF612009964F77700005F2DB0305F2D44F612000000000064F61200BE47F17700005F2D
B0305F2D44F6120064F612000000130019F2F87724000000800C130000001300D80E17003CF61200C4F6120064F71200D42CF97760D8F977FFFFFFFF28F71200
5447F677800C130010031E000800000044FA1200FF000000F8EBFD7F0A00000000ECFD7F6AA9E7770000000000ECFD7F0A000000C4F61200FF00000000000000
10031E00765B4800CAD0470053031E00ABA9420000005F2D2C790000685B4800FF000000C1AA42002C790000685B4800FF00000053031E003DF71200A9DC4100
2C79000010031E00000000005CFB1200885FE877430000000E00000043000000CD0000002A2E6769663B2A2E626D703B2A2E6A70200100006A7065673B2A2E74
74F71200AA28F07700001300080004001801000010031E0000000000000000000000000000000000C4C04400050F170074741500090F170075FA1200FFFFFFFF
D80E17002EC14400050F170021F90400000000002C000000005A0015004008FF00011C1848B0A0C1030012263CC8B0A1C08610093E8CE85061420101326ADCB8
B18001840B0B70E45800A1C184044692345930A101951B09589C29D0804D030306E0CCC9F3A600900004F0CCB97328D19B3609082D5AD428D2A44F9FCAA44995
80489204B2BE1CF933E5480205055CD5F813E3CAB05F0F8CD5F891A0D99833DF6A2C607180CA816B3302156877A300005E3BCE54CB5166DF8D03A82A0E2AA0B1
E3C790234B9E4CB9B2E5CB910F28D59C1726C7BF873DC3142B5A34E9D22AA72A949BB1E4C0C01B4D76C61BC0F567C023E95AAD8D1BEE56BF005E16C85A386E6E
B0074E2316389B7000DA57FFC26E2D90BAD7AB327FB305D0573555E7A83B12E3081D9E6CE7F2DAB92EB678A0BCFBF7F0E31736504080D502F8F3EBDFAF732AFD
FD000658DF000216989F58061608D46EF11D909E7B42C9178072EF79D79B600A91178001D58D041248ACFDD51E4934A597DD481C2E1414477B5DD8117E240DB7
904A30EA05DE842ECE35578E279274984C90B5381D6A298EC811811AB124518E1921C9DB4403B994DB581656959B45ACD978974059E528DD955C0259DC83D235
D6224D0C76A4134E34A689D8509D29759E51716AD86495DFC5370042768647E17B5902B7DE42421965E8518726AAE8A28CEAE468A3869AC49C8494564AE97801
0C1010003B}}
\par\par \b \uc2 Merck Releases Zilmax Progress Report;  \highlight22\uc2 Announces New \highlight\uc2  Label Approval\b0\par\par\uc2 Merck Animal Health   \par \uc2 1,116 \uc2 words\par \uc2 5 November 2014\par \uc2 BEEF\par \uc2 BEEF\par \uc2 Beef Magazine\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Penton Business Media. All rights reserved.   \par \par \uc2 Merck Animal Health is announcing significant progress in the implementation of its {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health-usa.com/news/2013-8-13.aspx"}}{\fldrslt{\cf2 \uc2 Zilmax Five-Step Plan}}}\uc2 . With insights from the company\u8217\'20\'19s advisory board, an extensive assessment and analysis of existing, as well as \b \highlight22\uc2 new, product\b0 \highlight\uc2  data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use.\par \par \uc2 In a release, Merck Animal Health provided an update on the {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health-usa.com/news/2013-12-13.aspx"}}{\fldrslt{\cf2 \uc2 Zilmax Five-Step Plan}}}\uc2 , and announced the following steps:\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Extensive review and analysis of research data completed\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Final stage to focus on planned in-field use studies\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Best Management Practices and Certification Program adopted\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 FDA approval of updates to Zilmax label, including new feed delivery method\par \par \uc2 The totality of the comprehensive review supported that Zilmax\u174\'00\'AE (zilpaterol hydrochloride) is safe when used according to the product label and in conjunction with sound animal husbandry practices. The research results and industry data showed that cattle weights, and thus feed consumption rates, have been steadily increasing over time. This created the possibility that certain cattle could consume feed quantities that result in ingestion of Zilmax in an amount that exceeds the approved dose. The review also noted that enhanced label language \u8211\'20\'13 coupled with the implementation of comprehensive certification requirements and a thorough best practices program \u8211\'20\'13 will ensure that usage of Zilmax remains compliant with the label.\u160\'00\'A0\u160\'00\'A0\par \par \uc2 An updated {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health.com/binaries/Zilmax_Type_A_Medicated_Article_Label__FINAL__tcm95-165067.pdf"}}{\fldrslt{\cf2 \uc2 Zilmax label}}}\uc2 , to include Component Feeding, which is an alternative method of administering Zilmax using a targeted lower dose, was submitted to and approved by the \uc2 U.S. Food and Drug Administration\uc2  (FDA). Component Feeding provides cattle feeders with an alternative option to deliver the appropriate dose of Zilmax to cattle every day. The new convenient feed delivery method allows cattle feeders to mix Zilmax in feed to deliver a lower targeted dose of 60 mg/head/day of zilpaterol.\u160\'00\'A0\u160\'00\'A0\par \par \uc2 In addition, to help ensure that use of Zilmax is appropriate and consistent with best practices, Merck Animal Health has taken the following steps:\par \par \uc2 Certification\par \par \uc2 As previously noted, every feedyard team member, distributor, feed manufacturer, nutritionist and veterinarian who uses Zilmax or provides consultative services on feeding Zilmax to cattle, must complete the Zilmax training program, as well as annual retraining, addressing the proper use of the product. The training will focus on best practices, product handling, mixing protocols, cattle management, product inventory, record keeping and clean-out procedures. Completion and adherence to the program will be a prerequisite for the use of Zilmax. Click here to view {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health.com/binaries/Certification_Final_tcm95-165066.pdf"}}{\fldrslt{\cf2 \uc2 certification program}}}\uc2 .\par \par \uc2 Best Management Practices\par \par \uc2 Merck Animal Health has worked with industry experts to develop comprehensive Best Management Practices. These include best regimens for the feeding of Zilmax, as well as a number of factors that are critical to animal well-being, including animal handling, proper nutrition/feeding protocols, environmental risk factors, transportation, and cattle management and selection. Click here to see {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health.com/binaries/Best_Management_Practices_FINAL_tcm95-165065.pdf"}}{\fldrslt{\cf2 \uc2 Best Management Practices }}}\uc2 Program.\par \par \uc2 \u8220\'20\'1CEmphasizing best management practices illustrates our commitment to our industry partners by helping set benchmarks for animal mobility, mitigating risk factors, and reinforcing the significant role of nutrition and handling in animal performance,\u8221\'20\'1D said KJ Varma, BVSc, Ph.D., Diplomate ACVCP, Senior Vice President Global R&D, Merck Animal Health. \u8220\'20\'1CWe remain committed to working closely with our customers to maintain the highest standards of care for the health and well-being of cattle.\u8221\'20\'1D\u160\'00\'A0\par \par \uc2 Planned In-Field Use Studies\par \par \uc2 Merck Animal Health also maintains its commitment to sound science \u8211\'20\'13 a cornerstone of the Five-Step Plan. The significant advances noted have enabled the company to move forward with the next step \u8211\'20\'13 the In-Field Use Studies, for which we will seek the participation of industry partners.\u160\'00\'A0 Given the addition of Component Feeding to the label, the planned In-Field Use Study design and protocols will be reviewed before the studies commence. As previously noted, these studies will be overseen by an independent third-party and will extend into the high heat months. The guiding principles of the studies remain the same:\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Observing cattle throughout the system \u8211\'20\'13 before and after receiving Zilmax \u8211\'20\'13 at the feedyard and at the packing plant;\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Evaluating the mobility of cattle by trained third-party experts utilizing an established mobility scoring system; and\par \par \uc2 \u8226\'20\'22\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0\u160\'00\'A0 Reviewing potential confounding factors, such as nutrition, transportation, receiving facilities, flooring surfaces and, cattle management and handling practices, given that mobility issues can be the result of numerous issues or even multifactorial in nature.\par \par \uc2 For the duration of the Planned In-Field Use Studies, Zilmax will be made available only to cattle feeders that can meet and maintain all conditions of the Best Management Practices initiative and the Certification Program, as well as fully comply with all protocols of the In-Field Use Studies. We believe the results of the In-Field Use Studies will help support the return of Zilmax to the market place in the future.\par \par \uc2 Additional Label Modifications\par \par \uc2 In addition to Component Feeding, the FDA has approved a revision to the existing Complete Feed indication in the label. The current Complete Feed label dose for zilpaterol is 6.8 grams/ton to provide 60 to 90 mg/head/day. The label will now include an updated caution statement that notes cattle should not be fed Zilmax in excess of 90 mg/head/day. If pen consumption of complete feed exceeds 26.5 lbs./head/day (90% on a dry matter basis), zilpaterol should not be fed in complete feed. This additional language will further ensure that Zilmax use remains compliant with the label, regardless of the delivery feed method chosen.\par \par \uc2 \u8220\'20\'1CWe are pleased to announce the addition of Component Feeding to the Zilmax label, and are equally excited to note we are moving ahead with the Five-Step Plan,\u8221\'20\'1D said Dr. Varma. \u8220\'20\'1CThe work supporting Zilmax has been complex and time intensive, and we appreciate the time and efforts of the Merck Animal Health Advisory Board, the input and continued support of our customers, and the FDA for its commitment to science and advancing animal well-being.\u8221\'20\'1D\par \par \uc2 Merck Animal Health has recently filed a label update submission in Canada. {\field{\*\fldinst{HYPERLINK "http://www.merck-animal-health.com/binaries/Zilmax_Type_A_Medicated_Article_Label__FINAL__tcm95-165067.pdf"}}{\fldrslt{\cf2 \uc2 Click here}}}\uc2  to view the updated U.S. Zilmax label.\par \par \uc2 Zilmax has a withdrawal period of 3 days prior to harvest.\u160\'00\'A0 Not for use in animals intended for breeding.\u160\'00\'A0 Do not allow horses or other equines access to feed containing zilpaterol.\u160\'00\'A0 Do not use in veal calves.\u160\'00\'A0 Not to be fed to cattle in excess of 90 mg/head/day in complete feed.\u160\'00\'A0 If pen consumption of complete feed exceeds 26.5 lb/head/day (90 percent dry matter basis), zilpaterol should not be fed in complete feed.\u160\'00\'A0 For complete information, refer to the product label.\par \par \uc2 Document BEEF000020141106eab50008e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update\b0\par\par\uc2 2,605 \uc2 words\par \uc2 5 November 2014\par 16:36\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update\par \par \uc2 MALVERN, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- \uc2 TetraLogic Pharmaceuticals Corporation\uc2  (\uc2 Nasdaq\uc2 :TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the \uc2 Securities and Exchange Commission\uc2 .\par \par \uc2 "This year we have advanced all of our clinical programs," said \uc2 J. Kevin Buchi\uc2 , President and Chief Executive Officer of TetraLogic. "First, based on in-vivo data indicating clearance of both hepatitis B DNA and surface antigen (HBsAg), we are advancing birinapant into the clinic in the study for the treatment of chronic hepatitis B. Second, in myelodysplastic syndrome (MDS), we were encouraged by the previously announced Phase 1 data and have commenced enrollment in a Phase 2 trial, to further evaluate the activity of birinapant in combination with standard of care azacitidine. Third, enrollment continues in our signal seeking study of birinapant in combination with \uc2 Amgen\uc2 's conatumumab, a TRAIL agonist antibody, in ovarian cancer patients. Finally, we are advancing SHAPE, our novel, topical HDAC inhibitor, into a randomized Phase 2 clinical trial to evaluate its activity in early stage cutaneous T-cell lymphoma (CTCL)."\par \par \uc2 Summary of Key Development Programs, Updates and Anticipated Milestones \par \par \uc2 \f2 \par    -- Birinapant HBV Program: In a mouse model we have generated data \par       demonstrating that birinapant induces apoptosis in mouse hepatocytes \par       infected with hepatitis B, while sparing normal hepatocytes.  In the \par       mouse model we have seen clearance of HBsAg. We are commencing enrollment \par       in a multiple ascending dose study of birinapant in subjects with chronic \par       hepatitis B in the fourth quarter of 2014.  We currently expect data to \par       be generated around the middle of 2015.  The trial will be conducted in \par       subjects over the age of 18 with hepatitis B who are receiving treatment \par       with either tenofavir or entecavir and who are HBsAg positive.  The trial \par       is expected to enroll approximately 6 cohorts of 8 subjects each, who \par       will receive 4 weekly treatments with either birinapant or placebo in a \par       3:1 ratio.  The study is being conducted at multiple clinical sites in \par       Australia and New Zealand.  Although predominantly a safety and \par       tolerability study, patients will also be monitored for reductions in \par       hepatitis B surface antigen as an indication of therapeutic activity. On \par       November 10, 2014, TetraLogic will be discussing its HBV program at an \par       investor forum at the \f28 \uc2 \f2 American Association for the Study of Liver \par       Diseases\f28 \uc2 \f2  Conference. \par  \par    -- Birinapant MDS Program:  In May, we announced that, based upon data from \par       our Phase 1b study of birinapant in combination with azacitidine in \par       patients with higher risk MDS who are either relapsed/refractory or \par       na\u239\'00\'EFve to azacitidine, we initiated a randomized Phase 2 clinical \par       trial in first line higher risk patients. While the primary objective of \par       the Phase 1b clinical study was to characterize the safety and \par       tolerability and determine the recommended Phase 2 dose of birinapant \par       when administered in combination with azacitidine, we did observe bone \par       marrow responses in a number of patients who had relapsed or were \par       refractory to azacitidine.  We currently expect interim data from the \par       Phase 2 study in the middle of 2015. \par  \par    -- SHAPE CTCL Program: In May, safety and efficacy data from the Phase 1b \par       randomized placebo controlled clinical study of SHAPE, our topical HDAC \par       inhibitor, in Stage IA --IIA Cutaneous T-cell Lymphoma (CTCL) were \par       presented at the annual Society of Investigative Dermatology meeting and \par       at \f28 \uc2 \f2 American Society of Clinical Oncology\f28 \uc2 \f2  meeting.  We are advancing SHAPE \par       into a randomized Phase 2 clinical trial in early stage CTCL.  We \par       currently expect data around the end of 2015. \par  \par    -- Birinapant/conatumumab Program:  Enrollment continues in a signal-seeking \par       study in combination with conatumumab, \f28 \uc2 \f2 Amgen\f28 \uc2 \f2 's TRAIL agonist antibody, in \par       3rd line ovarian cancer.  We currently expect data around the end of \par       2014. \f28 \par \par \uc2 \f2 Third Quarter 2014 Financial Highlights \f28 \par \par \uc2 \f2 \par    -- Cash, cash equivalents, and marketable securities totaled $65.1 million \par       at September 30, 2014, as compared to $55.1 million at December 31, \par       2013. \par  \par    -- Research and Development expenses were $5.7 million for the third quarter \par       of 2014, excluding $0.2 million in non-cash, stock based compensation \par       expense, compared to $2.1 million for the same period in 2013. The \par       increase primarily results from additional costs associated with clinical \par       trials, including the manufacturing and formulation of our clinical drug \par       supplies. \par  \par    -- General and Administrative expenses were $2.0 million for the third \par       quarter of 2014, excluding $0.6 million in non-cash, stock based \par       compensation expense, compared to $1.9 million for the same period in \par       2013, excluding $0.3 million in non-cash, stock based compensation \par       expense. \par  \par    -- Adjusted net loss for the third quarter of 2014 was $8.6 million, \par       compared to an adjusted net loss of $4.2 million for the same period in \par       2013. Adjusted net loss excludes (i) non-cash stock based compensation \par       expense; (ii) non-cash interest expense; (iii) non-cash fair value \par       adjustments to the company's derivative liabilities: and (iv) non-cash \par       fair value adjustments to the contingent consideration liability \par       recognized as part of the Shape acquisition in April 2014. \par  \par    -- Shares issued and outstanding as of September 30, 2014 were 22.3 million, \par       not including outstanding stock options to purchase 3.2 million shares \par       and 7.0 million shares underlying the company's outstanding convertible \par       notes. \f28 \par \par \uc2 \f2 Non-GAAP Financial Measures\f28 \par \par \uc2 \f2 In the attached press release, the Company discloses "Adjusted net loss, " "Basic adjusted net loss per common share," and "Diluted adjusted net loss per common share" for certain historical periods, all of which are considered "non-GAAP financial measures" under \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2  rules. A "non-GAAP financial measure" is defined as a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes (or includes) amounts, or is subject to adjustments that have the effect of excluding (or including) amounts, that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in the Company's financial statements. Management does not intend the presentation of non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP.\f28 \par \par \uc2 \f2 For all periods presented, the Company reconciles net loss on a GAAP basis to adjusted net loss. Management believes that the presentation of these adjusted measures is useful to investors because it provides a means of evaluating the Company's operating performance and results from period to period on a comparable basis not otherwise apparent on a GAAP basis, since many non-cash, infrequent, or unusual charges, including items that may not affect the Company's operations, do not meet the strict GAAP definition of unusual non-recurring items. Furthermore, in preparing operating plans, budgets and forecasts, and in assessing historical performance, management relies, in part, on trends in the Company's historical results, exclusive of these items. Finally, management believes that this presentation is useful in facilitating comparisons between the Company and other companies in its industry, many of whom exclude similar items.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 TetraLogic Pharmaceuticals Corporation\f28 \par \par \uc2 \f2 TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also entering a Phase 1b/2a clinical trial in hepatitis B. SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.\f28 \par \par \uc2 \f2 Forward Looking Statements\f28 \par \par \uc2 \f2 Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic's pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the \f28 \uc2 \f2 U.S. Securities and Exchange Commission\f28 \uc2 \f2  (\f28 \uc2 \f2 SEC\f28 \uc2 \f2 ) on March 19, 2014 and in our form 10-Q filed with the \f28 \uc2 \f2 SEC\f28 \uc2 \f2  on November 5, 2014. Any forward-looking\f28 \par \par \uc2 \f2 5 Nov 2014 16:36 ET \par Press Release: TetraLogic Reports Third Quarter -2-\f28 \par \par \uc2 \f2 statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. \f28 \par \par \uc2 \f2 TetraLogic Pharmaceuticals Corporation\f28 \uc2 \f2  \par                Consolidated Statements of Operations and Comprehensive \par                                          Loss \par                                      (unaudited) \par  \par                       Three months ended September \par                                   30,                Nine months ended September 30, \par                           2013            2014            2013             2014 \par                      --------------  --------------  ---------------  --------------- \par  \par Revenues                  $ --            $ --             $ --             $ -- \par  \par Expenses: \par   General and \par    administrative         2,173,728       2,623,538        4,147,292        8,136,735 \par   Research and \par    development            2,148,424       5,968,181        6,438,941       13,955,119 \par   Change in fair \par    value of \par    contingent \par    consideration                 --         984,000               --        1,902,000 \par                      --------------  --------------  ---------------  --------------- \par Total expenses            4,322,152       9,575,719       10,586,233       23,993,854 \par                      --------------  --------------  ---------------  --------------- \par  \par Loss from \par  operations             (4,322,152)     (9,575,719)     (10,586,233)     (23,993,854) \par  \par Change in fair \par  value of \par  derivative \par  liabilities            (1,391,316)       1,799,501      (1,334,827)        1,637,381 \par Interest and other \par  income                          53          41,375               65           72,571 \par Interest expense          (262,137)     (1,595,275)      (1,375,378)      (1,734,721) \par                      --------------  --------------  ---------------  --------------- \par Net loss              $ (5,975,552)   $ (9,330,118)   $ (13,296,373)   $ (24,018,623) \par Cumulative \par  preferred stock \par  dividends                (853,194)              --      (2,565,708)               -- \par                      --------------  --------------  ---------------  --------------- \par Net loss \par  attributable to \par  common \par  stockholders         $ (6,828,746)   $ (9,330,118)   $ (15,862,081)   $ (24,018,623) \par                      ==============  ==============  ===============  =============== \par  \par Per share \par information: \par    Net loss per \par    common share: \par      Basic                 $ (4.34)        $ (0.42)        $ (12.41)         $ (1.08) \par      Diluted               $ (4.34)        $ (0.42)        $ (12.41)         $ (1.10) \par  \par    Weighted average \par    shares \par    outstanding: \par      Basic                1,575,040      22,307,138        1,278,400       22,280,232 \par      Diluted              1,575,040      22,364,231        1,278,400       22,344,129 \par  \par Net loss              $ (5,975,552)   $ (9,330,118)   $ (13,296,373)   $ (24,018,623) \par Foreign currency \par  gains/(losses)                  --        (41,626)               --         (39,004) \par Unrealized \par  gains/(losses) on \par  available-for-sale \par  securities                      --           1,635               --            (369) \par                      --------------  --------------  ---------------  --------------- \par Comprehensive loss    $ (5,975,552)   $ (9,370,109)   $ (13,296,373)   $ (24,057,996) \par                      ==============  ==============  ===============  =============== \par  \par  \par  \par                                   \f28 \uc2 \f2 TetraLogic Pharmaceuticals Corporation\f28 \uc2 \f2  \par                            Reconciliation of GAAP Net Loss to Adjusted Net Loss \par                                                 (Unaudited) \par  \par In accordance with Regulation G of the \f28 \uc2 \f2 Securities \par  and Exchange Commission\f28 \uc2 \f2 , the table set forth below \par  reconciles certain financial measures used in this \par  press release that are not calculated in accordance \par  with generally accepted accounting principles, or \par  GAAP, with the most directly comparable financial \par  measure calculated in accordance with GAAP. \par  \par                          Three months ended September 30,            Nine months ended September 30, \par                             2013                  2014                 2013                  2014 \par                      -------------------  -------------------  --------------------  -------------------- \par  \par Net loss \par  attributable to \par  common \par  stockholders - \par  GAAP                 $ (6,828,746)        $ (9,330,118)        $ (15,862,081)        $ (24,018,623) \par  \par     General and \par      administrative \par      adjustments            299,926  (1)         617,765  (1)          374,922  (1)        1,796,122    (1) \par     Research and \par      development \par      adjustments             41,248  (1)         226,580  (1)          172,149  (1)          690,355    (1) \par     Change in fair \par      value of \par      contingent \par      consideration               --              984,000  (2)               --             1,902,000    (2) \par     Change in fair \par      value of \par      derivative \par      liabilities          1,391,316  (3)     (1,799,501)  (3)        1,334,827  (3)      (1,637,381)    (3) \par     Interest \par      expense                     --              654,130  (4)               --               711,165    (4) \par     Cumulative \par      preferred \par      stock \par      dividends              853,194  (5)              --             2,565,708  (5)               -- \par                      --------------       --------------       ---------------       --------------- \par                           2,585,684              682,974             4,447,606             3,462,261 \par                      --------------       --------------       ---------------       --------------- \par  \par Adjusted net loss     $ (4,243,062)        $ (8,647,144)        $ (11,414,475)        $ (20,556,362) \par                      ==============       ==============       ===============       =============== \par  \par Per share \par information: \par     Adjusted net \par     loss per common \par     share: \par       Basic                $ (2.69)             $ (0.39)              $ (8.93)              $ (0.92) \par       Diluted              $ (2.69)             $ (0.39)              $ (8.93)              $ (0.94) \par  \par     Weighted \par     average shares \par     outstanding: \par       Basic               1,575,040           22,307,138             1,278,400            22,280,232 \par       Diluted             1,575,040           22,364,231             1,278,400            22,344,129 \par  \par  \par                            Notes to Reconciliation of GAAP Net Loss to Adjusted \par                                                   Net Loss \par  \par (1) To exclude non-cash charges for stock compensation \par  expense. \par  \par (2) In 2014, to exclude the change in fair value of \par  contingent consideration related to the acquisition \par  of Shape Pharmaceuticals, Inc. \par  \par (3) To exclude the change in fair value of our warrant \par  liabilities and, in 2014, the change in fair value \par  of the interest make-whole derivative related to our \par  8% Convertible Notes. \par  \par (4) In 2014, to exclude the amortization of debt discount \par  and the amortization of deferred financing costs related \par  to our 8% Convertible Notes. \par  \par (5) In 2013, to exclude cumulative dividends on our \par  series C and C-1 convertible preferred stock. \par  \par  \par  \par                     \f28 \uc2 \f2 TetraLogic Pharmaceuticals Corporation\f28 \uc2 \f2  \par                          Consolidated Balance Sheets \par  \par                                                  December 31,   September 30, \par                                                       2013           2014 \par                                                  -------------  -------------- \par Assets                                                           (unaudited) \par Current assets: \par   Cash and cash equivalents                       $ 55,135,508    $ 17,020,047 \par   Short-term investments                                    --      48,104,088 \par   Deferred financing costs, short-term                      --         375,808 \par   Prepaid expenses and other current assets            153,210       1,719,813 \par   Restricted cash                                       20,000              -- \par                                                  -------------  -------------- \par Total current assets                                55,308,718      67,219,756 \par Property and equipment, net                            139,577         460,933 \par Intangible assets                                           --      35,230,516 \par \f28 \uc2 \f2 Goodwill\f28 \uc2 \f2                                                     --      14,326,396 \par Deferred financing costs, long-term                         --       1,393,625 \par Other assets                                            54,126       1,432,551 \par                                                  -------------  -------------- \par Total assets                                      $ 55,502,421   $ 120,063,777 \par                                                  =============  ============== \par  \par Liabilities and stockholders' equity \par Current liabilities: \par   Accounts payable                                 $ 1,215,198     $ 1,902,904 \par   Accrued expenses                                   2,921,458       4,432,938 \par   Derivative liabilities                               793,744         282,643 \par                                                  -------------  -------------- \par Total current liabilities                            4,930,400       6,618,485 \par    Convertible notes payable, net of discount \par     of $18,611,375                                          --      28,388,625 \par    Derivative liabilities                                   --       1,900,000 \par    Deferred taxes                                           --      14,303,589 \par   Contingent consideration and other \par    liabilities                                          22,968      24,494,354 \par                                                  -------------  -------------- \par Total liabilities                                    4,953,368      75,705,053 \par  \par Commitments and contingencies \par Stockholders' equity: \par   Preferred stock, $0.0001 par value; \par   25,000,000 shares authorized, none issued and \f28 \par \par \uc2 \f2 5 Nov 2014 16:36 ET \par Press Release: TetraLogic Reports Third Quarter -3-\f28 \par \par \uc2 \f2 \par   outstanding                                               --              -- \par   Common stock, $0.0001 par value; 100,000,000 \par    shares authorized, 22,199,256 and 22,307,138 \par    shares issued and outstanding at December \par    31, 2013 and September 30, 2014, \par    respectively                                          2,220           2,231 \par   Additional paid-in capital                       140,419,071     158,286,727 \par   Cumulative unrealized loss on investments                 --           (369) \par   Cumulative translation adjustment                         --        (39,004) \par   Accumulated deficit                             (89,872,238)   (113,890,861) \par                                                  -------------  -------------- \par Total stockholders' equity                          50,549,053      44,358,724 \par                                                  -------------  -------------- \par Total liabilities and stockholders' equity        $ 55,502,421   $ 120,063,777 \par                                                  =============  ============== \par  \par CONTACT: Company Contact: \par          Pete A. Meyers \par          Chief Financial Officer and Treasurer \par          TetraLogic Pharmaceuticals Corporation \par          (610) 889-9900, x103 \par          pete.meyers@tlog.com \par  \par          Investor Relations Contact: \par          Ami Bavishi \par          Burns McClellan, Inc. \par          (212) 213-0006 \par          abavishi@burnsmc.com \f28 \par \par \uc2 \f2 5 Nov 2014 16:37 ET *TetraLogic Pharm 3Q Loss/Shr 42c >TLOG\f28 \par \par \uc2 \f2 5 Nov 2014 16:37 ET *TetraLogic Pharm 3Q Loss $9.33M >TLOG\f28 \par \par \uc2 \f2 (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)\f28 \par \par \uc2 \f2 November 05, 2014 16:37 ET (21:37 GMT)\f28 \par \par \uc2 Document DJDN000020141105eab5004jt\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Loestrin 24 Fe\b0\par\par\uc2 149 \uc2 words\par \uc2 5 November 2014\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2014 NoticiasFinancieras. All Rights Reserved.   \par \par \uc2 (RTTNews) - Generic drugmaker \uc2 Mylan Inc\uc2 . (MYL) Wednesday announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of \uc2 Warner Chilcott\uc2 's Loestrin 24 Fe.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for the product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. THe company has started shipping product.\par \par \uc2 Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate had U.S. sales of about $24.4 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2014 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020141105eab5005v5\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of \uc2 Warner Chilcott\uc2 's Loestrin 24 Fe in the U.S.\b0\par\par\uc2 122 \uc2 words\par \uc2 5 November 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of \uc2 Warner Chilcott\uc2 's (WCRX) Loestrin 24 Fe. Mylan received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Mylan has begun shipping product. Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate had U.S. sales of approximately $24.4M for the 12 months ending September 30.\par \par \uc2 Document FLYWAL0020141105eab5001mr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Loestrin 24 Fe(R)\b0\par\par\uc2 399 \uc2 words\par \uc2 5 November 2014\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, Nov. 5, 2014 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) today announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of \uc2 Warner Chilcott\uc2 's Loestrin 24 Fe(R) . Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.\par \par \uc2 Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate had U.S. sales of approximately $24.4 million for the 12 months ending September 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 287 ANDAs pending FDA approval representing $112.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.\par \par \uc2 (1) Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use and this risk increases with age. Women who use oral contraceptives should be advised to not smoke. Consult your physician prior to beginning oral contraceptive use.\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020141105eab50006c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 BIOTIME\uc2  FILES CURRENT REPORT\b0\par\par\uc2 870 \uc2 words\par \uc2 5 November 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, Nov. 5 -- \uc2 BioTime Inc\uc2 ., Alameda, Calif., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on Nov. 4.\par \par \uc2 State or other jurisdiction of incorporation: California\par \par \uc2 Forward-Looking Statements\par \par \uc2 Any statements that are not historical fact (including, but not limited to statements that contain words such as "may, "will," "believes," "plans," "intends," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in \uc2 BioTime\uc2 's periodic reports filed with the \uc2 SEC\uc2  under the heading "Risk Factors" and other filings that \uc2 BioTime\uc2  may make with the \uc2 Securities and Exchange Commission\uc2 . Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, \uc2 BioTime\uc2  disclaims any intent or obligation to update these forward-looking statements.\par \par \uc2 Section 8 - Other Events\par \par \uc2 Item 8.01 Other Events\par \par \uc2 We have received authorization from the \uc2 Spanish Agency of Medicines and Medical Devices\uc2  (AEMPS) to begin a pivotal human clinical trial of Renevia in Spain. In the trial, Renevia will be used in combination with the patient's own fat-derived cells and injected into portions of the patient's face where there has been a loss of fat from under the skin (lipoatrophy). Lipoatrophy is estimated to occur in 35-50% of the 10 million HIV patients on antiretroviral therapy.\par \par \uc2 About the Renevia Clinical Trial\par \par \uc2 We will conduct a randomized, evaluator-blinded, delayed-treatment-controlled study of the effectiveness and safety of Renevia as a resorbable matrix for the delivery of autologous adipose-derived cells to treat subcutaneous facial lipoatrophy defects arising from HIV infection. The study will include a minimum of 56 and up to 92 HIV positive males and females between 18-65 years of age. Subjects will be randomized with half in the treatment group and half in a delayed-treatment cohort, each receiving a single treatment course of Renevia with autologous adipose cells harvested by liposuction and implanted in the mid-facial region. The primary effectiveness measure will be the comparison of the change in skin thickness between the treatment and delayed treatment groups. A secondary endpoint will be mid-face volume deficit and global aesthetic improvement scores. Patients will be monitored at one, three, and six-month intervals after treatment. Patient enrollment, which has begun, is expected to be completed in 2015. Additional information on the trial will be made available on \uc2 BioTime\uc2 's website at {\field{\*\fldinst{HYPERLINK "http://www.biotimeinc.com"}}{\fldrslt{\cf2 \uc2 www.biotimeinc.com}}}\uc2 .\par \par \uc2 The trial will be conducted at The Stem Center in Palma de Mallorca, Spain, an innovative patient therapy center, laboratory, and professional research facility located within the Clinica USP Palma Planas hospital in Palma. The Medical Director of The Stem Center and Principal Investigator for the Renevia studies, Ramon Llull, MD, PhD, is a leading expert on advanced regenerative therapies based on adipose technology.\par \par \uc2 About Facial Lipoatrophy\par \par \uc2 Facial lipoatrophy is a condition characterized by localized loss of fat under the skin. It is common in HIV-infected patients on antiretroviral therapy (ART), and the resulting facial wasting ages the individual's appearance prematurely and, along with a thinning of the skin, allows musculature and vasculature to be easily seen, resulting in what is commonly known as "the face of AIDS." Treatment of the condition has been determined to be medically advisable to improve the individual's self esteem and quality of life.\par \par \uc2 While the use of highly active ART in the treatment of HIV-positive patients has greatly increased longevity, the reported incidence of HIV-associated lipoatrophy has correspondingly risen. According to statistics published by AVERT ({\field{\*\fldinst{HYPERLINK "http://www.avert.org"}}{\fldrslt{\cf2 \uc2 www.avert.org}}}\uc2 ), worldwide there were 34 million people living with HIV/AIDS in 2011 with 900,000 of these in western and central Europe and 1.4 million in North America. \uc2 UNICEF\uc2 , UNAIDS, and the \uc2 World Health Organization\uc2  (WHO) reported in 2013 that the number of people receiving ART has tripled in five years to approximately 10 million people. A substantial effort is underway to reach a global target of 15 million people receiving ART by the end of 2015.\par \par \uc2 At present, commonly-used products for the treatment of HIV-related lipoatrophy include dermal fillers or products that trigger fibrotic reactions which create fibrous tissue that has an effect of bulking the skin, but not a restoration of natural subcutaneous fat with its associated texture and appearance. A full course of treatment of those products can require multiple injections over a period of several months. We expect that a single treatment of Renevia with adipose-derived cells when injected with a small gauge cannula will result in a reconstitution of normal subcutaneous fat and restoration of skin contour.\par \par \uc2 Section 9-Financial Statements and Exhibits\par \par \uc2 Item 9.01 Financial Statements and Exhibits.\par \par \uc2 Exhibit Number - Description\par \par \uc2 99.1 - Press Release dated November 4, 2014\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752314004320/a50976043.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752314004320/a50976043.htm}}}\par \par \uc2 Document INDFED0020141105eab5001v1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 *St. Jude Medical Received in October FDA Approval of TactiCath Irrigated Ablation Catheter\b0\par\par\uc2 82 \uc2 words\par \uc2 4 November 2014\par 17:19\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 4 Nov 2014 17:19 ET *St. Jude Medical Sees 4Q Charge of $11 Million to Reflect Value at Which Contingent Consideration Will Be Settled\par \par \uc2 4 Nov 2014 17:25 ET *St. Jude Medical: At Oct. 31, Company Aware of 73 Lawsuits Related to Riata and Riata ST Silicone Defibrillation Leads\par \par \uc2 (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)\par \par \uc2 November 04, 2014 17:25 ET (22:25 GMT)\par \par \uc2 Document DJDN000020141104eab4004m0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Bacterin International\uc2  Files 8K - Regulation FD >BONE\b0\par\par\uc2 244 \uc2 words\par \uc2 4 November 2014\par 08:30\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Bacterin International Holdings Inc\uc2 . (BONE) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 04, 2014.\par \par \uc2 The Company has issued a press release entitled "Bacterin to Showcase New Product Line at the \uc2 North American Spine Society\uc2  Annual Meeting" which is attached as Exhibit 99.1 and incorporated herein.\par \par \uc2 The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1453593/000114420414064806/v393020_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1453593/000114420414064806/v393020_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1453593/000114420414064806/0001144204-14-064806-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1453593/000114420414064806/0001144204-14-064806-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 04, 2014 08:30 ET (13:30 GMT)\par \par \uc2 Document DJDN000020141104eab40024k\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:09\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}